



# **TEJNAKSH HEALTHCARE LIMITED**

**ANNUAL REPORT - 2020-21**

**Board of Directors**

Dr. Ashish Vishwas Rawandale  
 Dr. Preeti Ashish Rawandale  
 Ms. Kiran Madhavrao Pawar  
 Mr. Vikramsinh Satish Khatal Patil  
 Mr. Pratap Tarachand Patil (Resigned on 29.06.2021)  
 Mr. Sanjay Bhikajirao Khatal (Appointed w.e.f. 13.07.2020)  
 Mr. Suhas Thorat (Appointed w.e.f. 14.08.2021)

**Chief Financial Officer (CFO)**

Mr. Ramesh Daulat Kuwar

**Company Secretary & Compliance Officer**

Mr. Prakash Sogam

**Registered Office**

A 601, Floor No.6, Kailash Business Park, Veer Savarkar Marg, Vikroli - West, Mumbai - 400079  
 Email - instituteofurology@gmail.com  
 Tel: 022-2754 2311;  
 Website: www.tejnaksh.com

**Hospital & Corporate Office**

Institute of Urology, Sakri Road,  
 Dhule - 424 001, Maharashtra  
 Tel: 91-2562- 245995/245322;

**Registrars & Share Transfer Agents**

M/s. Cameo Corporate Services Ltd.  
 Submaramanian Building,  
 1 Club House Road, Chennai - 600 002  
 Tel No.: +91-44-2846 0390/1989  
 Fax No.: +91-44-2846 0129  
 Website: www.cameoindia.com  
 E-mail ID: investor@cameoindia.com

**Secretarial Auditors**

Bhuwnesh Bansal & Associates  
 Company Secretaries  
 002, Dreamland Park C wing CHS Ltd.  
 Gokuldharm Road, Near Vijay Park, Mira Road -  
 East, Thane - 401 107, Mumbai - 400022  
 Tel : +91-07738181976  
 Email Id:- csbbansal@gmail.com  
 Contact Person: CS Bhuwnesh Bansal

**Statutory Auditors**

M/s. P.D. Dalal & Co.,  
 Chartered Accountants  
 102, B Wing, Lake Florence ABCDEF&G CHS,  
 Phase-I, Adi Shankaracharya Road,  
 Near Gopal Sharma High School,  
 Powai, Mumbai - 400076  
 Tel : +91-22-2857 3379  
 Email Id:- askakaria@gmail.com  
 Contact Person: CA Aashish Kakaria

**Main Banker**

HDFC Bank

| CONTENTS                                  | PAGE NO. |
|---|----------|
| General Information                       | 2        |
| Notice                                    | 3        |
| Directors Report                          | 14       |
| Management Discussion and Analysis        | 36       |
| Report on Corporate Governance            | 42       |
| Auditors Report - Standalone Financial    | 54       |
| Standalone Balance Sheet                  | 62       |
| Standalone Statement of Profit & Loss     | 63       |
| Standalone Cash Flow Statement            | 64       |
| Notes to Standalone Financial Statement   | 65       |
| Auditors Report - Consolidate Financial   | 93       |
| Consolidate Balance Sheet                 | 100      |
| Consolidated Statement of Profit & Loss   | 101      |
| Consolidate Cash Flow Statement           | 102      |
| Notes to Consolidated Financial Statement | 103      |

**Corporate Identity Number (CIN)**

L85100MH2008PLC179034

**Website**

www.tejnaksh.com

**Investors Relations Email Id**

cs.tejnaksh@gmail.com

**Important Communication to Members**

The Ministry of Corporate Affairs has taken a "Green Initiative in the Corporate Governance" by allowing paperless compliances by the companies and has issued circulars stating that service of notice/ documents including Annual Report can be sent by e-mail to its members. To support this green initiative of the Government in full measure, members who have not registered their e-mail addresses, so far, are requested to register their e-mail addresses, in respect of electronic holdings with the Depository through their concerned Depository Participants. Members who hold shares in physical form are requested to update their email address with the Company or M/s. Cameo Corporate Services Ltd. (RTA), to enable us to send all the documents through electronic mode in future.

## NOTICE

**NOTICE** is hereby given that the **14<sup>th</sup> Annual General Meeting** of the Members of **Tejnaksh Healthcare Limited** will be held on **Thursday, 30<sup>th</sup> September, 2021 at 10.30 A.M.** through video Conferencing ("VC") / Other Audio Visual Means ("OAVM") to transact the following business:

---

### **ORDINARY BUSINESS:-**

1. To receive, consider and adopt the Audited Financial Statement of the Company for the year ended 31<sup>st</sup> March 2021 including Audited Balance Sheet as at 31<sup>st</sup> March, 2021 and the Statement of Profit & Loss Account and Statement of Cash Flow, for the year ended as on that date together with the reports of the Board of Directors and Auditors thereon and the Audited Consolidated Financial Statements of the Company for the financial year ended March 31, 2021, together with the Report of the Auditors thereon.
2. To appoint Mr. Sanjay Bhikajirao Khatal (Din: 06616883) as Director of the Company, who retires by rotation and being eligible, offers himself for re-appointment.

### **SPECIAL BUSINESS:-**

3. Regularization of Additional Director, Mr. Suhas Vasantrao Thorat (Din: 09241231) by appointing him as Independent Director of The Company

To consider, and if thought fit, to pass the following resolution as an **Ordinary resolution**:

**"RESOLVED THAT** pursuant to the provisions of Section 149, 152, 161(1) and any other applicable provisions of the companies Act, 2013, read with Companies (Appointment and Qualification of Directors) Rules, 2014, subject to the statutory modification(s) or re-enactment thereof for time being in force and SEBI (LODR) Regulations, 2015, as recommend by the Nomination and Remuneration Committee and Board of Directors, consent of the Members of the Company be and hereby accorded to regularize and to appoint Mr. Suhas Vasantrao Thorat (Din: 09241231) as a Non-Executive Independent Director of the Company, who has submitted a declaration that he meets the criteria for independence as provided in Section 149(6) of the Act and who is eligible for appointment, who shall hold office for five(5) consecutive years commencing from 14<sup>th</sup> August, 2021, not liable to retire by rotation."

**RESOLVED FURTHER THAT** the Board be and is hereby authorized to do all acts and take all such steps as may be necessary, proper or expedient to give effect to this resolution."

4. Authorization under Section 180 of the Companies, Act, 2013

To consider and if thought fit to pass, with or without modification, the following resolution as a **Special Resolution**:

**"RESOLVED THAT** pursuant to the provisions of Section 180 (1) (c) and other applicable provisions, if any, of the Companies Act, 2013 and relevant rules made thereto including any statutory modifications or re-enactments thereof, the consent of the shareholders of the Company be and is hereby accorded to the Board of Directors to borrow money, as and when required, from, including without limitation, any Bank and/ or other Financial Institution and/or foreign lender and/or anybody corporate/ entity/ entities and/or authority/authorities, either in rupees or in such other foreign currencies as may be permitted by law from time to time, as may be deemed appropriate by the Board for an aggregate amount not exceeding a sum of Rs.100,00,00,000 (Rupees One Hundred Crore Only), notwithstanding that money so borrowed together with the monies already borrowed by the Company, if any (apart from temporary loans obtained from the Company's bankers in the ordinary course of business) may exceed the aggregate of the paid-up share capital of the Company and its free reserves.

**RESOLVED FURTHER THAT** pursuant to Section 180(1)(a) and other applicable provisions if any, of the Companies Act, 2013 and relevant rules made thereto including any statutory modifications or re-enactments thereof, consent of the shareholders of the company be and is hereby accorded, to the Board of Directors of the Company to pledge, mortgage, hypothecate and/or charge all or any part of the moveable or immovable properties of the Company and the whole or part of the undertaking of the Company of every nature and kind whatsoever and/or creating a floating charge in all or any movable or immovable properties of the Company and the whole of the undertaking of the Company to or in favour of banks, financial institutions, investors and any other lenders to secure the amount borrowed by the Company or any third party from time to time for the due payment of the principal and/or together with interest, charges, costs, expenses and all other monies payable by the Company or any third party in respect of such borrowings provided that the aggregate indebtedness secured by the assets of the Company does not exceed a sum of Rs.100,00,00,000 (Rupees One Hundred Crore Only).

**RESOLVED FURTHER THAT** the Board of Directors be and is hereby authorized to take such steps as may be necessary for obtaining approvals, statutory, contractual or otherwise, in relation to the above and to settle all matters arising out of and incidental thereto, and to sign and to execute deeds, applications, documents and writings that may be required, on behalf of the Company and generally to do all such acts, deeds, matters and things as may be necessary, proper, expedient or incidental for giving effect to this resolution."

**Notes:-**

1. In view of the continuing COVID-19 pandemic, the Ministry of Corporate Affairs ("MCA") has vide its circular nos. 14/2020 and 17/2020 dated April 8, 2020 and April 13, 2020 respectively, in relation to "Clarification on passing of ordinary and special resolutions by companies under the Companies Act, 2013 and the rules made thereunder on account of the threat posed by Covid-19", circular no. 20/2020 dated May 5, 2020 in relation to "Clarification on holding of annual general meeting (AGM) through video conferencing (VC) or other audio visual means (OAVM)" and Circular no. 02/2021 dated January 13, 2021 in relation to "Clarification on holding of annual general meeting (AGM) through video conferencing (VC) or other audio visual means (OAVM)" (collectively referred to as "MCA Circulars") and Securities and Exchange Board of India ("SEBI") vide its circular no. SEBI/HO/CFD/CMD1/CIR/P/2020/79 dated May 12, 2020 in relation to "Additional relaxation in relation to compliance with certain provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 - Covid-19 pandemic" and circular no. SEBI/HO/CFD/CMD2/CIR/P/2021/11 dated January 15, 2021 in relation to "Relaxation from compliance with certain provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 due to the COVID -19 pandemic" (collectively referred to as "SEBI Circulars") permitted the holding of the Annual General Meeting ("AGM") through VC / OAVM, without the physical presence of the Members at a common venue. In compliance with the MCA Circulars and SEBI Circulars, the AGM of the members of the Company is being held through VC/ OAVM. The registered office of the Company shall be deemed to be the venue for the AGM.
2. Pursuant to the Circular No. 14/2020 dated April 08, 2020, issued by the Ministry of Corporate Affairs, the facility to appoint proxy to attend and cast vote for the members is not available for this AGM. However, the Body Corporates are entitled to appoint authorised representatives to attend the EGM/AGM through VC/OAVM and participate there at and cast their votes through e-voting.
3. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding), Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.
4. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Act.
5. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs dated April 08, 2020, April 13, 2020 and May 05, 2020 the Company is providing facility of remote e-Voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-Voting system as well as venue voting on the date of the AGM will be provided by NSDL.
6. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM has been uploaded on the website of the Company at [www.tejnaksh.com](http://www.tejnaksh.com). The Notice can also be accessed from the websites of the Stock Exchanges i.e. BSE Limited and National Stock Exchange of India Limited at [www.bseindia.com](http://www.bseindia.com) and [www.nseindia.com](http://www.nseindia.com) respectively and the AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
7. AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular No. 14/2020 dated April 08, 2020 and MCA Circular No. 17/2020 dated April 13, 2020, MCA Circular No. 20/2020 dated May 05, 2020 and MCA Circular No. 2/2021 dated January 13, 2021.
8. As per the provisions of Clause 3.A.II. of the General Circular No. 20/ 2020 dated 5th May 2020, the matters of Special Business as appearing at Item Nos. 3 and 4 of the accompanying Notice, are considered to be unavoidable by the Board and hence, form part of this Notice.

9. The relative Explanatory Statement pursuant to Section 102 of the Act, in regard to the business as set out in Item Nos. 3 and 4 above and the relevant details of the Director seeking re-appointment as set out in Item No.2 and 3 above as required under Regulation 26(4) and 36(3) of the Listing Regulations, is annexed hereto.
10. **PURSUANT TO THE PROVISIONS OF THE ACT, A MEMBER ENTITLED TO ATTEND AND VOTE AT THE AGM IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON HIS/HER BEHALF AND THE PROXY NEED NOT BE A MEMBER OF THE COMPANY. SINCE THIS AGM IS BEING HELD PURSUANT TO THE MCA CIRCULARS THROUGH VC/OAVM, THE REQUIREMENT OF PHYSICAL ATTENDANCE OF MEMBERS HAS BEEN DISPENSED WITH. ACCORDINGLY, IN TERMS OF THE MCA CIRCULARS AND THE SEBI CIRCULAR, THE FACILITY FOR APPOINTMENT OF PROXIES BY THE MEMBERS WILL NOT BE AVAILABLE FOR THIS AGM AND HENCE, THE PROXY FORM, ATTENDANCE SLIP AND ROUTE MAP OF AGM ARE NOT ANNEXED TO THIS NOTICE.**
11. Institutional Investors, who are Members of the Company, are encouraged to attend and vote at the AGM through VC/OAVM facility. Corporate Members intending to appoint their authorized representatives to attend the AGM through VC or OAVM and to vote thereat through remote e-Voting are requested to send a certified copy of the Board Resolution to the Scrutinizer by e-mail at [csbbansal@gmail.com](mailto:csbbansal@gmail.com) with a copy marked to [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in) and [cs.tejnaksh@gmail.com](mailto:cs.tejnaksh@gmail.com).
12. In case of joint holders attending the AGM, only such joint holder who is higher in the order of names will be entitled to vote.
13. Further, due to non-availability of postal and courier services, on account of the threat posed by COVID-19 and in terms of the MCA Circulars and the SEBI Circular, the Company is sending this AGM Notice along with the Annual Report for FY21 in electronic form only to those Members whose e-mail addresses are registered with the Company/Depositories. The Notice convening the AGM and the Annual Report for FY21 has been uploaded on the website of the Company at [www.tejnaksh.com](http://www.tejnaksh.com) and may also be accessed from the relevant section of the websites of the Stock Exchange i.e. BSE Limited ("BSE") at [www.bseindia.com](http://www.bseindia.com). The AGM Notice is also available on the website of NSDL at [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
14. **The Register of Members and Share Transfer Books of the Company will remain closed from Friday, 24<sup>th</sup> September 2021 to Thursday, 30<sup>th</sup> September 2021, both days inclusive.**
15. Members are requested to intimate changes, if any, pertaining to their name, postal address, e-mail address, telephone/mobile numbers, PAN, registering of nomination and power of attorney, Bank Mandate details such as name of the bank and branch details, bank account number, MICR code, IFSC code, etc., to their DP in case the shares are held in electronic form and to the RTA in case the shares are held in physical form.
16. Pursuant to Section 72 of the Companies Act, 2013, members holding shares in physical form may file nomination in the prescribed Form SH-13 and for cancellation / variation in nomination in the prescribed Form SH-14 with the Company's RTA. In respect of shares held in electronic / demat form, the nomination form may be filed with the respective Depository Participant.
17. Members desiring inspection of statutory registers during the AGM may send their request in writing to the Company at [cs.tejnaksh@gmail.com](mailto:cs.tejnaksh@gmail.com).
18. Members who wish to inspect the relevant documents referred to in the Notice can send an e-mail to [cs.tejnaksh@gmail.com](mailto:cs.tejnaksh@gmail.com) up to the date of the AGM.
19. This AGM Notice is being sent by e-mail only to those eligible Members who have already registered their e-mail address with the Depositories/the DP/the Company's RTA/the Company.
20. For permanent registration of their e-mail address, Members are requested to register their e-mail address, in respect of electronic holdings, with their concerned DP and in respect of physical holdings, with the RTA.
21. Those Members who have already registered their e-mail addresses are requested to keep their e-mail addresses validated with their DP/RTA to enable servicing of notices/ documents/Annual Reports and other communications electronically to their e-mail address in future.
22. Process and manner for Members opting for e-Voting is, as under:-
  - I. The Members can join the AGM in the VC/OAVM mode 15 minutes before and after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice. The facility of participation at the AGM through VC/OAVM will be made available for 1000 members on first come first served basis. This will not include large Shareholders (Shareholders holding 2% or more shareholding),

Promoters, Institutional Investors, Directors, Key Managerial Personnel, the Chairpersons of the Audit Committee, Nomination and Remuneration Committee and Stakeholders Relationship Committee, Auditors etc. who are allowed to attend the AGM without restriction on account of first come first served basis.

- II. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Companies Act, 2013.
- III. Pursuant to the provisions of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies (Management and Administration) Rules, 2014 (as amended) and Regulation 44 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended), and the Circulars issued by the Ministry of Corporate Affairs dated April 08, 2020, April 13, 2020 and May 05, 2020 the Company is providing facility of remote e-voting to its Members in respect of the business to be transacted at the AGM. For this purpose, the Company has entered into an agreement with National Securities Depository Limited (NSDL) for facilitating voting through electronic means, as the authorized agency. The facility of casting votes by a member using remote e-voting system as well as venue voting on the date of the AGM will be provided by NSDL.
- IV. In line with the Ministry of Corporate Affairs (MCA) Circular No. 17/2020 dated April 13, 2020, the Notice calling the AGM has been uploaded on the website of the Company at [www.tejnaksh.com](http://www.tejnaksh.com). The Notice can also be accessed from the websites of the Stock Exchange i.e. BSE Limited at [www.bseindia.com](http://www.bseindia.com) and the AGM Notice is also available on the website of NSDL (agency for providing the Remote e-Voting facility) i.e. [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
- V. AGM has been convened through VC/OAVM in compliance with applicable provisions of the Companies Act, 2013 read with MCA Circular No. 14/2020 dated April 08, 2020 and MCA Circular No. 17/2020 dated April 13, 2020 and MCA Circular No. 20/2020 dated May 05, 2020.
- VI. **The remote e-voting period commences on Monday 27<sup>th</sup> September, 2021 (9:00 am IST) and ends on Wednesday 29<sup>th</sup> September, 2021 (5:00 pm IST). During this period members' of the Company, holding shares either in physical form or in dematerialized form, as on the cut-off date i.e. 23<sup>rd</sup> September, 2021, may cast their vote by remote e-voting. The remote e-voting module shall be disabled by NSDL for voting thereafter. Once the vote on resolutions is cast by the member, the member shall not be allowed to change it subsequently.**
- VII. **THE INSTRUCTIONS FOR MEMBERS FOR REMOTE E-VOTING ARE AS UNDER:-**

**Monday 27<sup>th</sup> September, 2021 (9:00 am IST) and ends on Wednesday 29<sup>th</sup> September, 2021 (5:00 pm IST). The remote e-voting module shall be disabled by NSDL for voting thereafter. The Members, whose names appear in the Register of Members / Beneficial Owners as on the record date (cut-off date) i.e. 23<sup>rd</sup> September, 2021, may cast their vote electronically. The voting right of shareholders shall be in proportion to their share in the paid-up equity share capital of the Company as on the cut-off date, being 23<sup>rd</sup> September, 2021.**

#### **How do I vote electronically using NSDL e-Voting system?**

*The way to vote electronically on NSDL e-Voting system consists of "Two Steps" which are mentioned below:*





##### **Step 1: Access to NSDL e-Voting system**

##### **A) Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode:**

In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are advised to update their mobile number and email Id in their demat accounts in order to access e-Voting facility.

Login method for Individual shareholders holding securities in demat mode is given below:

| Type of shareholders  | Login Method  |
|---|---|
| Individual Shareholders holding securities in demat mode with NSDL. | 1. Existing <b>IDeAS</b> user can visit the e-Services website of NSDL Viz. <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a> either on a Personal Computer or on a mobile. On the e-Services home page click on the " <b>Beneficial Owner</b> " icon under " <b>Login</b> " which is available under ' <b>IDeAS</b> ' section, this will prompt you to enter your existing User ID and Password. After successful authentication, you will be able to see e-Voting services under Value added services. Click on " <b>Access to e-Voting</b> " under e-Voting services and you will be able to see e-Voting page. Click on |

|   |   |
|---|---|
|   | <p>company name or <b>e-Voting service provider i.e. NSDL</b> and you will be re-directed to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</p> <ol style="list-style-type: none"> <li>If you are not registered for IDeAS e-Services, option to register is available at <a href="https://eservices.nsdl.com">https://eservices.nsdl.com</a>. Select “<b>Register Online for IDeAS Portal</b>” or click at <a href="https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp">https://eservices.nsdl.com/SecureWeb/IdeasDirectReg.jsp</a></li> <li>Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <a href="https://www.evoting.nsdl.com/">https://www.evoting.nsdl.com/</a> either on a Personal Computer or on a mobile. Once the home page of e-Voting system is launched, click on the icon “Login” which is available under ‘Shareholder/Member’ section. A new screen will open. You will have to enter your User ID (i.e. your sixteen digit demat account number hold with NSDL), Password/OTP and a Verification Code as shown on the screen. After successful authentication, you will be redirected to NSDL Depository site wherein you can see e-Voting page. Click on company name or <b>e-Voting service provider i.e. NSDL</b> and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting &amp; voting during the meeting.</li> <li>Shareholders/Members can also download NSDL Mobile App “<b>NSDL Speede</b>” facility by scanning the QR code mentioned below for seamless voting experience.</li> </ol> <div style="text-align: center;"> <p><b>NSDL Mobile App is available on</b></p> <div style="display: flex; justify-content: space-around; align-items: center;"> <div style="text-align: center;">  <p>App Store</p> </div> <div style="text-align: center;">  <p>Google Play</p> </div> </div> <div style="display: flex; justify-content: space-around; align-items: center; margin-top: 10px;">   </div> </div> |
| <p>Individual Shareholders holding securities in demat mode with CDSL</p> | <ol style="list-style-type: none"> <li>Existing users who have opted for Easi / Easiest, they can login through their user id and password. Option will be made available to reach e-Voting page without any further authentication. The URL for users to login to Easi / Easiest are <a href="https://web.cdslindia.com/myeasi/home/login">https://web.cdslindia.com/myeasi/home/login</a> or <a href="http://www.cdslindia.com">www.cdslindia.com</a> and click on New System Myeasi.</li> <li>After successful login of Easi/Easiest the user will be also able to see the E Voting Menu. The Menu will have links of <b>e-Voting service provider i.e. NSDL</b>. Click on <b>NSDL</b> to cast your vote.</li> <li>If the user is not registered for Easi/Easiest, option to register is available at <a href="https://web.cdslindia.com/myeasi/Registration/EasiRegistration">https://web.cdslindia.com/myeasi/Registration/EasiRegistration</a></li> <li>Alternatively, the user can directly access e-Voting page by providing demat Account Number and PAN No. from a link in <a href="http://www.cdslindia.com">www.cdslindia.com</a> home page. The system will authenticate the user by sending OTP on registered Mobile &amp; Email as recorded in the demat Account. After successful authentication, user will be provided links for the respective ESP i.e. <b>NSDL</b> where the e-Voting is in progress.</li> </ol>   |



|  |  |
|--|--|
| Individual Shareholders (holding securities in demat mode) login through their depository participants | You can also login using the login credentials of your demat account through your Depository Participant registered with NSDL/CDSL for e-Voting facility. upon logging in, you will be able to see e-Voting option. Click on e-Voting option, you will be redirected to NSDL/CDSL Depository site after successful authentication, wherein you can see e-Voting feature. Click on company name or e-Voting service provider i.e. NSDL and you will be redirected to e-Voting website of NSDL for casting your vote during the remote e-Voting period or joining virtual meeting & voting during the meeting. |
|--|--|

Important note: Members who are unable to retrieve User ID/ Password are advised to use Forget User ID and Forget Password option available at abovementioned website.

Helpdesk for Individual Shareholders holding securities in demat mode for any technical issues related to login through Depository i.e. NSDL and CDSL.

| Login type   | Helpdesk details  |
|--|---|
| Individual Shareholders holding securities in demat mode with NSDL | Members facing any technical issue in login can contact NSDL helpdesk by sending a request at <a href="mailto:evoting@nsdl.co.in">evoting@nsdl.co.in</a> or call at toll free no.: 1800 1020 990 and 1800 22 44 30              |
| Individual Shareholders holding securities in demat mode with CDSL | Members facing any technical issue in login can contact CDSL helpdesk by sending a request at <a href="mailto:helpdesk.evoting@cdslindia.com">helpdesk.evoting@cdslindia.com</a> or contact at 022- 23058738 or 022-23058542-43 |

**B) Login Method for e-Voting and joining virtual meeting for shareholders other than Individual shareholders holding securities in demat mode and shareholders holding securities in physical mode.**

**How to Log-in to NSDL e-Voting website?**

1. Visit the e-Voting website of NSDL. Open web browser by typing the following URL: <https://www.evoting.nsdl.com/> either on a Personal Computer or on a mobile.
2. Once the home page of e-Voting system is launched, click on the icon "Login" which is available under 'Shareholder/Member' section.
3. A new screen will open. You will have to enter your User ID, your Password/OTP and a Verification Code as shown on the screen.  
*Alternatively, if you are registered for NSDL eservices i.e. IDEAS, you can log-in at <https://eservices.nsdl.com/> with your existing IDEAS login. Once you log-in to NSDL eservices after using your log-in credentials, click on e-Voting and you can proceed to Step 2 i.e. Cast your vote electronically.*
4. Your User ID details are given below :

| Manner of holding shares i.e. Demat (NSDL or CDSL) or Physical | Your User ID is:  |
|--|---|
| a) For Members who hold shares in demat account with NSDL.     | 8 Character DP ID followed by 8 Digit Client ID<br>For example if your DP ID is IN300*** and Client ID is 12***** then your user ID is IN300***12*****.   |
| b) For Members who hold shares in demat account with CDSL.     | 16 Digit Beneficiary ID<br>For example if your Beneficiary ID is 12***** then your user ID is 12*****.  |
| c) For Members holding shares in Physical Form.                | EVEN Number followed by Folio Number registered with the company<br>For example if folio number is 001*** and EVEN is 101456 then user ID is 101456001*** |



5. Password details for shareholders other than Individual shareholders are given below:
  - a) If you are already registered for e-Voting, then you can use your existing password to login and cast your vote.
  - b) If you are using NSDL e-Voting system for the first time, you will need to retrieve the 'initial password' which was communicated to you. Once you retrieve your 'initial password', you need to enter the 'initial password' and the system will force you to change your password.
  - c) How to retrieve your 'initial password'?
    - (i) If your email ID is registered in your demat account or with the company, your 'initial password' is communicated to you on your email ID. Trace the email sent to you from NSDL from your mailbox. Open the email and open the attachment i.e. a .pdf file. Open the .pdf file. The password to open the .pdf file is your 8 digit client ID for NSDL account, last 8 digits of client ID for CDSL account or folio number for shares held in physical form. The .pdf file contains your 'User ID' and your 'initial password'.
    - (ii) If your email ID is not registered, please follow steps mentioned below in **process for those shareholders whose email ids are not registered.**
6. If you are unable to retrieve or have not received the "Initial password" or have forgotten your password:
  - a) Click on "Forgot User Details/Password?" (If you are holding shares in your demat account with NSDL or CDSL) option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
  - b) Physical User Reset Password?" (If you are holding shares in physical mode) option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com).
  - c) If you are still unable to get the password by aforesaid two options, you can send a request at [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in) mentioning your demat account number/folio number, your PAN, your name and your registered address etc.
  - d) Members can also use the OTP (One Time Password) based login for casting the votes on the e-Voting system of NSDL.
7. After entering your password, tick on Agree to "Terms and Conditions" by selecting on the check box.
8. Now, you will have to click on "Login" button.
9. After you click on the "Login" button, Home page of e-Voting will open.

## **Step 2: Cast your vote electronically and join General Meeting on NSDL e-Voting system.**

### **How to cast your vote electronically and join General Meeting on NSDL e-Voting system?**

1. After successful login at Step 1, you will be able to see all the companies "EVEN" in which you are holding shares and whose voting cycle and General Meeting is in active status.
2. Select "EVEN" of company for which you wish to cast your vote during the remote e-Voting period and casting your vote during the General Meeting. For joining virtual meeting, you need to click on "VC/OAVM" link placed under "Join General Meeting".
3. Now you are ready for e-Voting as the Voting page opens.
4. Cast your vote by selecting appropriate options i.e. assent or dissent, verify/modify the number of shares for which you wish to cast your vote and click on "Submit" and also "Confirm" when prompted.
5. Upon confirmation, the message "Vote cast successfully" will be displayed.
6. You can also take the printout of the votes cast by you by clicking on the print option on the confirmation page.
7. Once you confirm your vote on the resolution, you will not be allowed to modify your vote.

### **General Guidelines for shareholders**

1. Institutional shareholders (i.e. other than individuals, HUF, NRI etc.) are required to send scanned copy (PDF/JPG Format) of the relevant Board Resolution/ Authority letter etc. with attested specimen signature of the duly authorized signatory(ies) who are authorized to vote, to the Scrutinizer by e-mail to [csbbansal@gmail.com](mailto:csbbansal@gmail.com) with a copy marked to [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in).

2. It is strongly recommended not to share your password with any other person and take utmost care to keep your password confidential. Login to the e-voting website will be disabled upon five unsuccessful attempts to key in the correct password. In such an event, you will need to go through the "[Forgot User Details/Password?](#)" or "[Physical User Reset Password?](#)" option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com) to reset the password.
3. In case of any queries, you may refer the Frequently Asked Questions (FAQs) for Shareholders and e-voting user manual for Shareholders available at the download section of [www.evoting.nsdl.com](http://www.evoting.nsdl.com) or call on toll free no.: 1800 1020 990 and 1800 22 44 30 or send a request to Mr. Anubhav Saxena at [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in)

**Process for those shareholders whose email ids are not registered with the depositories for procuring user id and password and registration of e mail ids for e-voting for the resolutions set out in this notice:**

1. In case shares are held in physical mode please provide Folio No., Name of shareholder, scanned copy of the share certificate (front and back), PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) by email to [cs.tejnaksh@gmail.com](mailto:cs.tejnaksh@gmail.com).
2. In case shares are held in demat mode, please provide DPID-CLID (16 digit DPID + CLID or 16 digit beneficiary ID), Name, client master or copy of Consolidated Account statement, PAN (self attested scanned copy of PAN card), AADHAR (self attested scanned copy of Aadhar Card) to [cs.tejnaksh@gmail.com](mailto:cs.tejnaksh@gmail.com). If you are an Individual shareholders holding securities in demat mode, you are requested to refer to the login method explained at **step 1 (A)** i.e. Login method for e-Voting and joining virtual meeting for Individual shareholders holding securities in demat mode.
3. Alternatively shareholder/members may send a request to [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in) for procuring user id and password for e-voting by providing above mentioned documents.
4. In terms of SEBI circular dated December 9, 2020 on e-Voting facility provided by Listed Companies, Individual shareholders holding securities in demat mode are allowed to vote through their demat account maintained with Depositories and Depository Participants. Shareholders are required to update their mobile number and email ID correctly in their demat account in order to access e-Voting facility.

**THE INSTRUCTIONS FOR MEMBERS FOR e-VOTING ON THE DAY OF THE AGM ARE AS UNDER:-**

1. The procedure for e-Voting on the day of the AGM is same as the instructions mentioned above for remote e-voting.
2. Only those Members/ shareholders, who will be present in the AGM through VC/OAVM facility and have not casted their vote on the Resolutions through remote e-Voting and are otherwise not barred from doing so, shall be eligible to vote through e-Voting system in the AGM.
3. Members who have voted through Remote e-Voting will be eligible to attend the AGM. However, they will not be eligible to vote at the AGM.
4. The details of the person who may be contacted for any grievances connected with the facility for e-Voting on the day of the AGM shall be the same person mentioned for Remote e-voting.

**INSTRUCTIONS FOR MEMBERS FOR ATTENDING THE AGM THROUGH VC/OAVM ARE AS UNDER:**

1. Member will be provided with a facility to attend the AGM through VC/OAVM through the NSDL e-Voting system. Members may access by following the steps mentioned above for **Access to NSDL e-Voting system**. After successful login, you can see link of "VC/OAVM link" placed under "**Join General meeting**" menu against company name. You are requested to click on VC/OAVM link placed under Join General Meeting menu. The link for VC/OAVM will be available in Shareholder/Member login where the EVEN of Company will be displayed. Please note that the members who do not have the User ID and Password for e-Voting or have forgotten the User ID and Password may retrieve the same by following the remote e-Voting instructions mentioned in the notice to avoid last minute rush.
2. Members are encouraged to join the Meeting through Laptops for better experience.
3. Further Members will be required to allow Camera and use Internet with a good speed to avoid any disturbance during the meeting.
4. Please note that Participants Connecting from Mobile Devices or Tablets or through Laptop connecting via Mobile Hotspot may experience Audio/Video loss due to Fluctuation in their respective network. It is therefore recommended to use Stable Wi-Fi or LAN Connection to mitigate any kind of aforesaid glitches.
5. Shareholders who would like to express their views/ask questions during the meeting may register themselves as a speaker by sending their request in advance at least 7 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at ([cs.tejnaksh@gmail.com](mailto:cs.tejnaksh@gmail.com)). The shareholders who do

not wish to speak during the AGM but have queries may send their queries in advance 7 days prior to meeting mentioning their name, demat account number/folio number, email id, mobile number at (cs.tejnakash@gmail.com). These queries will be replied to by the company suitably by email.

- VIII. **The voting rights of Members shall be in proportion to their shares of the paid-up equity share capital of the Company as on the cut-off date of Thursday, 23<sup>rd</sup> September, 2021.**
- IX. Any person, who acquires shares of the Company and become member of the Company after dispatch of the notice and holding shares as of the cut-off date i.e. 23<sup>rd</sup> September, 2021, may obtain the login ID and password by sending a request at [evoting@nsdl.co.in](mailto:evoting@nsdl.co.in) or Issuer/RTA.
- However, if you are already registered with NSDL for remote e-voting then you can use your existing user ID and password for casting your vote. If you forgot your password, you can reset your password by using “Forgot User Details/Password” or “Physical User Reset Password” option available on [www.evoting.nsdl.com](http://www.evoting.nsdl.com) or contact NSDL at the following toll free no.: 1800-222-990.
- X. A person whose name is recorded in the Register of Members or in the Register of Beneficial Owners maintained by the Depositories as on the cut-off date only shall be entitled to avail the facility of remote e-Voting, as well as voting at the meeting.
- XI. M/s. Bhuwnesh Bansal & Associates, Practicing Company Secretaries (Membership No. FCS 6526 & COP 9089), has been appointed as the Scrutinizer to conduct the voting process in a fair and transparent manner.
- XII. The Chairman shall, at the AGM, at the end of discussion on the resolutions on which voting is to be held, allow voting, by use of remote e-Voting system for all those Members who are present during the AGM through VC/OAVM but have not cast their votes by availing the remote e-Voting facility. The remote e-Voting module during the AGM shall be disabled by NSDL for voting 15 minutes after the conclusion of the Meeting.
- XIII. The Scrutinizer shall, after the conclusion of voting at the AGM, first count the votes cast during the AGM and, thereafter, unblock the votes cast through remote e-Voting and shall make, not later than 48 hours from the conclusion of the AGM, a Consolidated Scrutinizer’s Report of the total votes cast in favour or against, if any, to the Chairman or a person authorised by him in writing, who shall countersign the same and declare the result of the voting forthwith.
- XIV. The Results declared, along with the Scrutinizer’s Report, shall be placed on the Company’s website [www.tejnaksh.com](http://www.tejnaksh.com) and on the website of NSDL [www.evoting.nsdl.com](http://www.evoting.nsdl.com), immediately after the declaration of the result by the Chairman or a person authorised by him in writing. The results shall also be immediately forwarded to the Stock Exchanges where the Company’s Equity Shares are listed i.e. BSE Limited on their websites viz. [www.bseindia.com](http://www.bseindia.com).

**By Order of the Board of Directors  
For Tejnash Healthcare Limited**

**Sd/-  
Dr. Ashish Vishwas Rawandale  
Chairman**

**Mumbai, 14<sup>th</sup> August, 2021**  
**CIN- L85100MH2008PLC179034**  
**Registered Office:-**  
A 601, Floor No.6, Kailash Business Park,  
Veer Savarkar Marg, Vikroli - West,  
Mumbai - 400079  
Email - [instituteofurology@gmail.com](mailto:instituteofurology@gmail.com)  
Website:- [www.tejnaksh.com](http://www.tejnaksh.com)

## **EXPLANATORY STATEMENT:-**

As required by Section 102 of the Companies Act, 2013 (the "Act"), the following Explanatory Statement sets out all material facts relating to the business mentioned under Item Nos. 3 and 4.

### **Item No.3:- Regularization of Additional Director, Mr. Suhas Vasantrao Thorat (Din: 09241231) by appointing him as Independent Director of The Company**

The Board appointed Mr. Suhas Vasantrao Thorat (Din: 09241231) as Additional (Non-Executive – Independent) Director of the Company w.e.f. 14<sup>th</sup> August, 2021 pursuant to Section 161 of the Companies Act, 2013. Pursuant to Section 161 of the Companies Act, 2013, Mr. Suhas Vasantrao Thorat will hold the office up to the date of ensuing AGM. The Company has received from Mr. Pratap Tarachand Patil:

- Consent in writing to act as Director in Form DIR-2 pursuant to Rule 8 of the Companies (Appointment & Qualification of Directors) Rules, 2014 and;
- Intimation in Form DIR-8 in terms of Companies Appointment & Qualification of Directors) Rules, 2014, to effect that he is not disqualified under subsection (2) of Section 164 of the Companies Act, 2013 and Form MBP-1.

Mr. Suhas Vasantrao Thorat, age 54 Years is a under graduate. He is having more than 15 years of experience as a Manager and rich Knowledge of supervising and coordinating the administration. He is professional with good experience of Managerial Skills and handling team. He possesses a diverse knowledge and wide range of experience in the Managerial field.

Except Mr. Suhas Vasantrao Thorat, being appointee, none of the other Director and Key Managerial Personnel of the Company and their relatives is concerned or interested, financially or otherwise, in the resolution set out at Item No. 3 of the Notice.

Your Board recommends the above resolution at item No. 3 of the accompanying Notice for your approval.

### **Item No.4:- Authorization under Section 180 of the Companies, Act, 2013**

Keeping in view the Company's long term strategic and business objectives, the Company may need additional funds. For this purpose, the Company may, from time to time, raise finance from various Banks and/or Financial Institutions and/ or any other lending institutions and/or Bodies Corporate and/or such other persons/ individuals as may be considered fit, which, together with the moneys already borrowed by the Company (apart from temporary loans obtained from the Company's bankers in ordinary course of business) may exceed the aggregate of the paid-up capital and free reserves of the Company. Pursuant to Section 180(1)(c) of the Companies Act, 2013, the Board of Directors cannot borrow more than the aggregate amount of the paid-up capital of the Company and its free reserves at any one time except with the consent of the members of the Company in a general meeting. In order to facilitate securing the borrowing made by the Company, it would be necessary to create charge on the assets or whole or part of the undertaking of the Company. Further, Section 180(1)(a) of the Companies Act, 2013 provides for the power to sell, lease or otherwise dispose of the whole or substantially the whole of the undertaking of the Company subject to the approval of members in the General Meeting.

The above proposal is in the interest of the Company and the Board recommends the Resolution as set out at Item No.4 for approval by the members of the Company.

None of the Directors or Key Managerial Personnel or their relatives are in any way concerned with or interested, financially or otherwise in the resolution at Item no. 5 of the accompanying notice. The Board recommends the resolution at Item no.4 to be passed as Special Resolution.

**By Order of the Board of Directors  
For Tejnakhsh Healthcare Limited**

**Sd/-  
Dr. Ashish Vishwas Rawandale  
Chairman**

**Mumbai, 14<sup>th</sup> August, 2021**  
**CIN- L85100MH2008PLC179034**  
**Registered Office:-**  
A 601, Floor No.6, Kailash Business Park,  
Veer Savarkar Marg, Vikroli - West,  
Mumbai - 400079  
Email - instituteofurology@gmail.com  
Website:- www.tejnakhsh.com

## ANNEXURE TO THE NOTICE

### **Details of Directors seeking appointment / re-appointment at the 14<sup>th</sup> Annual General Meeting.**

(In pursuance of Regulations 26(4) and 36(3) of the Listing Regulations and Secretarial Standard-2 on General Meetings)

#### **Item No.2 of the Notice**

##### **Mr. SANJAY BHIKAJIRAO KHATAL (DIN:- 06616883)**

|  |   |
|--|---|
| Name of the Director   | Mr. Sanjay Bhikajirao Khatal  |
| Director Identification Number (DIN)   | 06616883  |
| Designation  | Director  |
| Date of Appointment  | 13th July, 2020   |
| Date of Birth  | 20/09/1958  |
| Qualification  | B.Tech (Agricultural - Engineering)   |
| Expertise in specific functional areas   | He has a distinguished career over a Span of 39 Years. Being a Technocrat he has wide Administrative and Technical Experience. Additionally he has served teaching stint for Agri, Business Management students as a full time Faculty with Symbiosis Institute of International Business, Pune. He is vivid reader and traveler. He believes in team work with dedication and honesty as special attributes. |
| Relationship between Directors inter-se  | N.A.  |
| Directorship held in other listed Companies  | NIL   |
| Membership/Chairmanships of committees of other public companies (Includes only Audit Committee and Stakeholders Relationship Committee) | NIL   |
| Shareholding in the Company  | 44160 Equity Shares   |

#### **Item No. 3 of the Notice**

##### **MR. SUHAS VASANTRAO THORAT (DIN: 09241231)**

|  |  |
|--|--|
| Name of the Director   | Mr. SUHAS VASANTRAO THORAT   |
| Director Identification Number (DIN)   | 09241231   |
| Designation  | Director   |
| Date of Appointment  | 14/08/2021   |
| Date of Birth  | 28/12/1966   |
| Qualification  | Undergraduate  |
| Expertise in specific functional areas   | He is having more than 15 years of experience as a Manager and rich Knowledge of supervising and coordinating the administration. He is professional with good experience of Managerial Skills and handling team. He possesses a diverse knowledge and wide range of experience in the Managerial field. |
| Relationship between Directors inter-se  | N.A.   |
| Directorship held in other listed Companies  | NIL  |
| Membership/Chairmanships of committees of other public companies (Includes only Audit Committee and Stakeholders Relationship Committee) | NIL  |
| Shareholding in the Company  | NIL  |

**By Order of the Board of Directors  
For Tejnakh Healthcare Limited**

**Sd/-  
Dr. Ashish Vishwas Rawandale  
Chairman  
Mumbai, 14<sup>th</sup> August, 2021**

## DIRECTORS' REPORT

Dear Members,

The Directors of your Company have pleasure in presenting Annual Report together with the Audited Accounts and Auditors' Report for the year ended 31<sup>st</sup> March, 2021.

### 1. Financial Performance:-

The financial performance of the Company for the Year ended 31<sup>st</sup> March, 2021 is as summarized below:-

(In Lacs)

| Particulars                                       | Standalone    |                | Consolidated   |                |
|---|---------------|----------------|----------------|----------------|
|   | 2020-21       | 2019-20        | 2020-21        | 2019-20        |
| <b>Total Revenue</b>                              | <b>871.15</b> | <b>1198.15</b> | <b>1209.86</b> | <b>1745.76</b> |
| Profit before Interest, Depreciation & Taxation   | 373.83        | 404.17         | 385.07         | 438.09         |
| Less – Interest                                   | 53.63         | 79.52          | 50.21          | 76.10          |
| Profit / (Loss) before Depreciation & Taxation    | 320.20        | 324.65         | 334.86         | 361.99         |
| Less – Depreciation                               | 61.19         | 58.59          | 68.05          | 65.44          |
| Profit / (Loss) before tax                        | 259.01        | 266.06         | 266.80         | 296.55         |
| Less– Provision for Taxation (Incl. Deferred Tax) | 58.59         | 73.71          | 59.88          | 81.99          |
| <b>Net Profit / (Loss) for the year</b>           | <b>200.42</b> | <b>192.35</b>  | <b>209.92</b>  | <b>214.56</b>  |

### 2. Performance Review:-

Your directors report that for the year under review, your Company has been able to achieve total revenue of Rs. 871.15 Lakhs as compared to Rs. 1198.15 Lakhs in the previous year. The total revenue for the year 2020-21 decreased by 27.29% and Net Profit has increased from Rs. 192.35 Lakhs to Rs. 200.42 Lakhs.

### 3. Extract of Annual Return:-

The Extract of Annual Return is prepared in Form MGT-9 as per the provisions of the Companies Act, 2013 and Rule 12 of Companies (Management and Administration) Rules, 2014 and the same is enclosed as **Annexure - I** to this Report.

### 4. Capital Structure:-

During the year under review, there is no change in the Authorized Share Capital of the Company. The Authorised Share Capital of the Company is Rs. 10,50,00,000 (Rupees Ten Crore Fifty Lacs) divided into 1,05,00,000 (One Crore Five Lakhs) Equity Shares of Rs.10/- each.

During the year under review, there is no change in the Paid up Equity Share Capital of the Company. The paid up share capital of the Company is 10,15,68,000 (Rupees Ten Crore Fifteen Lakhs Sixty Eight Thousand) divided into 1,01,56,800 (One Crore One Lakh Fifty Six Thousand Eight Hundred) Equity Shares of Rs. 10/- each.

### 5. Bonus Issue:-

During the year under review, the Company has not issued any Bonus shares.

### 6. Dividend:-

Your Directors do not recommend any dividend for the year under review.

### 7. Reserve:-

The Company has transferred current year's profit of Rs. 200.42 Lakhs to the Reserve & Surplus and the same is in Compliance with the applicable provisions prescribed under the Companies Act, 2013.

### 8. Board of Directors:-

The Company has following composition of the Board

| Sr. No | Name of the Directors              | Designation                              |
|--------|------------------------------------|--|
| 1      | Dr. Ashish Vishwas Rawandale       | Executive Director-Chairperson           |
| 2      | Dr. Preeti Ashish Rawandale        | Non-Executive - Non Independent Director |
| 3      | Mr. Kiran Madhavrao Pawar          | Non-Executive - Independent Director     |
| 4      | Mr. Vikramsinh Satish Khatal Patil | Non-Executive - Independent Director     |
| 5      | Mr. Sanjay Bhikajirao Khatal       | Non-Executive - Non Independent Director |
| 6*     | Mr. Pratap Tarachand Patil         | Non-Executive - Independent Director     |
| 7#     | Mr. Suhas Thorat                   | Non-Executive - Independent Director     |

\* Mr. Pratap Tarachand Patil resigned from the Company on 09.06.2021

# Mr. Suhas Thorat appointed Additional Director of the Company w.e.f. 14.08.2021

#### **Director Retiring by Rotation**

Mr. Sanjay Bhikajirao Khatal (DIN: 06616883) Director, retire from the Board by rotation and being eligible has offered himself for re-appointment at the ensuing Annual General Meeting.

#### **Formal Annual Evaluation:**

The Board has formulated a code of conduct policy for formal annual evaluation purpose which has been made by the Board of its own performance and that of its committees and individual directors.

9. **Company Secretary and Compliance Officer:-** There is no change in Company Secretary and Compliance officer during the Year. CS Prakash Sogam (Membership No. A42727) is a Company Secretary and Compliance Officer of the Company since 16<sup>th</sup> July, 2018.

#### **10. Directors' Responsibility Statement:-**

Your Directors state that: -

- In the preparation of the annual accounts for the financial year 2020-21, the applicable accounting standards read with requirements set out under Schedule III of the Companies Act, 2013, have been followed and there are no material departures from the same;
- Appropriate accounting policies have been selected and applied consistently and such judgments & estimates have been made that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at 31<sup>st</sup> March, 2021 and of the Profit of the Company for the accounting year ended on that date;
- Proper & sufficient care has been taken for the maintenance of adequate accounting records in accordance with the provisions of the Companies Act, 2013 for safeguarding the assets of the Company and for preventing & detecting fraud and other irregularities; and
- The annual accounts of the Company have been prepared on a going concern basis.
- The Directors had devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems were adequate and operating effectively.
- The Directors had laid down internal financial controls to be followed by the company and that such internal financial controls are adequate and were operating effectively.

#### **11. Auditors:-**

At 12<sup>th</sup> Annual General Meeting held on 30<sup>th</sup> September, 2019 the members approved appointment of M/s. P.D. Dalal & Co., Chartered Accountants, as a Statutory Auditors of the Company to holds office till the conclusion of the 17<sup>th</sup> Annual General Meeting of the Company subject to ratification of their appointment by Members at every AGM, if so required under the Act. The requirement to place the matter relating to appointment of auditors for ratification by Members at every AGM has been done away by the Companies (Amendment) Act, 2017 with effect From May 7, 2018. Accordingly, no resolution is being proposed for ratification of appointment of statutory auditors at the 14<sup>th</sup> Annual General Meeting.



The observations and comments given in the Auditors Report read together with the notes to the accounts are self-explanatory and hence do not call for any further information and explanation under section 134(3) of the Companies Act, 2013.

**12. Auditors' Report:-**

The Notes on Financial statement referred to in the Auditors report are self – explanatory and do not call for any further comments. The Auditors Report does not contain any qualification, reservation or adverse remark.

**13. Subsidiary Company:-**

The Company has one Subsidiary Company in the name of Tej Vedaant Healthcare Private Limited.

**14. Secretarial Auditors Report:-**

As per the provisions of Section 204 of the Companies Act, 2013, the Board of Directors of the Company has appointed M/s. Bhunwesh Bansal & Associates, Practicing Company Secretary firm (FCS -6526 & COP.No: 9089) as Secretarial Auditor to conduct Secretarial audit of the Company for the financial year ended on March 31, 2021. Secretarial Audit Report issued by M/s. Bhunwesh Bansal & Associate, Practicing Company Secretary firm in form MR-3 is enclosed as **Annexure - II** to this Annual Report.

**15. Tax Provisions:-**

The Company has made adequate provisions as required under the provisions of Income Tax Act, 1961 as well as other relevant laws governing taxation on the company.

**16. Fixed Deposits:-**

The Company has not accepted any deposits from the public in terms of Section 73 of the Companies Act, 2013 and the Companies (Acceptance of Deposits) Rules, 2014.

**17. Conservation of energy, technology absorption and foreign exchange earnings and outgo:-**

The particular as prescribed under sub-Section (3)(m) of section 134 of the Companies Act, 2013 read with Rule 8(3) the Companies (Accounts) Rules, 2014,

(i) Part A and B of the Rules, pertaining to conservation of energy and technology absorption, are not applicable to the Company.

(ii) Foreign Exchange Earnings and Outgo:

Foreign Exchange Earned - Rs. Nil

Foreign Exchange Used - Rs. Nil

**18. Corporate Social Responsibility:-**

The Company is not required to constitute a Corporate Social Responsibility Committee as it does not fall within purview of Section 135(1) of the Companies Act, 2013 and hence it is not required to formulate policy on Corporate Social Responsibility.

**19. Disclosure under the Sexual harassment Of Women:-**

Your Company is committed to provide and promote safe and healthy environment to all its employees without any discrimination. During the year under review there was no case filled pursuant to Sexual Harassment of women at workplace (Prevention, Prohibition and Redressal) Act, 2013.

**20. Change in Nature of Business , if Any:-**

There is no change in the nature of business of the Company during the year under review.

**21. Particulars of Employees:-**

Disclosures with respect to the remuneration of Directors and employees as required under Section 197 of Companies Act, 2013 and Rule 5 (1) Companies (Appointment and Remuneration of Managerial Personnel), 2014 has been appended as Annexure to this Report. The information as required under Rule 5 (2) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 will be provided upon request by any member of the Company. In terms of Section 136 (1) of the Companies Act, 2013, the Report and the Accounts are being sent to the members excluding the said Annexure. Any member interested in obtaining copy of the same may write to the Company Secretary at the Registered Office of the Company.

**22. Number of Meetings of the Board of Directors:-**

During the year ended March 31, 2021, Five (5) Board Meetings were held. The dates on which the Board meetings were held are 30.06.2020, 13.07.2020, 15.09.2020, 13.11.2020 and 13.02.2021.

**23. Statement on Declaration Given By Independent Directors Under Sub-Section (6) Of Section 149:-**

The independent directors have submitted the declaration of independence, as required pursuant to Section 149(7) of the Companies Act, 2013 stating that they meet the criteria of independence as provided in sub-Section(6).

**24. Particulars of Loan, Guarantees And Investments By Company:-**

During the financial year ended March 31, 2021, no loan, guarantee and investment under Section 186 of the Companies Act, 2013 was made by the Company.

**25. Related Party Transactions:-**

During the year under review, besides the transactions reported in Notes to Accounts, forming part of the Annual Report. There were no other related party transactions with its promoters, directors, directors and management that had a potential conflict of interest of the Company at large.

**26. Significant And Material Orders Passed By The Regulators or Court:-**

There are no Significant and Material orders passed by the regulators or Courts that would impact the going concern status of the Company and its future operations.

**27. Audit Committee:-**

In accordance with the provisions of Section 177 of the Companies Act, 2013 the Company has constituted an Audit Committee comprising of the following Directors viz., Mr. Vikramsingh Satish Khatal Patil (Chairman), Mr. Kiran Madhavrao Pawar, Dr. Ashish Vishwas Rawandale and Mr. Pratap Tarachand Patil\*. Audit Committee acts in accordance with the terms of reference specified from time to time by the Board.

\* Mr. Pratap Tarachand Patil appointed on 13.02.2021 and resigned from the committee on 09.06.2021

There is no such incidence where Board has not accepted the recommendation of the Audit Committee during the year under review.

During the year 2020-21, Four (4) Audit Committee meetings were held on 13.07.2020, 15.09.2020, 13.11.2020, and 13.02.2021.

**28. Nomination and Remuneration Committee:-**

In accordance with the provisions of Section 178(1) of the Companies Act, 2013, the Company has constituted a Nomination and Remuneration Committee comprising of the following Directors viz., Mr. Kiran Madhavrao Pawar (Chairman), Mr. Vikramsingh Satish Khatal Patil, Dr. Preeti Ashish Rawandale and Mr. Pratap Tarachand Patil\*.

\* Mr. Pratap Tarachand Patil appointed on 13.02.2021 and resigned from the committee on 09.06.2021

Nomination and Remuneration Committee acts in accordance with the terms of reference specified from time to time by the Board.

During the year 2020-21, Four (4) Nomination and Remuneration Committee was held on 13.07.2020, 15.09.2020, 13.11.2020, and 13.02.2021.

**29. Stakeholders Relationship Committee:-**

In accordance with the provisions of Section 178(5) of the Companies Act, 2013, the Company has constituted a Stakeholders Relationship Committee comprising of the following Directors viz., Mr. Kiran Madhavrao Pawar (Chairman), Mr. Vikramsingh Satish Khatal Patil, Dr. Preeti Ashish Rawandale and Mr. Pratap Tarachand Patil\*. Stakeholders Relationship Committee acts in accordance with the terms of reference specified from time to time by the Board.

\* Mr. Pratap Tarachand Patil appointed on 13.02.2021 and resigned from the committee on 09.06.2021

During the year 2020-21, Four (4) Nomination and Remuneration Committee was held on 13.07.2020, 15.09.2020, 13.11.2020, and 13.02.2021.

**30. Details in Respect of Adequacy of Internal Financial Controls with Reference to the Financial Statement:-**

Internal Control Systems has been designed to provide reasonable assurance that assets are safeguarded, transactions are executed in accordance's with management's authorization and properly recorded and accounting records are adequate for preparation of financial statements and other financial information. Internal check is conducted on a periodical basis to ascertain the adequacy and effectiveness of internal control systems.

Further, the testing of such controls shall also be carried out independently by the Statutory Auditors as mandated under the provisions of the Companies Act, 2013.

In the opinion of the Board, the existing internal control framework is adequate and commensurate to the size and nature of the business of the Company.

**31. Risk Management Policy:-**

The Company has established a well-defined process of risk management, wherein the identification, analysis and assessment of the various risks, measuring of the probable impact of such risks, formulation of risk mitigation strategy and implementation of the same takes place in a structured manner. Though the various risks associated with the business cannot be eliminated completely, all efforts are made to minimize the impact of such risks on the operations of the Company. The Company on various activities also puts necessary internal control systems in place across the board to ensure that business operations are directed towards attaining the stated organizational objectives with optimum utilization of the resources.

**32. Nomination And Remuneration policy of Directors, Key Managerial Personnel And other Employees:-**

In adherence of Section 178(1) of the Companies Act, 2013, the Board of Directors of the Company in its Meetings, approved a policy on directors' appointment and remuneration including criteria for determining qualifications, positive attributes, independence of a director and other matters provided u/s 178(3), based on the recommendations of the Nomination and Remuneration Committee. The broad parameters covered under the Policy are – Company Philosophy, Guiding Principles, Nomination of Directors, Remuneration of Directors, Nomination and Remuneration of the Key Managerial Personnel (other than managing/ Whole-time Directors), Key-Executives and Senior Management and the Remuneration of Other Employees.

**33. Management's Discussion and Analysis Report:-**

A detailed review of the operations, performance and future outlook of the Company and its businesses is given in the Management's Discussion and Analysis Report i.e **Annexure III**, which forms part of this Report.

**34. Corporate Governance:-**

We adhere to the principle of Corporate Governance mandated by the Securities and Exchange Board of India (SEBI) and have implemented all the prescribed stipulations. As required by Regulation 27 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, a detailed report on Corporate Governance forms part of this Report. The Auditors' Certificate on compliance with Corporate Governance requirements by the Company is enclosed in **Annexure IV**, which forms part of this report.

**35. Acknowledgement:-**

The Board wishes to place on record its sincere appreciation for the assistance and co-operation received from Bankers, Government Departments and other Business Associates for their continued support towards the conduct of operations of the Company efficiently.

The Directors express their gratitude to the shareholders for their continuing confidence in the Company. The Directors also acknowledge the hard work and persuasive efforts put in by the employees of the Company in carrying forward Company's vision and mission.

**On behalf of the Board of Directors,  
For Tejnakh Healthcare Limited**

**Sd/-  
Dr. Ashish Vishwas Rawandale  
Chairman**

**Place: Mumbai,  
Date: 29.06.2021**

## Annexures- I

**FORM NO. MGT-9**  
**EXTRACT OF ANNUAL RETURN**

**As on the financial year ended on 31<sup>st</sup> March, 2021**

[Pursuant to section 92(3) of the Companies Act, 2013 and rule 12(1) of the Companies (Management and Administration) Rules, 2014]

**I. REGISTRATION AND OTHER DETAILS:**

|             |   |  |
|-------------|---|--|
| <b>i.</b>   | CIN   | L85100MH2008PLC179034  |
| <b>ii.</b>  | Registration Date   | 18 <sup>th</sup> February, 2008  |
| <b>iii.</b> | Name of the Company   | Tejnaksh Healthcare Limited  |
| <b>iv.</b>  | Category / Sub-Category of the Company                                    | Public Company - Limited by Shares   |
| <b>v.</b>   | Address of the Registered office and Contact Details                      | A 601, Floor No.6, Kailash Business Park, Veer Savarkar Marg, Vikroli - West, Mumbai - 400079 Tel: 022-2754 2311<br>Email - instituteofurology@gmail.com |
| <b>vi.</b>  | Whether listed company  | Yes  |
| <b>vii.</b> | Name, Address and Contact details of Registrar and Transfer Agent, if any | M/s. Cameo Corporate Services Ltd.<br>Submaramanian Building,<br>1 Club House Road, Chennai 600 002.<br>Tel No.: +91-44-2846 0390/1989                   |

**II. PRINCIPAL BUSINESS ACTIVITIES OF THE COMPANY**

All the business activities contributing 10 % or more of the total turnover of the company shall be stated:-

| Sr. No | Name and Description of main products / services | NIC Code of the Product/ service | % to total turnover of the Company |
|--------|--|----------------------------------|------------------------------------|
| 1.     | Healthcare Services and Pharmacies               | 86100                            | 98.24                              |

**III. PARTICULARS OF HOLDING, SUBSIDIARY AND ASSOCIATE COMPANIES -**

| Sr.No | Name and Address of The Company  | CIN/GIN               | Holding/ Subsidiary / Associate | % of Shares Held | Applicable Section |
|-------|--|-----------------------|---------------------------------|------------------|--------------------|
| 1.    | <b>Tej Vedaant Healthcare Private Limited</b><br>A 601, Floor No.6,<br>Kailash Business Park,<br>Veer Savarkar Marg,<br>Vikroli - West, Mumbai - 400079. | U85100MH2016PTC288972 | Subsidiary                      | 75.00%           | Section 2(87)      |

**IV. SHARE HOLDING PATTERN (Equity Share Capital Breakup as percentage of Total Equity)****i) Category-wise Share Holding**

| Category of Shareholders | No. of Shares held at the beginning of the year<br>31/03/2020 |          |           |                   | No. of Shares held at the end of the year<br>31/03/2021 |          |         |                   | % of Change during the year |
|--------------------------|---|----------|-----------|-------------------|---|----------|---------|-------------------|-----------------------------|
|                          | Demat   | Physical | Total     | % of Total TOTSHR | Demat   | Physical | Total   | % of Total TOTSHR |                             |
| <b>A. Promoters</b>      |   |          |           |                   |   |          |         |                   |                             |
| (1) <b>Indian</b>        |   |          |           |                   |   |          |         |                   |                             |
| (a) Individuals/ HUF     | 38,73,201   | 0        | 38,73,201 | 38.14             | 3874601   | 0        | 3874601 | 38.15             | 0.01                        |

|   |                  |          |                  |              |                  |          |                  |              |             |
|---|------------------|----------|------------------|--------------|------------------|----------|------------------|--------------|-------------|
| (b) Central Govt  | 0                | 0        | 0                | 0            | 0                | 0        | 0                | 0            | 0           |
| (c) State Govt(s)   | 0                | 0        | 0                | 0            | 0                | 0        | 0                | 0            | 0           |
| (d) Bodies Corp.  | 0                | 0        | 0                | 0            | 0                | 0        | 0                | 0            | 0           |
| (e) Banks / FI  | 0                | 0        | 0                | 0            | 0                | 0        | 0                | 0            | 0           |
| (f) Any Other....   |                  |          |                  |              |                  |          |                  |              |             |
| * Directors   | 36,08,966        | 0        | 36,08,966        | 35.53        | 36,08,966        | 0        | 36,08,966        | 35.53        | 0.00        |
| * Directors Relatives                                     | 16,018           | 0        | 16,018           | 0.16         | 16,018           | 0        | 16,018           | 0.16         | 0.00        |
| * Person Acting In Concern                                | 0                | 0        | 0                | 0            | 0                | 0        | 0                | 0            | 0           |
| <b>Sub Total (A)(1):-</b>                                 | <b>74,98,185</b> | <b>0</b> | <b>74,98,185</b> | <b>73.83</b> | <b>74,99,585</b> | <b>0</b> | <b>74,99,585</b> | <b>73.84</b> | <b>0.01</b> |
| <b>(2) Foreign</b>  |                  |          |                  |              |                  |          |                  |              |             |
| (a) NRI Individuals                                       | 0                | 0        | 0                | 0            | 0                | 0        | 0                | 0            | 0           |
| (b) Other Individuals                                     |                  |          |                  |              |                  |          |                  |              |             |
| (c) Bodies Corp.  | 0                | 0        | 0                | 0            | 0                | 0        | 0                | 0            | 0           |
| (d) Banks / FI  | 0                | 0        | 0                | 0            | 0                | 0        | 0                | 0            | 0           |
| (e) Any Other....   |                  |          |                  |              |                  |          |                  |              |             |
| <b>Sub Total (A)(2):-</b>                                 | <b>0</b>         | <b>0</b> | <b>0</b>         | <b>0</b>     | <b>0</b>         | <b>0</b> | <b>0</b>         | <b>0</b>     | <b>0</b>    |
| <b>Total shareholding of Promoter (A) = (A)(1)+(A)(2)</b> | <b>74,98,185</b> | <b>0</b> | <b>74,98,185</b> | <b>73.83</b> | <b>74,99,585</b> | <b>0</b> | <b>74,99,585</b> | <b>73.84</b> | <b>0.01</b> |
| <b>B. Public Shareholding</b>                             |                  |          |                  |              |                  |          |                  |              |             |
| <b>(1) Institutions</b>                                   |                  |          |                  |              |                  |          |                  |              |             |
| (a) Mutual Funds  | 0                | 0        | 0                | 0            | 0                | 0        | 0                | 0            | 0           |
| (b) Banks FI  | 0                | 0        | 0                | 0            | 0                | 0        | 0                | 0            | 0           |
| (c) Central Govt  | 0                | 0        | 0                | 0            | 0                | 0        | 0                | 0            | 0           |
| (d) State Govet(s)  | 0                | 0        | 0                | 0            | 0                | 0        | 0                | 0            | 0           |
| (e) Venture Capital Funds                                 | 0                | 0        | 0                | 0            | 0                | 0        | 0                | 0            | 0           |
| (f) Insurance Companies                                   | 0                | 0        | 0                | 0            | 0                | 0        | 0                | 0            | 0           |
| (g) FIIs  | 0                | 0        | 0                | 0            | 0                | 0        | 0                | 0            | 0           |
| (h) Foreign Venture Capital Funds                         | 0                | 0        | 0                | 0            | 0                | 0        | 0                | 0            | 0           |
| (i) Others (specify)                                      |                  |          |                  |              |                  |          |                  |              |             |
| <b>Sub-total (B)(1):-</b>                                 | <b>0</b>         | <b>0</b> | <b>0</b>         | <b>0</b>     | <b>0</b>         | <b>0</b> | <b>0</b>         | <b>0</b>     | <b>0</b>    |
| <b>(2) Non-</b>   |                  |          |                  |              |                  |          |                  |              |             |

|  |                    |          |                    |              |                    |          |                    |              |               |
|--|--------------------|----------|--------------------|--------------|--------------------|----------|--------------------|--------------|---------------|
| <b>Institutions</b>  |                    |          |                    |              |                    |          |                    |              |               |
| (a) Bodies Corp.   |                    |          |                    |              |                    |          |                    |              |               |
| (i) Indian   | 0                  | 0        | 0                  | 0            | 0                  | 0        | 0                  | 0            | 0             |
| (ii) Overseas  | 0                  | 0        | 0                  | 0            | 0                  | 0        | 0                  | 0            | 0             |
| (b) Individuals  |                    |          |                    |              |                    |          |                    |              |               |
| (i) Individual shareholders holding nominal share capital upto Rs. 1 lakh          | 4,16,846           | 0        | 4,16,846           | 4.10         | 501,450            | 0        | 501,450            | 4.94         | 0.83          |
| (ii) Individual shareholders holding nominal share capital in excess of Rs. 1 lakh | 19,79,636          | 0        | 19,79,636          | 19.49        | 18,78,256          | 0        | 18,78,256          | 18.49        | (1.00)        |
| (c) Others (specify)   |                    |          |                    |              |                    |          |                    |              |               |
| Non Resident Indian (NRI)  | 1,31,145           | 0        | 1,31,145           | 1.29         | 1,11,695           | 0        | 1,11,695           | 1.10         | (0.19)        |
| Bodies Corporate   | 91,445             | 0        | 91,445             | 0.90         | 80,898             | 0        | 80,898             | 0.80         | (0.10)        |
| Clearing Member  | 103                | 0        | 103                | 0.00         | 16,856             | 0        | 16,856             | 0.17         | (0.16)        |
| Hindu Undivided Family   | 39,440             | 0        | 39,440             | 0.39         | 68,060             | 0        | 68,060             | 0.67         | 0.28          |
| <b>Sub-total (B)(2):-</b>  | <b>26,58,615</b>   | <b>0</b> | <b>26,58,615</b>   | <b>26.18</b> | <b>26,57,215</b>   | <b>0</b> | <b>26,57,215</b>   | <b>26.16</b> | <b>(0.01)</b> |
| <b>Total Public Shareholding (B) = (B)(1)+(B)(2)</b>                               | <b>26,58,615</b>   | <b>0</b> | <b>26,58,615</b>   | <b>26.18</b> | <b>26,57,215</b>   | <b>0</b> | <b>26,57,215</b>   | <b>26.16</b> | <b>(0.01)</b> |
| <b>C. TOTSHR held by Custodian for GDRs &amp; ADRs</b>                             | <b>0</b>           | <b>0</b> | <b>0</b>           | <b>0</b>     | <b>0</b>           | <b>0</b> | <b>0</b>           | <b>0</b>     | <b>0</b>      |
| <b>Grand Total(A + B + C)</b>  | <b>1,01,56,800</b> | <b>0</b> | <b>1,01,56,800</b> | <b>100</b>   | <b>1,01,56,800</b> | <b>0</b> | <b>1,01,56,800</b> | <b>100</b>   | <b>0</b>      |

**(ii) Shareholding of Promoters and Promoters group**

| S. No | Shareholder's Name           | Shareholding at the beginning of the year |                                  |  | Shareholding at the end of the year |                                  |  | % change in shareholding during the year# |
|-------|------------------------------|---|----------------------------------|--|-------------------------------------|----------------------------------|--|---|
|       |                              | No. of shares                             | % of total Shares of the company | % of Shares Pledged / Encumbered to total shares | No. of shares                       | % of total Shares of the company | % of Shares Pledged / encumbered to total shares |   |
| 1     | Dr. Ashish Vishwas Rawandale | 38,73,201                                 | 38.13                            | 0  | 38,74,601                           | 38.15                            | 0  | 0.01                                      |
| 2     | Dr. Preeti Ashish Rawandale  | 36,08,966                                 | 35.53                            | 0  | 36,08,966                           | 35.53                            | 0  | 0.00                                      |
| 3     | Mr. Utkarsh V. Rawandale     | 9   | 0.00                             | 0  | 9                                   | 0.00                             | 0  | 0   |
| 4     | Ms. Pramila Bai Rawandale    | 16,009                                    | 0.16                             | 0  | 16,009                              | 0.16                             | 0  | 0.00                                      |



# Change in shareholding during the year is due to acquisition of shares on different dates in open market.

(iii). Change in Promoters' Shareholding

|       |  | Shareholding at the beginning of the year |                                  | Cumulative Shareholding during the year |                                  |                  |            |
|-------|--|---|----------------------------------|---|----------------------------------|------------------|------------|
| SI No | Name of the Share holder                 | No of shares                              | % of total shares of the company | No of shares                            | % of total shares of the company | FOLIO/DP_C L_ID  | PAN        |
|       |  |   |                                  |   |                                  |                  |            |
| 1     | ASHISH VISHWAS RAWANDALE                 |   |                                  |   |                                  |                  |            |
|       | At the beginning of the year 01-Apr-2020 | 3873201                                   | 38.1340                          | 3873201                                 | 38.1340                          | IN30021418275731 | ADNPR0113M |
|       | Purchase 10-Apr-2020                     | 1400                                      | 0.0137                           | 3874601                                 | 38.1478                          |                  |            |
|       | At the end of the Year 31-Mar-2021       | 3874601                                   | 38.1478                          | 3874601                                 | 38.1478                          |                  |            |
|       |  |   |                                  |   |                                  |                  |            |
| 2     | PREETI ASHISH RAWANDALE                  |   |                                  |   |                                  |                  |            |
|       | At the beginning of the year 01-Apr-2020 | 3608966                                   | 35.5325                          | 3608966                                 | 35.5325                          | IN30021418254987 | AEJPR5236E |
|       | At the end of the Year 31-Mar-2021       | 3608966                                   | 35.5325                          | 3608966                                 | 35.5325                          |                  |            |
|       |  |   |                                  |   |                                  |                  |            |
| 3     | PRAMILA VISHWASRAO PATIL                 |   |                                  |   |                                  |                  |            |
|       | At the beginning of the year 01-Apr-2020 | 16009                                     | 0.1576                           | 16009                                   | 0.1576                           | IN30021418848343 | AGBPP0107G |
|       | At the end of the Year 31-Mar-2021       | 16009                                     | 0.1576                           | 16009                                   | 0.1576                           |                  |            |
|       |  |   |                                  |   |                                  |                  |            |
| 4     | UTKARSH VISHWAS RAWANDALE                |   |                                  |   |                                  |                  |            |
|       | At the beginning of the year 01-Apr-2020 | 9   | 0.0000                           | 9                                       | 0.0000                           | IN30021416888550 | AEJPR5271B |
|       | At the end of the Year 31-Mar-2021       | 9   | 0.0000                           | 9                                       | 0.0000                           |                  |            |

(iii) Shareholding Pattern of top ten Shareholders (other than Directors and Promoters):

|       |                              | Shareholding at the beginning of the year |                                  | Cumulative Shareholding during the year |                                  |                 |         |
|-------|------------------------------|---|----------------------------------|---|----------------------------------|-----------------|---------|
| SI No | Name of the Share holder     | No of shares                              | % of total shares of the company | No of shares                            | % of total shares of the company | FOLIO/DP_C L_ID | PAN     |
|       |                              |   |                                  |   |                                  |                 |         |
| 1     | SANDEEP ACHYUTRAO CHAVAN     |   |                                  |   |                                  |                 |         |
|       | At the beginning of the year | 299920                                    | 2.9528                           | 299920                                  | 2.9528                           | IN300214184     | ABAPC16 |

|   |  |        |        |        |        |                  |            |
|---|--|--------|--------|--------|--------|------------------|------------|
|   | 01-Apr-2020                              |        |        |        |        | 16224            | 41A        |
|   | Sale 31-Dec-2020                         | -25000 | 0.2461 | 274920 | 2.7067 |                  |            |
|   | Sale 08-Jan-2021                         | -13000 | 0.1279 | 261920 | 2.5787 |                  |            |
|   | Sale 15-Jan-2021                         | -30080 | 0.2961 | 231840 | 2.2826 |                  |            |
|   | Sale 22-Jan-2021                         | -8367  | 0.0823 | 223473 | 2.2002 |                  |            |
|   | Sale 19-Feb-2021                         | -21858 | 0.2152 | 201615 | 1.9850 |                  |            |
|   | Sale 12-Mar-2021                         | -3918  | 0.0385 | 197697 | 1.9464 |                  |            |
|   | Sale 19-Mar-2021                         | -1430  | 0.0140 | 196267 | 1.9323 |                  |            |
|   | At the end of the Year 31-Mar-2021       | 196267 | 1.9323 | 196267 | 1.9323 |                  |            |
|   |  |        |        |        |        |                  |            |
| 2 | PRASHANT JANARDAN MORE                   |        |        |        |        |                  |            |
|   | At the beginning of the year 01-Apr-2020 | 241040 | 2.3731 | 241040 | 2.3731 | IN30021418416216 | BAYPM2533B |
|   | Sale 31-Dec-2020                         | -15000 | 0.1476 | 226040 | 2.2255 |                  |            |
|   | Sale 15-Jan-2021                         | -5100  | 0.0502 | 220940 | 2.1752 |                  |            |
|   | Sale 22-Jan-2021                         | -1400  | 0.0137 | 219540 | 2.1615 |                  |            |
|   | Sale 19-Feb-2021                         | -10000 | 0.0984 | 209540 | 2.0630 |                  |            |
|   | At the end of the Year 31-Mar-2021       | 209540 | 2.0630 | 209540 | 2.0630 |                  |            |
|   |  |        |        |        |        |                  |            |
| 3 | GIRIJA DODAMANI                          |        |        |        |        |                  |            |
|   | At the beginning of the year 01-Apr-2020 | 207920 | 2.0471 | 207920 | 2.0471 | IN30021418289457 | AKAPD2610B |
|   | Sale 30-Oct-2020                         | -1000  | 0.0098 | 206920 | 2.0372 |                  |            |
|   | Sale 26-Feb-2021                         | -42950 | 0.4228 | 163970 | 1.6143 |                  |            |
|   | Sale 05-Mar-2021                         | -4157  | 0.0409 | 159813 | 1.5734 |                  |            |
|   | Sale 12-Mar-2021                         | -360   | 0.0035 | 159453 | 1.5699 |                  |            |
|   | Sale 19-Mar-2021                         | -2594  | 0.0255 | 156859 | 1.5443 |                  |            |
|   | Sale 31-Mar-2021                         | -10000 | 0.0984 | 146859 | 1.4459 |                  |            |
|   | At the end of the Year 31-Mar-2021       | 146859 | 1.4459 | 146859 | 1.4459 |                  |            |
|   |  |        |        |        |        |                  |            |
| 4 | SHEETAL UTKARSH RAWANDALE                |        |        |        |        |                  |            |
|   | At the beginning of the year 01-Apr-2020 | 147200 | 1.4492 | 147200 | 1.4492 | IN30021418322734 | AEJPR5235H |
|   | At the end of the Year 31-               | 147200 | 1.4492 | 147200 | 1.4492 |                  |            |

|   |   |        |        |        |        |                       |                |
|---|---|--------|--------|--------|--------|-----------------------|----------------|
|   | Mar-2021                                    |        |        |        |        |                       |                |
|   |   |        |        |        |        |                       |                |
| 5 | UTSAV PRAMODKUMAR<br>SHRIVASTAV .           |        |        |        |        |                       |                |
|   | At the beginning of the year<br>01-Apr-2020 | 105007 | 1.0338 | 105007 | 1.0338 | '12012200000<br>90730 | AQGGS76<br>69M |
|   | Sale 03-Apr-<br>2020                        | -1000  | 0.0098 | 104007 | 1.0240 |                       |                |
|   | Sale 10-Apr-<br>2020                        | -298   | 0.0029 | 103709 | 1.0210 |                       |                |
|   | Sale 17-Apr-<br>2020                        | -3709  | 0.0365 | 100000 | 0.9845 |                       |                |
|   | Sale 22-May-<br>2020                        | -1     | 0.0000 | 99999  | 0.9845 |                       |                |
|   | Sale 03-Jul-<br>2020                        | -4000  | 0.0393 | 95999  | 0.9451 |                       |                |
|   | Sale 24-Jul-<br>2020                        | -10    | 0.0000 | 95989  | 0.9450 |                       |                |
|   | Sale 31-Jul-<br>2020                        | -290   | 0.0028 | 95699  | 0.9422 |                       |                |
|   | Sale 14-Aug-<br>2020                        | -699   | 0.0068 | 95000  | 0.9353 |                       |                |
|   | Sale 21-Aug-<br>2020                        | -5700  | 0.0561 | 89300  | 0.8792 |                       |                |
|   | Sale 04-Sep-<br>2020                        | -994   | 0.0097 | 88306  | 0.8694 |                       |                |
|   | Sale 11-Sep-<br>2020                        | -2968  | 0.0292 | 85338  | 0.8402 |                       |                |
|   | Sale 18-Sep-<br>2020                        | -17770 | 0.1749 | 67568  | 0.6652 |                       |                |
|   | Sale 23-Sep-<br>2020                        | -1987  | 0.0195 | 65581  | 0.6456 |                       |                |
|   | Sale 30-Sep-<br>2020                        | -4884  | 0.0480 | 60697  | 0.5975 |                       |                |
|   | Sale 01-Oct-<br>2020                        | -2413  | 0.0237 | 58284  | 0.5738 |                       |                |
|   | Sale 09-Oct-<br>2020                        | -8647  | 0.0851 | 49637  | 0.4887 |                       |                |
|   | Sale 16-Oct-<br>2020                        | -5524  | 0.0543 | 44113  | 0.4343 |                       |                |
|   | Sale 30-Oct-<br>2020                        | -1528  | 0.0150 | 42585  | 0.4192 |                       |                |
|   | Purchase 06-<br>Nov-2020                    | 1815   | 0.0178 | 44400  | 0.4371 |                       |                |
|   | Sale 13-Nov-<br>2020                        | -6308  | 0.0621 | 38092  | 0.3750 |                       |                |
|   | Sale 20-Nov-<br>2020                        | -6488  | 0.0638 | 31604  | 0.3111 |                       |                |
|   | Sale 27-Nov-<br>2020                        | -1604  | 0.0157 | 30000  | 0.2953 |                       |                |
|   | Sale 15-Jan-<br>2021                        | -1000  | 0.0098 | 29000  | 0.2855 |                       |                |
|   | Sale 29-Jan-<br>2021                        | -3606  | 0.0355 | 25394  | 0.2500 |                       |                |
|   | Sale 05-Feb-<br>2021                        | -25394 | 0.2500 | 0      | 0.0000 |                       |                |
|   | At the end of the Year 31-                  | 0      | 0.0000 | 0      | 0.0000 |                       |                |

|   |  |        |        |       |        |                    |             |
|---|--|--------|--------|-------|--------|--------------------|-------------|
|   | Mar-2021                                 |        |        |       |        |                    |             |
| 6 | ALACRITY SECURITIES LIMITED              |        |        |       |        |                    |             |
|   | At the beginning of the year 01-Apr-2020 | 76301  | 0.7512 | 76301 | 0.7512 | '13011903000 50938 | AACCA07 37D |
|   | Sale 06-Nov-2020                         | -15000 | 0.1476 | 61301 | 0.6035 |                    |             |
|   | Purchase 13-Nov-2020                     | 1000   | 0.0098 | 62301 | 0.6133 |                    |             |
|   | Sale 11-Dec-2020                         | -10000 | 0.0984 | 52301 | 0.5149 |                    |             |
|   | Sale 18-Dec-2020                         | -10000 | 0.0984 | 42301 | 0.4164 |                    |             |
|   | Sale 08-Jan-2021                         | -20000 | 0.1969 | 22301 | 0.2195 |                    |             |
|   | Sale 15-Jan-2021                         | -20000 | 0.1969 | 2301  | 0.0226 |                    |             |
|   | Purchase 29-Jan-2021                     | 7001   | 0.0689 | 9302  | 0.0915 |                    |             |
|   | Purchase 19-Feb-2021                     | 1650   | 0.0162 | 10952 | 0.1078 |                    |             |
|   | Sale 26-Feb-2021                         | -10952 | 0.1078 | 0     | 0.0000 |                    |             |
|   | Purchase 05-Mar-2021                     | 1000   | 0.0098 | 1000  | 0.0098 |                    |             |
|   | At the end of the Year 31-Mar-2021       | 1000   | 0.0098 | 1000  | 0.0098 |                    |             |
| 7 | SONAL SAWHNEY                            |        |        |       |        |                    |             |
|   | At the beginning of the year 01-Apr-2020 | 71760  | 0.7065 | 71760 | 0.7065 | 'IN300118117 30278 | JPEPS53 36R |
|   | At the end of the Year 31-Mar-2021       | 71760  | 0.7065 | 71760 | 0.7065 |                    |             |
| 8 | SUNITA D KHARIWAL                        |        |        |       |        |                    |             |
|   | At the beginning of the year 01-Apr-2020 | 58880  | 0.5797 | 58880 | 0.5797 | 'IN300450148 83017 | ADOPK37 04G |
|   | Sale 26-Mar-2021                         | -58880 | 0.5797 | 0     | 0.0000 |                    |             |
|   | At the end of the Year 31-Mar-2021       | 0      | 0.0000 | 0     | 0.0000 |                    |             |
| 9 | AJIT KUMAR                               |        |        |       |        |                    |             |
|   | At the beginning of the year 01-Apr-2020 | 58880  | 0.5797 | 58880 | 0.5797 | 'IN303028608 41286 | AIIPK767 3F |
|   | Sale 09-Oct-2020                         | -7143  | 0.0703 | 51737 | 0.5093 |                    |             |
|   | Sale 12-Feb-2021                         | -5530  | 0.0544 | 46207 | 0.4549 |                    |             |
|   | At the end of the Year 31-Mar-2021       | 46207  | 0.4549 | 46207 | 0.4549 |                    |             |
|   | HAVING SAME PAN                          |        |        |       |        |                    |             |
| 9 | AJIT KUMAR                               |        |        |       |        |                    |             |

|    |   |        |        |        |        |                       |                |
|----|---|--------|--------|--------|--------|-----------------------|----------------|
|    | At the beginning of the year<br>01-Apr-2020 | 46260  | 0.4554 | 46260  | 0.4554 | 'IN303028608<br>42465 | AIIPK767<br>3F |
|    | Sale 15-Jan-<br>2021                        | -4547  | 0.0447 | 41713  | 0.4106 |                       |                |
|    | At the end of the Year 31-<br>Mar-2021      | 41713  | 0.4106 | 41713  | 0.4106 |                       |                |
|    |   |        |        |        |        |                       |                |
| 10 | ARUN LAXMAN KHAIRNAR                        |        |        |        |        |                       |                |
|    | At the beginning of the year<br>01-Apr-2020 | 47271  | 0.4654 | 47271  | 0.4654 | 'IN300214183<br>06181 | AXAPK53<br>14N |
|    | Sale 15-May-<br>2020                        | -1     | 0.0000 | 47270  | 0.4654 |                       |                |
|    | Purchase 28-<br>Aug-2020                    | 1844   | 0.0181 | 49114  | 0.4835 |                       |                |
|    | At the end of the Year 31-<br>Mar-2021      | 49114  | 0.4835 | 49114  | 0.4835 |                       |                |
|    | NEW TOP 10 AS ON (31-<br>Mar-2021)          |        |        |        |        |                       |                |
|    |   |        |        |        |        |                       |                |
| 11 | VITTHALBHAI NATHUBHAI<br>SHAH               |        |        |        |        |                       |                |
|    | At the beginning of the year<br>01-Apr-2020 | 0      | 0.0000 | 0      | 0.0000 | 'IN301645100<br>07284 | ACWPS4<br>622C |
|    | Purchase 31-<br>Dec-2020                    | 18240  | 0.1795 | 18240  | 0.1795 |                       |                |
|    | Purchase 01-<br>Jan-2021                    | 61760  | 0.6080 | 80000  | 0.7876 |                       |                |
|    | Purchase 08-<br>Jan-2021                    | 17205  | 0.1693 | 97205  | 0.9570 |                       |                |
|    | Purchase 15-<br>Jan-2021                    | 2795   | 0.0275 | 100000 | 0.9845 |                       |                |
|    | At the end of the Year 31-<br>Mar-2021      | 100000 | 0.9845 | 100000 | 0.9845 |                       |                |
|    |   |        |        |        |        |                       |                |
| 12 | BMG COMMODITIES PVT.<br>LTD.                |        |        |        |        |                       |                |
|    | At the beginning of the year<br>01-Apr-2020 | 0      | 0.0000 | 0      | 0.0000 | '12026700000<br>26308 | AABCG27<br>58F |
|    | Purchase 25-<br>Dec-2020                    | 1000   | 0.0098 | 1000   | 0.0098 |                       |                |
|    | Purchase 22-<br>Jan-2021                    | 7698   | 0.0757 | 8698   | 0.0856 |                       |                |
|    | Purchase 29-<br>Jan-2021                    | 3269   | 0.0321 | 11967  | 0.1178 |                       |                |
|    | Purchase 05-<br>Feb-2021                    | 1233   | 0.0121 | 13200  | 0.1299 |                       |                |
|    | Sale 12-Feb-<br>2021                        | -200   | 0.0019 | 13000  | 0.1279 |                       |                |
|    | Purchase 19-<br>Feb-2021                    | 35000  | 0.3445 | 48000  | 0.4725 |                       |                |
|    | Purchase 26-<br>Feb-2021                    | 8590   | 0.0845 | 56590  | 0.5571 |                       |                |
|    | Purchase 05-<br>Mar-2021                    | 510    | 0.0050 | 57100  | 0.5621 |                       |                |
|    | Purchase 12-<br>Mar-2021                    | 2900   | 0.0285 | 60000  | 0.5907 |                       |                |

|    |  |       |        |       |        |                   |            |
|----|--|-------|--------|-------|--------|-------------------|------------|
|    | Purchase 19-Mar-2021                     | 10000 | 0.0984 | 70000 | 0.6891 |                   |            |
|    | At the end of the Year 31-Mar-2021       | 70000 | 0.6891 | 70000 | 0.6891 |                   |            |
|    |  |       |        |       |        |                   |            |
| 13 | VUMMIDI ANANTH                           |       |        |       |        |                   |            |
|    | At the beginning of the year 01-Apr-2020 | 0     | 0.0000 | 0     | 0.0000 | '1601430105797961 | AAFPV3128D |
|    | Purchase 15-Jan-2021                     | 10750 | 0.1058 | 10750 | 0.1058 |                   |            |
|    | Purchase 26-Feb-2021                     | 50000 | 0.4922 | 60750 | 0.5981 |                   |            |
|    | Sale 26-Mar-2021                         | -163  | 0.0016 | 60587 | 0.5965 |                   |            |
|    | At the end of the Year 31-Mar-2021       | 60587 | 0.5965 | 60587 | 0.5965 |                   |            |
|    | HAVING SAME PAN                          |       |        |       |        |                   |            |
|    |  |       |        |       |        |                   |            |
| 13 | VUMMIDI ANANTH                           |       |        |       |        |                   |            |
|    | At the beginning of the year 01-Apr-2020 | 0     | 0.0000 | 0     | 0.0000 | 'IN30169612379103 | AAFPV3128D |
|    | Purchase 22-Jan-2021                     | 46894 | 0.4617 | 46894 | 0.4617 |                   |            |
|    | Sale 19-Feb-2021                         | -1674 | 0.0164 | 45220 | 0.4452 |                   |            |
|    | Sale 26-Feb-2021                         | -1088 | 0.0107 | 44132 | 0.4345 |                   |            |
|    | Sale 19-Mar-2021                         | -93   | 0.0009 | 44039 | 0.4335 |                   |            |
|    | Sale 26-Mar-2021                         | -14   | 0.0001 | 44025 | 0.4334 |                   |            |
|    | At the end of the Year 31-Mar-2021       | 44025 | 0.4334 | 44025 | 0.4334 |                   |            |
|    |  |       |        |       |        |                   |            |
| 14 | RAJEEV SHRIMAL                           |       |        |       |        |                   |            |
|    | At the beginning of the year 01-Apr-2020 | 0     | 0.0000 | 0     | 0.0000 | '1201700000392545 | BBMPS0628C |
|    | Purchase 26-Mar-2021                     | 58880 | 0.5797 | 58880 | 0.5797 |                   |            |
|    | At the end of the Year 31-Mar-2021       | 58880 | 0.5797 | 58880 | 0.5797 |                   |            |
|    |  |       |        |       |        |                   |            |
| 15 | JAGRUTI ATUL SHAH                        |       |        |       |        |                   |            |
|    | At the beginning of the year 01-Apr-2020 | 0     | 0.0000 | 0     | 0.0000 | '1205810000080400 | AAIPS3785N |
|    | Purchase 11-Dec-2020                     | 12000 | 0.1181 | 12000 | 0.1181 |                   |            |
|    | Purchase 18-Dec-2020                     | 40000 | 0.3938 | 52000 | 0.5119 |                   |            |
|    | At the end of the Year 31-Mar-2021       | 52000 | 0.5119 | 52000 | 0.5119 |                   |            |

(iv) Shareholding of Directors and Key Managerial Personnel:

| SI No | Name of the Share holder                 | Shareholding at the beginning of the year |                                  | Cumulative Shareholding during the year |                                  | FOLIO/DP_C L_ID   | PAN        |
|-------|--|---|----------------------------------|---|----------------------------------|-------------------|------------|
|       |  | No of shares                              | % of total shares of the company | No of shares                            | % of total shares of the company |                   |            |
| 1     | ASHISH VISHWAS RAWANDALE                 |   |                                  |   |                                  |                   |            |
|       | At the beginning of the year 01-Apr-2020 | 3873201                                   | 38.1340                          | 3873201                                 | 38.1340                          | 'IN30021418275731 | ADNPR0113M |
|       | Purchase 10-Apr-2020                     | 1400                                      | 0.0137                           | 3874601                                 | 38.1478                          |                   |            |
|       | At the end of the Year 31-Mar-2021       | 3874601                                   | 38.1478                          | 3874601                                 | 38.1478                          |                   |            |
| 2     | PREETI ASHISH RAWANDALE                  |   |                                  |   |                                  |                   |            |
|       | At the beginning of the year 01-Apr-2020 | 3608966                                   | 35.5325                          | 3608966                                 | 35.5325                          | 'IN30021418254987 | AEJPR5236E |
|       | At the end of the Year 31-Mar-2021       | 3608966                                   | 35.5325                          | 3608966                                 | 35.5325                          |                   |            |
| 3     | SANJAY B KHATAL                          |   |                                  |   |                                  |                   |            |
|       | At the beginning of the year 01-Apr-2020 | 44160                                     | 0.4348                           | 44160                                   | 0.4348                           | 'IN30051316698727 | ABQPK4776J |
|       | At the end of the Year 31-Mar-2021       | 44160                                     | 0.4348                           | 44160                                   | 0.4348                           |                   |            |

V. INDEBTEDNESS

Indebtedness of the Company including interest outstanding/accrued but not due for payment

|  | Secured Loans excluding deposits | Unsecured Loans  | Deposits | Total Indebtedness  |
|--|----------------------------------|------------------|----------|---------------------|
| <b>Indebtedness at the beginning of the financial year</b> |                                  |                  |          |                     |
| i) Principal Amount  | 6,59,34,377 -                    | 6,35,559         | -        | 6,65,69,936         |
| ii) Interest due but not paid                              | -                                | -                | -        | -                   |
| iii) Interest accrued but not due                          | -                                | -                | -        | -                   |
| <b>Total (i+ii+iii)</b>                                    | <b>6,59,34,377</b>               | <b>6,35,559</b>  | <b>-</b> | <b>6,65,69,936</b>  |
| <b>Change in Indebtedness during the financial year</b>    |                                  |                  |          |                     |
| • Addition   | -                                | -                | -        | -                   |
| • Reduction  | 2,41,12,859                      | 2,22,622         | -        | 2,43,35,481         |
| <b>Net Change</b>  | <b>-2,41,12,859</b>              | <b>-2,22,622</b> | <b>-</b> | <b>-2,43,35,481</b> |
| <b>Indebtedness at the end of the financial year</b>       |                                  |                  |          |                     |
| i) Principal Amount  | 4,18,21,518                      | 4,12,937         | -        | 4,22,34,455         |
| ii) Interest due but not paid                              | -                                | -                | -        | -                   |
| iii) Interest accrued but not due                          | -                                | -                | -        | -                   |
| <b>Total (i+ii+iii)</b>                                    | <b>4,18,21,518</b>               | <b>4,12,937</b>  | <b>-</b> | <b>4,22,34,455</b>  |



# **XI. REMUNERATION OF DIRECTORS AND KEY MANAGERIAL PERSONNEL**

## **Remuneration to Managing Directors:**

| Sr. No. | Particulars of Remuneration  | Name of MD – Dr. Ashish Vishwas Rawandale | Total Amount |
|---------|--|---|--------------|
| 1.      | Gross salary<br><br>(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961<br><br>(b) Value of perquisites u/s 17(2) Income-tax Act, 1961<br><br>(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961 | 700,000<br><br>-<br><br>-                 | 700,000      |
| 2.      | Stock Option   | -   | -            |
| 3.      | Sweat Equity   | -   | -            |
| 4.      | Commission<br>- as % of profit<br>- others, specify...   | -   | -            |
| 5.      | Others, please specify   | -   | -            |
|         | Total (A)  | 700,000                                   | 700,000      |
|         | Ceiling as per the Act   | -   |              |

*Note: The remuneration is within the limit prescribed by schedule V of the companies Act, 2013*

## **A. Remuneration to other directors:**

| Sr. no. | Particulars of Remuneration  | Name of Directors                  |                           |                  | Total Amount   |
|---------|--|------------------------------------|---------------------------|------------------|----------------|
| 1       | Independent Directors  | Mr. Vikramsinh Satish Khatal Patil | Mr. Kiran Madhavrao Pawar | Mr. Pratap Patil |                |
|         | <ul style="list-style-type: none"> <li>Fee for attending board / committee meetings</li> <li>Commission</li> <li>Others, please specify</li> </ul>   | Nil                                | Nil                       | Nil              | Nil            |
|         | Total (1)  | Nil                                | Nil                       | Nil              | Nil            |
| 2       | Other Non-Executive and Non-Independent Directors  | Dr. Preeti A. Rawandale            | Mr. Sanjay Khatal         |                  |                |
|         | Gross salary<br>(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961<br>(b) Value of perquisites u/s 17(2) Income-tax Act, 1961<br>(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961 | 600,000<br>-<br>-                  | -<br>-<br>-               |                  | 600,000        |
|         | Total (2)  | 600,000                            | -                         |                  | 600,000        |
|         | <b>Total (B)=(1+2)</b>   | <b>600,000</b>                     | <b>-</b>                  |                  | <b>600,000</b> |
|         | Total Managerial Remuneration  |                                    |                           |                  |                |
|         | Overall Ceiling as per the Act   |                                    |                           |                  |                |

*Note: The remuneration is within the limit prescribed by schedule V of the companies Act, 2013*

**B. REMUNERATION TO KEY MANAGERIAL PERSONNEL OTHER THAN MD/MANAGER/WTD**

| Sr. no. | Particulars of Remuneration  | Key Managerial Personnel               |                                |                  |
|---------|--|--|--------------------------------|------------------|
|         |  | Company Secretary<br>Mr. Prakash Sogam | CFO<br>Mr. Ramesh Daulat Kuwar | Total            |
| 1.      | Gross salary<br>(a) Salary as per provisions contained in section 17(1) of the Income-tax Act, 1961<br>(b) Value of perquisites u/s 17(2) Income-tax Act, 1961<br>(c) Profits in lieu of salary under section 17(3) Income-tax Act, 1961 | 595296<br>-<br>-                       | 228403<br>-<br>-               | 823699<br>-<br>- |
| 2.      | Stock Option   | -                                      | -                              | -                |
| 3.      | Sweat Equity   | -                                      | -                              | -                |
| 4.      | Commission<br>- as % of profit<br>- others, specify...   | -                                      | -                              | -                |
| 5.      | Others, please specify   | -                                      | -                              | -                |
|         | <b>Total</b>   | 595296                                 | 228403                         | 823699           |

**XII. PENALTIES / PUNISHMENT/ COMPOUNDING OF OFFENCES:**

Against the Company, Directors and other Officer in Default under the Companies Act, 2013: None

**Annexure to the Board's Report**

**Particulars of Employees pursuant to Section 197(12) of the Companies Act, 2013 read with rule 5 (1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014.**

i. The ratio of the remuneration of each Director to the median remuneration of the employees of the company for the financial year.

**Dr. Ashish Rawandale (MD):-** 0.31:1

**Dr. Preeti Rawandale:-** 0.365:1

ii. The percentage increase in remuneration of each Director, Chief Financial Officer, Chief Executive Officer, Company Secretary or Manager, if any, in the financial year.

**Director:**

- **Dr. Ashish Rawandale (MD):** N.A.
- **Dr. Preeti Rawandale** : N.A.

**Key Managerial Personnel:**

- **Mr. Prakash Sogam:** Nil
- **Mr. Ramesh Kuwar (CFO):** Nil

iii. The percentage increase in the median remuneration of employees in the financial year Nil

iv. The number of permanent employees on rolls of the company: 36 employees as on March 31, 2021.

v. Average percentile increase already made in the salaries of employees other than the managerial personnel in the last Financial year and its comparison with the percentile increase in the managerial remuneration and justification thereof and point out if there are any exceptional circumstances for increase in the managerial remuneration.

Average Salary increase for KMP other than MD and WTD: N. A.

Average Salary increase for non KMPs: N.A.

**Form No. AOC 2**  
**RELATED PARTY DISCLOSURE**  
(Pursuant to clause (h) of sub-section (3) of section 134 of the Companies Act 2013 and Rule 8(2) of the Companies (Accounts) Rules, 2014.

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arm's length transaction under third proviso thereto.

**1. Details of contracts or arrangements or transactions not at Arm's length basis.**

There is no such Transaction which is not on arm's length basis.

**2. Details of contracts or arrangements or transactions at Arm's length basis.**

| Sr. No | Particulars   |   |
|--------|---|---|
| a)     | Name (s) of the related party and Nature of relationship  | 1) Tej Vedaant Healthcare Limited – Subsidiary Company<br>2) Dr. Ashish Rawandale – Managing Director<br>3) Dr. Preeti Rawandale – Director<br>4) Tejnakh Healthcare Foundation - Enterprise that have a member of key management in common with the reporting enterprise |
| c)     | Nature of contracts/arrangements/transaction  | 1) Sale of Product of Rs. 3,29,707 and Services rendered of Rs. 4140000<br>2) Professional fees of Rs. 1,500,000<br>3) Professional Fees of Rs. 600,000<br>4) Service Rendered of Rs. 5400000   |
| d)     | Duration of the contracts/arrangements/transaction  | Yearly  |
| e)     | Salient terms of the contracts or arrangements or transaction including the value, if any                         | Same as point C   |
| f)     | Justification for entering into such contracts or arrangements or transactions                                    | In the normal course of business  |
| g)     | Date of approval by the Board   | 13.07.2020  |
| h)     | Amount paid as advances, if any   | N.A.  |
| i)     | Date on which the special resolution was passed in general meeting as required under first proviso to section 188 | -   |

**By Order of the Board of Directors**  
**For, Tejnakh Healthcare Limited**

**Sd/-**  
**Dr. Ashish Vishwas Rawandale**  
**Chairman**  
**Mumbai, 29<sup>th</sup> June, 2021**

**SECRETARIAL AUDIT REPORT  
FORM NO. MR - 3  
FOR THE FINANCIAL YEAR ENDED 31<sup>ST</sup> MARCH, 2021**

[Pursuant to section 204(1) of the Companies Act, 2013 and rule No.9 of the Companies  
(Appointment and Remuneration personnel Rule, 2014)]

To,  
**The Members,**  
**Tejnaksh Healthcare Limited**  
Lion Tarachand Bapa Hospital,  
Lion Tarachand Bapa Hospital Marg,  
Sion – West,  
Mumbai – 400 022

I have conducted the secretarial audit of the Compliance of applicable statutory provisions and the adherence to good corporate practices by Tejnaksh Healthcare Limited (hereinafter called the Company). Secretarial Audit was conducted in a manner that provided me a reasonable basis for evaluating the corporate conduct/Statutory compliances and expressing my opinion thereon.

Based on my verification of Tejnaksh Healthcare Limited's books, papers, minute books, form and returns filed and other records maintained by the Company and also the information provided by the Company, its officers, agents and authorized representatives during the conduct of Secretarial audit, I hereby report that in my opinion, the Company has, during the audit period covering the Financial year ended March 31, 2021, complied with the statutory provisions listed hereunder and also that the Company has proper Board-processes and compliance mechanism in place to the extent, in the manner and subject to the reporting made hereinafter.

I have examined the books, papers, minute books, form and returns filed and other records maintained by the Company for the financial year ended on March 31, 2021 according to the provisions of

- (1) The Companies Act, 2013 (the Act) and the rules made thereunder;
- (2) The Securities Contracts (Regulation) Act, 1956 (SCRA) and the rules made thereunder;
- (3) The SEBI (Depositories and Participants) Regulations, 2018 and the Regulations and bye-laws framed thereunder;
- (4) Foreign Exchange Management Act 1999 and the rules and regulations made thereunder to the extent of Foreign Direct Investment, Overseas Direct Investment and External Commercial Borrowings;
- (5) The following Regulation and Guidelines prescribed under the Securities and Exchange Board of India Act 1992 ('SEBI Act'):-
  - a. The Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011;
  - b. The Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015;
  - c. The Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 2015;
  - d. The Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018; **(Not applicable to the Company during the Audit period)**
  - e. The Securities and Exchange Board of India (Share Based Employee Benefits) Regulations, 2014; **(Not applicable to the Company during the Audit period)**
  - f. The Securities and Exchange Board of India (Issue and Listing of Debt Securities) Regulations, 2008; **(Not applicable to the Company during the Audit period)**
  - g. The Securities and Exchange Board of India (Registrars to an Issue and Share Transfer Agents) Regulation, 1993, regarding the Companies Act and dealing with client;
  - h. The Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009; **(Not applicable to the Company during the Audit period)**

- i. The Securities and Exchange Board of India (Buyback of Securities) Regulations, 2018; **(Not applicable to the Company during the Audit period)**

I have also examined Compliance with the applicable clauses of the following:

- (i) Secretarial Standards issued by The Institute of Company Secretaries of India.
- (ii) The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 pursuant to listing agreement entered into by the Company with BSE Limited.

During the period under review the Company has complied with the provision of the Act, Rules, Regulations, Guidelines, Standards, etc. mentioned above.

**I further report that**, having regard to compliance system prevailing in the Company and on examination of relevant documents and records in pursuance thereof on test-check basis, the Company has complied with the following laws applicable specifically to the Company:

1. Drug & Cosmetic Act, 1940 & Rules made there under;
2. The Bombay Nursing Homes Registration Act, 1949 (Amendment Act, 2005);
3. Transplantation of Human Organs Act, 1994 and bye laws made thereunder;
4. Food & Drugs Administration, Dhule.

**I further report that** the Board of Directors of the Company is duly constituted with Proper balance of Executive Directors, Non-Executive Directors and Independent Directors. The changes in the composition of the Board of Directors that took place during the period under review were carried out in compliance with the provisions of the Act.

Adequate notice is given to all Directors to schedule the Board Meetings, agenda and detailed notes on agenda were sent at least seven days in advance, and a system exists for seeking and obtaining further information and clarification on the agenda items before the meeting and for meaningful participation at the meeting.

Majority decision is carried through while the dissenting members' views are captured and recorded as part of the minutes.

**I further report that** there are adequate systems and processes in the Company commensurate with size and operations of the Company to monitor and ensure compliance with applicable laws, rules, regulations and guidelines.

**I further report that** during the audit period, the Company has passed following Special Resolutions which are having major bearing on the company's affairs in pursuance of the above referred laws, rules, regulations, guidelines.

- i. Re-Appointment of Dr. Ashish Rawandale (Din: 02005733) as a Chairman & Managing Director of the Company for a Period of Five Years.

**I further report that** during the audit period, there were no instances of:

- (i) Public/Right/ preferential issue of shares/ debentures/ sweat equity.
- (ii) Redemption/ buy-back of securities.
- (iii) Merger/ amalgamation/ reconstruction etc.
- (iv) Foreign technical collaborations.

Place: Mumbai

Date: 29<sup>th</sup> June 2021

For Bhwnesh Bansal & Associates

Sd/-  
Bhwnesh Bansal  
Proprietor  
FCS No. - 6526  
CP No. - 9089  
UDIN: F006526C000524747

This Report is to be read with my letter of even date which is annexed as **Annexure A** and forms an integral part of this report.

**‘Annexure A’**

**To,**  
**The Members,**  
**Tejnaksh Healthcare Limited**  
Lion Tarachand Bapa Hospital,  
Lion Tarachand Bapa Hospital Marg,  
Sion – West, Mumbai - 400022

My report of even date is to be read along with this letter.

1. Maintenance of Secretarial record is responsibility of the Management of the Company. My responsibility is to express an opinion on these secretarial records based on my audit.
2. I have followed the audit practices and process as were appropriate to obtain reasonable assurance about the correctness of the contents of the Secretarial records. The verification was done on test basis to ensure that correct facts are reflected in Secretarial records. I believe that the process and practices, I followed provide a reasonable basis for my opinion.
3. I have not verified the correctness and appropriateness of financial records and Books of Accounts of the Company.
4. Where ever required, I have obtained the Management representation about the Compliance of laws, rules and regulations and happening of events etc.
5. The Compliance of the provisions of Corporate and other applicable laws, rules, regulations, standards is the responsibility of management. My examination was limited to the verification of procedure on test basis.
6. The Secretarial Audit report is neither an assurance as to the future viability of the Company nor of the efficacy or effectiveness with which the management has conducted the affairs of the Company.

**Place:** Mumbai  
**Date:** 29<sup>th</sup> June 2021

**For Bhwnesh Bansal & Associates**

**Sd/-**  
**Bhwnesh Bansal**  
**Proprietor**  
**FCS No. - 6526**  
**CP No. - 9089**  
**UDIN: F006526C000524747**

**INDUSTRY OVERVIEW:**

Healthcare has become one of India's largest sector, both in terms of revenue and employment. Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance and medical equipment. The Indian healthcare sector is growing at a brisk pace due to its strengthening coverage, services and increasing expenditure by public as well private players.

Indian healthcare delivery system is categorised into two major components public and private. The Government, i.e. public healthcare system, comprises limited secondary and tertiary care institutions in key cities and focuses on providing basic healthcare facilities in the form of primary healthcare centres (PHCs) in rural areas. The private sector provides majority of secondary, tertiary, and quaternary care institutions with major concentration in metros and tier I and tier II cities.

India's competitive advantage lies in its large pool of well-trained medical professionals. India is also cost competitive compared to its peers in Asia and Western countries. The cost of surgery in India is about one-tenth of that in the US or Western Europe.

As of June 15, 2021, >26.69 crore (26, 69, 14,930) COVID-19 vaccine doses have been administered across the country.

The public healthcare facilities in India have been unable to scale adequately to serve the needs of the large population; reaching the interiors of the country has been another challenge. Additionally, several of these facilities are understaffed, poorly equipped in terms of basic infrastructure and equipment, and in need of enhanced quality standards and protocols. This unmet opportunity combined with strong fundamentals has largely led to the private sector taking center stage in the healthcare landscape. The late 1990s witnessed improvement in the economic conditions and made private healthcare affordable to many Indians. These hospitals turned into Centres of Excellence and over time, became preferred choice for patients and communities over Government hospitals. The private service providers dominate the Indian Healthcare industry and they are using innovative means to overcome some of the operational challenges. These healthcare institutions provide world class facilities, employ highly skilled and globally recognized professionals, leverage advanced technology in treatments, and maintain high standards of quality. The private sector players have been able to occupy a major share of nearly 80% of the country's total healthcare market. They also account for almost 74% of the country's total healthcare expenditure. Their share in hospitals alone is estimated at 74% while its share of hospital beds is estimated at 40%.

Today, the healthcare sector in India offers a potent mix of opportunities and challenges. The significant gap between 'required' and 'actual' healthcare infrastructure has driven considerable investment over the years into assets like hospitals and other facilities. Healthcare in India today provides corporations with a unique opportunity for innovation, differentiation and profits; it has become a preferred sector for strategic and financial investments.

Medical tourism (also called medical travel, health tourism or global health care) is a term initially coined by travel agencies and the mass media to describe the rapidly-growing practice of traveling across international borders to obtain health care.

Such services typically include elective procedures as well as complex specialized surgeries such as joint replacement (knee/hip), cardiac surgery, dental surgery, and cosmetic surgeries. However, virtually every type of health care, including psychiatry, alternative treatments, convalescent care, and even burial services are available. As a practical matter, providers and customers commonly use informal channels of communication-connection-contract, and in such cases, this tends to mean less regulatory or legal oversight to assure quality and less formal recourse to reimbursement or redress, if needed.

Over 50 countries have identified medical tourism as a national industry. However, accreditation and other measures of quality vary widely across the globe, and there are risks and ethical issues that make this method of accessing medical care controversial. Also, some destinations may become hazardous or even dangerous for medical tourists to contemplate.

**SWOT ANALYSIS FOR THE SECTOR****STRENGTHS:-**

- Widespread network
- Proficient medical team with rich medical expertise
- Low-cost, quality healthcare
- Growing number of medical colleges
- Growing private investments



- High brand salience
- Availability of highly qualified doctors
- Proficient medical team with rich medical expertise
- Technological experience

#### **WEAKNESSES:-**

- Rural urban service imbalance
- Capital intensive nature of industry
- Lower public expenditure on health equating to just 1.28% of the GDP
- Lack of capital investment
- Lower accessibility
- Heterogeneous markets

#### **OPPORTUNITIES:-**

- Government schemes
- Growing life expectancy
- Growing medical tourism
- Growing middle class income
- Growing lifestyle diseases
- Availability of health insurance
- Underserved and poorly-served markets

#### **THREATS:-**

- Shortage of skilled manpower
- Regulatory headwinds
- Capital intensive industry
- Imbalance in cost expectation and service
- Threat to doctors from mob lynching

#### **GOVERNMENT INITIATIVES:**

Some of the major initiatives taken by the Government of India to promote Indian healthcare industry are as follows:

- In June 2021, the government invited bids for using drones to deliver COVID-19 vaccines and drugs to remote and difficult-to-reach areas to ensure last-mile coverage in select locations of the country.
- As of May 2021, 11.9 lakh Health IDs have been generated and 3,106 doctors and 1,490 facilities have registered on the National Digital Health Mission (NDHM) platform.
- In May 2021, Defense Minister Mr. Rajnath Singh launched 'Services e-Health Assistance & Tele-consultation (SeHAT)' OPD portal to provide telemedicine services to armed forces personnel and veterans.
- On May 12, 2021, the Drugs Controller General of India (DCGI), accepted recommendation of Subject Expert Committee (SEC) and accorded permission to conduct the Phase II/III clinical trials of Covaxin (COVID vaccine) for the age group of 2-18 years to its manufacturer, Bharat Biotech Ltd.
- On May 17, 2021, the Defence Ministry launched the first batch of anti-COVID drug, 2-deoxy-D-glucose (2-DG) that was developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), along with Dr. Reddy's Laboratories (DRL), Hyderabad.
- In May 2021, the government announced its plan to ramp up supply and availability of Amphotericin-B, the anti-fungal drug, for treatment of the 'Black Fungus' disease. It has also given the license to five manufactures to produce the drug within the country.
- In March 2021, various states and UTs started implementation of the 'Intensified Mission Indradhanush 3.0' – a campaign aimed to reach those children and pregnant women who were missed out or have been left out of the routine immunisation programme due to the COVID-19 pandemic. This is aimed to accelerate the full immunisation of children and pregnant women through a mission mode intervention.
- In March 2021, the Parliament passed the National Commission for Allied, Healthcare Professions Bill 2021, which aims to create a body that will regulate and maintain educational and service standards for healthcare professionals.
- In the Union Budget 2021, investment in health infrastructure expanded 2.37x, or 137% YoY; the total health sector allocation for FY22 stood at Rs. 223,846 crore (US\$ 30.70 billion).
- The government announced Rs. 64,180 crore (US\$ 8.80 billion) outlay for the healthcare sector over six years in the Union Budget 2021-22 to strengthen the existing 'National Health Mission' by developing capacities of primary, secondary and tertiary care, healthcare systems and institutions for detection and cure of new & emerging diseases.

- In Union Budget 2021-22, the government announced its plans to launch 'Mission Poshan 2.0' to merge 'Supplementary Nutrition Programme' with 'Poshan Abhiyan' (Nutrition Mission) in order to improve nutritional outcomes across 112 aspirational districts.
- The Government of India approved continuation of 'National Health Mission' with a budget of Rs. 37,130 crore (US\$ 5.10 billion) under the Union Budget 2021-22.
- In the Union Budget 2021, the Ministry of AYUSH was allocated Rs. 2,970 crore (US\$ 407.84 million), up from Rs. 2,122 crore (US\$ 291.39 million).

## **RECENT DEVELOPMENTS**

Between April 2000 and December 2020, FDI inflows for drugs and pharmaceuticals sector stood at US\$ 17.99 billion, according to the data released by Department for Promotion of Industry and Internal Trade (DPIIT). Some of the recent initiatives in the Indian healthcare industry are as follows:

- By June 2021, the Health Ministry's eSanjeevani telemedicine service crossed 6 million (60 lakh) teleconsultations since its launch, enabling patient-to-doctor consultations, from the confines of their home, and doctor-to-doctor consultations.
- In April 2021, Tata Digital infused Rs. 100 crore (US\$ 13.45 million) debt in 1mg, the online medicine start-up, and was in the final stages of acquiring a controlling stake in the company.
- In April 2021, the Ministry of Ayush and Council of Scientific & Industrial Research completed multi-centre clinical trial of a AYUSH 64 (a medicine) and found it useful for treatment of mild-to-moderate COVID-19 infections.
- By March 2021, India exported more vaccines than it had administered to its citizens – 60 million doses had been dispatched to 76 countries, while 52 million doses had been administered to Indian citizens. Apart from vaccines, drugs indicated for Covid-19 treatment too witnessed an uptrend in exports. For example, Remdesivir exports doubled in March 2021 to \$14.8 million from \$5.75 million in February 2021.
- In March 2021, Union Health Minister Harsh Vardhan informed the Rajya Sabha that 157 medical colleges are under various stages of implementation across India. Of this, 58 colleges are in the first phase of implementation, 24 in the second phase and 75 are in the third phase.
- In March 2021, gross written premiums of health insurance companies in the non-life insurance sector increased by 41% YoY to Rs. 2,185.05 crore (US\$ 294 million), driven by rising demand for health insurance products amid COVID-19 surge.
- On March 17, 2021, the Health Ministry's eSanjeevani telemedicine service crossed 3 million (30 lakh) teleconsultations since its launch, enabling patient-to-doctor consultations from the confines of their home, and doctor-to-doctor consultations.
- In March 2021, Virchow Biotech, a Hyderabad-based firm, and the Russian Direct Investment Fund (RDIF) announced a collaboration to manufacture up to 200 million doses of the Sputnik V vaccine in India.
- In February 2021, India approved the commercial supply of 24 million doses of COVID-19 vaccines to 25 countries, more than 2x the 10.5 million vaccines exported in January 2021. Through this, seven countries, including Brazil, Morocco and South Africa, were sent >~10 million doses on a commercial basis.
- On February 2021, the National Backward Classes Finance and Development Corporation (NBCFDC) signed a MOU with Apollo Medskills Pvt Ltd. to co-fund a COVID Vaccine Administration training programmes for nurses, medical & nursing students and pharmacists belonging to the NBCFDC target community.
- In February 2021, the Competition Commission of India (CCI) approved acquisition of Varian Medical Systems, Inc. by Siemens Healthineers Holding I GmbH (SHS GmbH).
- In February 2021, the Minister for Commerce and Industry of India, Mr. Piyush Goyal, and the UK Secretary of State for International Trade, Ms. Elizabeth Truss MP, completed a meeting to discuss the bilateral trade and economic relations of India-UK trade and investment relationship. The Ministers also welcomed enhancement of bilateral health cooperation between the two countries, such as on vaccines, which is allowing India to serve as a global source of strength in overcoming COVID-19-imposed challenges.
- In February 2021, Prime Minister Narendra Modi laid the foundation stones for two hospitals and launched 'Asom Mala', a programme for state highways and major district roads, in Assam. He also added that ~1.25 crore people in the state are being benefitted from Ayushman Bharat Scheme.

## **HEALTHCARE DELIVERY IN INDIA**

Healthcare Delivery system comprises institutions, organisations and persons that operate within the healthcare system, and are responsible for the promotion of health, prevention of illness, detection and treatment of disease and rehabilitation. Healthcare Delivery infrastructure in India has been lagging behind when compared with many countries that are poorer than India in other economic parameters. India's

## **COVID-19**

The COVID-19 pandemic has caused immense disruption and highlighted the importance of adequate resources for managing such crises without excessive economic disruption.

COVID 19 had a very major impact on 20-21. The ongoing pandemic made most of its dent, during the first two quarters of the financial year 20-21, a recovery made was during the last leg of financial year 21 before the second wave gripped us.

The company is being pro-active to take all necessary actions and negate the ill effects of Covid-19 and ensure functioning, but at the same time are being cautious of the pandemic in the future.

However, there is also an opportunity to convert the challenge into opportunities. Considering the massive industrial base and growing healthcare demand, ramping up the spending on health infrastructure and healthcare R&D with a focus on healthcare equipment and services is needed to support India's economic recovery and to protect the well-being of its citizens by providing access to high quality and affordable healthcare.

## **FINANCIAL POSITION:**

During the financial year 2020-21, your Company has achieved total turnover of Rs. 871.15 Lakh and has incurred net profit of Rs. 200.42 Lakh. The Company has net worth of about Rs. 1702.56 Lakh as on March 31, 2021.

## **OUTLOOK FOR THE COMPANY:**

With financial sustainability, care delivery, patient centricity, digital transformation, and regulatory compliance at the top of the agenda, health care sector leaders need to collaborate with all stakeholders—both within the health care ecosystem and those in converging industries—as they look to shape the future of health care and establish a sustainable smart health community.

There is an exponential increase in the pace and scale with which digital health care innovations are emerging. Digital technologies are supporting health systems' efforts to transition to new models of patient-centered care and helping them develop "smart health" approaches to increase access and affordability, improve quality, and lower costs. From blockchain, RPA, cloud, artificial intelligence (AI), and robotics, to internet of medical things (IoMT), digital and virtual reality are just some of the ways technology is disrupting health care. These technologies are helping with diagnosis and treatment, helping with speed, quality and accuracy, and improving the patient experience.

Tejnakh has managed to continue its growth in the year under review, despite the challenges coming from the coronavirus outbreak. The Company is confident of its service capabilities and domain expertise that has created a niche in the healthcare market. It is committed to outperform the industry average growth in the coming fiscal year backed by its unique business model and service edge.

## **ROAD AHEAD**

India is a land full of opportunities for players in the medical devices industry. The country has also become one of the leading destinations for high-end diagnostic services with tremendous capital investment for advanced diagnostic facilities, thus catering to a greater proportion of population. Besides, Indian medical service consumers have become more conscious towards their healthcare upkeep.

Indian healthcare sector is much diversified and is full of opportunities in every segment, which includes providers, payers, and medical technology. With the increase in the competition, businesses are looking to explore for the latest dynamics and trends which will have positive impact on their business. The hospital industry in India is forecast to increase to Rs. 8.6 trillion (US\$ 132.84 billion) by FY22 from Rs. 4 trillion (US\$ 61.79 billion) in FY17 at a CAGR of 16-17%.

The Government of India is planning to increase public health spending to 2.5% of the country's GDP by 2025.

India's competitive advantage also lies in the increased success rate of Indian companies in getting Abbreviated New Drug Application (ANDA) approvals. India also offers vast opportunities in R&D as well as medical tourism. To sum up, there are vast opportunities for investment in healthcare infrastructure in both urban and rural India.

Note: Conversion rate used for May 2021 is Rs. 1 = US\$ 0.01365

*References: Department for Promotion of Industry and Internal Trade (DPIIT), RNCOS Reports, Media Reports, Press Information Bureau (PIB), Union Budget 2021-22*

## **MARKET SIZE:**

The healthcare market can increase three-fold to Rs. 8.6 trillion (US\$ 133.44 billion) by 2022. In Budget 2021, India's public expenditure on healthcare stood at 1.2% as a percentage of the GDP.

A growing middle-class, coupled with rising burden of new diseases, are boosting the demand for health insurance coverage. With increasing demand for affordable and quality healthcare, penetration of health insurance is poised to expand in the coming years. In FY21, gross written premiums in the health segment grew at 13.7% YoY to Rs. 58,584.36 crore (US\$ 8.00 billion). The health segment has a 29.5% share in the total gross written premiums earned in the country.

The Healthcare sector is divided into three major categories: primary, secondary and tertiary.

### **Primary Healthcare:**

Primary care facilities are outpatient units that offer basic, point-of-contact medical and preventive healthcare services, where patients come for routine health screenings and vaccinations. This is the first point of contact between the populace and the healthcare service providers. These facilities do not have intensive care units (ICU) or operation theatres.

Their infrastructure offers basic medical and health prevention services through a network of Sub Centers and Primary Health Centers in rural areas, whereas in urban areas it is provided through Health Posts and Family Welfare Centers. Primary Care Centres also act as feeders for secondary / tertiary care hospitals, where patients are referred to for treatment of chronic / serious ailments.

### **Secondary Healthcare:**

Secondary care facilities diagnose and treat ailments that cannot be treated in primary care facilities. These act as the second point of contact in the healthcare system. In India, the health centers for secondary health care include District Hospitals and Community Health Centres at the block level.

This infrastructure provides inpatient as well as outpatient medical services which includes simple surgical procedures. Some of medical specialties offered under secondary healthcare include internal medicine, pediatrics and limited coverage of other specialties like urology, cardiology, and other specialties.

### **Tertiary Healthcare:**

Tertiary care hospitals provide advanced healthcare services, usually on referral from primary or secondary medical care Providers. Specialized Intensive Care Units, advanced diagnostic support services and specialized medical personnel are key features of tertiary health care. Single-specialty tertiary care hospitals treat a particular ailment such as cardiac, cancer, etc. On the other hand, there are multi-specialty tertiary hospitals that offer all medical specialties under one roof and treat complex cases such as multi organ failure, high-risk, and trauma cases. In India, under the public health system, tertiary care service is also provided by medical colleges and advanced medical research institutes.

## **HUMAN RESOURCES AND INDUSTRIAL RELATION:**

At Tejnakhsh, we believe that our success is the end results of the achievement of our team. Our performance metrics are clearly defined and for real achievers we offer an accelerated career growth unhindered by any hierarchy. Tejnakhsh offers a merit led environment where talent is respected and achievements are rewarded. Our flat management structure allows genuine appreciation of good work and we believe in delegating responsibilities.

We continually empower our team members to better themselves and offer clear career paths for advancement. The Company takes extreme pride in its greatest resource and asset - the employees. Our constant endeavours have been towards encouraging a culture of employee recognition & motivation and we are able to achieve this through are well designed policies & processes like Rewards & Recognition and other various employee benefit schemes. We also believe that the young talent has out of the box creativity and we nurture them to have become a proficient leader. We ensure that there is full adherence to the code of business conduct and fair business practices.

All safety and personal protective apparels are provided to the employees working in the related field in order to ensure their life security and surety. Regular safety training is provided to all employees as well as external professional expert was hired to empower the employees to work with managers to create easy-to understand safety procedures and protocols. Encourage people to think first, act second, and consider safety protocols as not just a rote function, but an essential fact of daily practice that will ensure to save their lives. The company has maintained very harmonious & cordial Industrial relations. There is continuous emphasis on development of human resources through training. The issues pertaining to workers are resolved in harmonious and in cordial manner through regular interactions. We believe whatever we achieved from where we started our journey long back is the result of efforts of our team. So, we consistently aim to provide a sustainable environment for learning right from the stage of recruitment to retention.

### **INTERNAL CONTROL SYSTEMS AND THEIR ADEQUACY:**

The Internal audit was carried out by firm of Chartered Accountants, who conduct the audit on the basis of Annual Audit Plan. The processes include review and evaluation of effectiveness of the existing processes, controls and compliances. It also ensures adherence to policies and systems, and mitigation of the operational risks perceived for each areas under audit. Significant observations including recommendations for improvement of the business processes were reviewed by the management before reporting to the Audit Committee. The committee has reviewed the Internal Audit procedures, findings and status of implementation of the agreed action plan.

Section 134(5) (e) of the Companies Act, 2013 requires a company to lay down Internal Financial Controls system (IFC) and to ensure that these are adequate and operating effectively. Internal financial controls, here, means the policy and procedure adopted by the company for ensuring the orderly and efficient conduct of its business including adherence to company's policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records and the timely preparation of reliable financial information.

The above requirement has the following elements:

1. Orderly and efficient conduct of business.
2. Safeguarding of its assets.
3. Adherence to company's policies.
4. Prevention and detection of frauds and errors.
5. Accuracy and completeness of the accounting records and timely preparation of reliable financial information.

At Tejnakh Healthcare Limited, the internal financial controls system is in place and incorporates all the five elements as mentioned above. In addition, the Company has a transparent framework for periodic evaluation of the internal financial controls in the form of internal audit exercise carried out through the year and online controls self-assessment through Controls Manager Software, thereby reinforcing the commitment to adopt best corporate governance practices.

### **CAUTIONARY STATEMENT**

Statements in the Management Discussion and Analysis Report, describing the Company's objectives, projections and estimates, are forward-looking statements and progressive within the meaning of applicable securities laws and regulations. Actual results may differ materially from those expressed in the statement. Important factors that could influence the company's operations include global and domestic demand and supply conditions affecting selling prices, input availability and prices, changes in government regulations, tax laws, economic developments within the country and other factors such as litigation and industrial relations.

**On behalf of the Board of Directors,  
For Tejnakh Healthcare Limited**

**Sd/-  
Dr. Ashish Rawandale  
Chairman**

**REPORT ON CORPORATE GOVERNANCE****(Pursuant to Regulation 34 (3) of SEBI (Listing Obligations & Disclosures Requirements) Regulations, 2015)**

Corporate Governance is the application of best management practices, compliance of laws and adherence to ethical standards to achieve the Company's objective of maximizing stakeholders' value and discharge of social responsibility. The Corporate Governance structure in the Company assigns responsibilities and entrusts authority among different participants in the organization viz. the Board of Directors, the Senior Management, Employees etc.

In addition to these, the Company has also adopted the requirements of Corporate Governance under Regulation 34 of SEBI (Listing Obligations & Disclosures Requirements) Regulations, 2015, the disclosure requirements of which are given below:

i. **Company's Philosophy on Corporate Governance:**

The Company's philosophy on Corporate Governance is to observe the highest level of ethics in all its dealings, to ensure the efficient conduct of the affairs of the Company to achieve its goal of maximizing value for all its stakeholders.

ii. **Board of Directors (Board):**

a) **Board Composition:**

The Board of the Company should consist of optimum combination of Executive, Non-Executive - Independent Directors, which should be in conformity with the requirement of Regulation 17 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015.

The present strength of the Board is Six (6) Directors, comprising of one Managing Director- Executive Director and Three Independent - Non Executive Directors and another Two Non-executive - Non-Independent Director. The Board Members possess the skills, expertise & experience necessary to guide the Company.

| <b>Name of Director</b>            | <b>Category of Directorship</b>          | <b>Designation</b>  |
|------------------------------------|--|---------------------|
| Dr. Ashish Vishwas Rawandale       | Executive Director                       | Managing Director   |
| Dr. Preeti Ashish Rawandale        | Non-Executive - Non Independent Director | Director            |
| Mr. Kiran Madhavrao Pawar          | Non-Executive - Independent Director     | Director            |
| Mr. Vikramsinh Satish Khatal Patil | Non-Executive - Independent Director     | Director            |
| *Mr. Pratap Tarachand Patil        | Non-Executive - Independent Director     | Director            |
| Mr. Sanjay Bhikajirao Khatal       | Non-Executive - Non Independent Director | Director            |
| #Mr. Suhas Thorat                  | Non-Executive - Independent Director     | Additional Director |

\* Mr. Pratap Tarachand Patil resigned from the Company on 09.06.2021

# Mr. Suhas Thorat appointed as Additional Director w.e.f. 14.08.2021

b) **Board Meetings and attendance of Directors:**

During the financial year ended on 31<sup>st</sup> March, 2021. Five (5) Board Meetings were held on the following dates: 30<sup>th</sup> June, 2020; 13<sup>th</sup> July, 2020, 15<sup>th</sup> September, 2020, 13<sup>th</sup> November, 2020, 13<sup>th</sup> February, 2021.

Agenda papers containing all necessary information / documents are made available to the Board in advance to enable the Board members to discharge their responsibilities effectively and take informed decisions. Where it is not practicable to attach or send the relevant information as part of agenda papers, the same are tabled at the meeting or / and the presentations are made by the concerned managers to the Board. Considerable time is spent by the Directors on discussions and deliberations at the Board Meetings.

The attendance at the Board Meetings held during the year and attendance at the last Annual General Meeting, number of directorships in other Public Limited Companies and membership/ chairmanship in committees across various Companies of which the Director is a Member / Chairman is given below:

| Name of Directors                  | No. of Board Meetings Attended | Attendance at last AGM held on 30.09.2020 | Directorship held in other Companies and Category of Directorship (Excluding Private Companies and Companies under Section 8 of the Companies Act, 2013.) | Committee Memberships / Chairmanships (including this Company) |              |
|------------------------------------|--------------------------------|---|---|--|--------------|
|                                    |                                |   |   | Membership   | Chairmanship |
| Dr. Ashish Vishwas Rawandale       | 5                              | Yes                                       | Nil   | 1  | 0            |
| Dr. Preeti Ashish Rawandale        | 5                              | Yes                                       | Nil   | 2  | 0            |
| Mr. Kiran Madhavrao Pawar          | 5                              | Yes                                       | Nil   | 3  | 2            |
| Mr. Vikramsinh Satish Khatal Patil | 5                              | Yes                                       | Nil   | 3  | 1            |
| Mr. Pratap Tarachand Patil*        | 3                              | Yes                                       | Nil   | 3  | 0            |
| Mr. Sanjay Bhikajirao Khatal       | 3                              | Yes                                       | Nil   | 0  | 0            |

\* Mr. Pratap Tarachand Patil resigned from the directorship of the Company on 09.06.2021

None of the Directors of the Company are related to each other except Dr. Ashish Rawandale and Dr. Preeti Rawandale

**Director retires by rotation:**

Mr. Sanjay Bhikajirao Khatal (DIN: 06616883) who retires by rotation and being eligible offers himself for re-appointment.

**c) Skill/Expertise/Competencies of the Board of Directors:**

The Board of Directors of the company has good experience in the Healthcare industry. Directors of the company also possess with significant experience in the field of advertising, marketing, public relations through entrepreneurial venture and some of the directors are looking after the marketing division. Apart from above, the Board has sound knowledge of finance, accounts and laws.

**d) In the opinion of the Board of Directors, the Independent Directors of the Company fulfills the conditions specified in the Regulation 16(1)(b) and are independent of the management and confirmed that has received an declaration from Independent Directors as specified in the regulation.**

**iii. Committees of the Board of Directors of the Company:**

**a) Audit Committee:**

**Composition:**

The Audit Committee comprises of experts specializing in accounting / financial management. The chairman of the Audit Committee is a "Non-executive Independent Director". The composition of Audit Committee is as follows:

During the year 2020-21, four (4) Audit Committee meetings were held on 13<sup>th</sup> July, 2020; 15<sup>th</sup> September, 2020; 13<sup>th</sup> November, 2020 and 13<sup>th</sup> February, 2021.

| Name of the Members                | Position | Category                             |
|------------------------------------|----------|--------------------------------------|
| Mr. Vikramsinh Satish Khatal Patil | Chairman | Non-Executive - Independent Director |
| Mr. Kiran Madhavrao Pawar          | Member   | Non-Executive - Independent Director |
| Dr. Ashish Vishwas Rawandale       | Member   | Executive Director                   |
| *Mr. Pratap Tarachand Patil        | Member   | Non-Executive - Independent Director |

\*Mr. Pratap Tarachand Patil appointed as member of the Audit Committee 13.02.2021 and he resigned from the Company from 09.06.2021

**The brief terms of reference of the Audit Committee include: -**

- oversight of the listed entity's financial reporting process and the disclosure of its financial information to ensure that the financial statement is correct, sufficient and credible; To seek information from any employee.
- recommendation for appointment, remuneration and terms of appointment of auditors of the listed entity;
- approval of payment to statutory auditors for any other services rendered by the statutory auditors;
  - matters required to be included in the director's responsibility statement to be included in the board's report in terms of clause (c) of sub-section (3) of Section 134 of the Companies Act, 2013;
  - changes, if any, in accounting policies and practices and reasons for the same;
  - major accounting entries involving estimates based on the exercise of judgment by management;
  - significant adjustments made in the financial statements arising out of audit findings;
  - compliance with listing and other legal requirements relating to financial statements;
  - disclosure of any related party transactions;
  - modified opinion(s) in the draft audit report;
- Carrying out any other function as is mentioned in the terms of reference of the audit committee.

**b) Nomination and Remuneration Committee:**

**Composition:**

The Nomination and Remuneration Committee comprises of three (3) members. The composition of Nomination and Remuneration Committee is as follows:

During the year 2020-21, Four (4) Nominations and Remuneration Committee meeting were held on 13<sup>th</sup> July, 2020; 15<sup>th</sup> September, 2020; 13<sup>th</sup> November, 2020 and 13<sup>th</sup> February, 2021.

| Name of the Members                | Position | Category                                 |
|------------------------------------|----------|--|
| Mr. Kiran Madhavrao Pawar          | Chairman | Non-Executive - Independent Director     |
| Mr. Vikramsinh Satish Khatal Patil | Member   | Non-Executive - Independent Director     |
| Dr. Preeti Ashish Rawandale        | Member   | Non-Executive - Non Independent Director |
| *Mr. Pratap Tarachand Patil        | Member   | Non-Executive - Independent Director     |

\*Mr. Pratap Tarachand Patil appointed as member of the Audit Committee 13.02.2021 and he resigned from the Company from 09.06.2021

**Terms of Reference:**

The broad terms of reference of the committee are to identify persons who are qualified to become directors and senior management personnel, to appraise the performance of Chairman, Managing Director, Whole Time Directors and Key Managerial Personnel and to determine and recommend to the Board compensation payable to Chairman, Managing Director, Whole Time Directors and Key Managerial Personnel. The Remuneration policy of the Company is based on review of achievements. The remuneration policy is in consonance with the existing industry practice.

**Remuneration Policy:**

Subject to approval of the Board of Directors and subsequent approval by the members at the Annual General Meeting and such authorities as the case may be, remuneration of Chairman, Managing Director, Whole Time Directors and Key Managerial Personnel is fixed by the Nomination and Remuneration Committee. The remuneration is decided by the Nomination and Remuneration Committee taking into consideration various factors such as qualifications, experience, expertise, prevailing remuneration in the competitive industries, and financial position of the Company etc.

**c) Stakeholders Relationship Committee:**

**Composition:**



The Board has delegated the powers to look into various aspects of interest of shareholders, debenture holders and other security holder to this Committee of Three (3) Directors. The composition of Stakeholders Relationship Committee is as follows:

During the year 2020-21, Four (4) Stakeholders Relationship Committee meeting were held on 13<sup>th</sup> July, 2020; 15<sup>th</sup> September, 2020; 13<sup>th</sup> November, 2020 and 13<sup>th</sup> February, 2021.

| Name of the Members                | Position | Category                                 |
|------------------------------------|----------|--|
| Mr. Kiran Madhavrao Pawar          | Chairman | Non-Executive - Independent Director     |
| Mr. Vikramsinh Satish Khatal Patil | Member   | Non-Executive - Independent Director     |
| Dr. Preeti Ashish Rawandale        | Member   | Non-Executive – Non Independent Director |
| *Mr. Pratap Tarachand Patil        | Member   | Non-Executive - Independent Director     |

\*Mr. Pratap Tarachand Patil appointed as member of the Audit Committee 13.02.2021 and he resigned from the Company from 09.06.2021

**Information on Investor Grievances for the period from 1<sup>st</sup> April, 2020 to 31<sup>st</sup> March, 2021:**

There are no outstanding complaints at the close of financial year which were received from shareholders during the year. The Company has no transfers pending at the close of the financial year.

The total no. of complaints received and complied during the year were:

Opening: Nil/ Complaints Received: Nil/ Complied: Nil/ Pending: Nil

The Outstanding complaints as on 31<sup>st</sup> March, 2021 – Nil

**Terms of Reference:**

The Company has a Stakeholders Relationship Committee, to look into redressal of Investors Complaints and requests such as delay in transfer of shares, non-receipt of Dividend, Annual Report, revalidation of Dividend warrants etc.

The Committee deals with various matters relating to:

- Transfer / transmission of shares.
- Issue of share certificate in lieu of lost, sub-divided, consolidated, rematerialized or defaced certificates.
- Consolidation / splitting of folios.
- Review of shares dematerialized and all other related matters.
- Investors' grievance and redressal mechanism and recommend measures to improve the level of investors' services.
- Review of measures taken for effective exercise of voting rights by shareholders.
- Review of adherence to the service standards adopted by the listed entity in respect of various services being rendered by the Registrar & Share Transfer Agent.
- Review of the various measures and initiatives taken by the listed entity for reducing the quantum of unclaimed dividends and ensuring timely receipt of dividend warrants/annual reports/statutory notices by the shareholders of the company.

The secretarial department of the Company and Registrar and Share Transfer Agents attend expeditiously to all grievances / correspondences of the shareholders and investors, received directly or through SEBI, Stock Exchanges, Ministry of Corporate Affairs and Registrar of Companies etc. The complaints are generally resolved within 15 days of receipt of letter, except in cases that are constrained by disputes or legal impediment.

**Compliance Officer:**

Mr. Prakash Sogam Company Secretary is the Compliance Officer for complying with the requirements of SEBI (Prohibition of Insider Trading) Regulation, 1992 and the Listing Regulations with the BSE.

iv) **Independent Directors Meeting:**

During the reporting financial year, a separate Meeting of the Independent Directors of the Company was held on 30<sup>th</sup> March, 2021 where at the following items as enumerated under Schedule IV to the Companies Act, 2013 and Regulation 25 of SEBI (LODR) Regulation, 2015 were set out as the Agenda:

- To Review the performance of the non-independent directors and the Board as a whole;
- To Review the performance of the chairperson of the Company, taking into account the views of executive directors and non-executive directors;
- To assess the quality, quantity and timeliness of flow of information between the management of the Company and Board.

Familiarization Programme imparted to Independent Director is available on the website of the Company (URL: [www.tejnaksh.com](http://www.tejnaksh.com))

v) **CEO/CFO Certification**

The Managing Director and the Chief Financial Officer have issued a certificate pursuant to Regulation 17 of the Listing Regulations certifying that the financial statements do not contain any untrue statement and these statements represent a true and fair view of the Company's affairs.

vi) **Auditors Report on Corporate Governance**

The auditors' certificate on compliance of Corporate Governance norms is annexed to this Report.

vii) **Detail of the Annual General Meeting of Last three year:**

**Details of the last three Annual General Meetings of the Company are given below:**

| Financial Year | AGM              | Date       | Locations   | Time       | No. of Special Resolutions Passed |
|----------------|------------------|------------|---|------------|-----------------------------------|
| 2019-20        | 13 <sup>th</sup> | 30.09.2020 | Through Video Conferencing / Other Audio Visual Means (VC/OAVM)   | 10.30 a.m. | 1                                 |
| 2018-19        | 12 <sup>th</sup> | 30.09.2019 | Lion Tarachand Bapa Hospital, Lion Tarachand Bapa Hospital Marg, Jain Society, Sion - West, Mumbai - 400022 | 12.00 Noon | Nil                               |
| 2017-18        | 11 <sup>th</sup> | 28.09.2018 | Lion Tarachand Bapa Hospital, Lion Tarachand Bapa Hospital Marg, Jain Society, Sion - West, Mumbai - 400022 | 2.30 p.m.  | Nil                               |

**Details of Special Resolutions passed in the previous three AGMs**

| Date of AGM | Particulars of Special Resolutions passed thereat  |
|-------------|--|
| 30.09.2020  | Re-appointment of Dr. Ashish Rawandale (DIN: 02005733) as a Chairman & Managing Director of the Company for a Period of Five Years |
| 30.09.2019  | Nil  |
| 28.09.2018  | Nil  |

**Postal ballot resolutions passed during the year under review:-**

No Postal Ballot resolutions passed during the year under review

viii) **Other Disclosures**

a) **Subsidiary Company:**

The Company does have Subsidiary Company (Tej Vedaant Healthcare Private Limited) in term of Regulation 24 of SEBI (Listing Obligation & Disclosure Requirements) Regulations, 2015 and hence, Company has appointed an independent director (Mr. Kiran Pawar) of the Company on the Board of such Subsidiary Company.

**b) Materially significant related party transactions:**

There were no materially significant related party transactions i.e. transactions of the Company of material nature with its promoters, directors or the management, their subsidiary or relatives etc. during the year, that may have potential conflict with interest of the Company at large.

The board has approved a policy for related party transactions which has been uploaded on the Company's website at the following link: [www.tejnaksh.com](http://www.tejnaksh.com)

**c) Statutory Compliance, Penalties and Strictures:**

The Company has complied with all requirements of the Listing Agreements entered with Stock Exchanges as well as applicable regulation and guidelines of SEBI. There were no strictures or penalties imposed by either SEBI or any Statutory Authorities for non-compliance of any matter related to the capital markets during the last three years.

**d) Whistle Blower Policy:**

The Board of Directors of the Company has adopted a Whistle Blower Policy for establishing a mechanism for employees to report to the management concerns about unethical behavior, actual or suspected fraud or violation of the Company's Code of Conduct or ethics policy. The said policy has been posted on the Company's website. The Company affirms that no employee has been denied access to the Audit Committee.

**e) Total fees for all services paid by Listed entity to the Statutory Auditor and all other network firm/network entity:**

P.D.Dalal & Co (firm registration number 102047W) was appointed as a Statutory Auditor of the Company for the period of 5 years from 2019-20 to 2023-24. The Company has paid the fees of Rs. 1,06,200 towards the audit services rendered by the firm for the financial year 2020-21 which was mutually agreed by the Board of Directors and auditors. There is no any other network firm/network entity of which Statutory Auditor is part.

**ix) NON-MANDATORY REQUIREMENTS:**

**a) Nomination and Remuneration Committee:**

The Board has set up a Nomination and Remuneration Committee. Please see details in Para on Nomination and Remuneration Committee.

**b) Shareholder Rights:**

Company's quarterly financials are published in English newspaper having a wide circulation all over India and in a Marathi newspaper widely circulated in Mumbai. The quarterly results and limited review report thereon are also put on the Company's website [www.tejnaksh.com](http://www.tejnaksh.com) periodically.

**Whistle Blower Policy:**

The Company has adopted a Whistle Blower Policy. It is also uploaded on Company's website i.e. [www.tejnaksh.com](http://www.tejnaksh.com).

**x) Details relating to utilization of IPO Proceeds:**

During the year, your Company did not raise any funds by way of Public Issues, Rights Issues and Preferential Issues, etc.

**xi) Means of Communication:**

|  |  |
|--|--|
| Quarterly / Half yearly financial results sent to each shareholder's residence.      | No, but published in the newspapers  |
| In Which Newspapers Quarterly, half yearly & annual results were normally Published. | English: Active Times<br>Marathi: Mumbai Lakshadeep  |
| Any website, where results or official news are displayed.                           | <a href="http://www.bseindia.com">www.bseindia.com</a><br><a href="http://www.tejnaksh.com">www.tejnaksh.com</a> |

The Board of Directors of the Company approved and took on record the Un-Audited / Audited financial results within 45 days and 60 days of quarter / half year respectively and communicated the result to the Stock Exchange where the shares of the Company is listed.

- a. Whether the Company also displays official News Releases- Not Applicable
- b. Presentations made to the institutional investors or to the analysts- Not Applicable

**xii) General Shareholder Information:**

**a) 14<sup>th</sup> Annual General Meeting:**

|                     |  |
|---------------------|--|
| <b>Date</b>         | 30 <sup>th</sup> September, 2021   |
| <b>Venue</b>        | The AGM will be held through Video Conferencing ('VC') / Other Audio Visual Means ('OAVM') only. |
| <b>Day and Time</b> | Thursday, 10.30 A.M.   |

**b) Financial Calendar:**

The Company follows the period of 01<sup>st</sup> April to 31<sup>st</sup> March, as the Financial Year.

For the Financial Year 2021-22, Financial Results will be announced as per the following tentative schedule.

|  |                                |
|--|--------------------------------|
| 1 <sup>st</sup> Quarter ending June, 2021                  | On or before August 14, 2021   |
| 2 <sup>nd</sup> Quarter & Half Year ending September, 2021 | On or before November 14, 2021 |
| 3 <sup>rd</sup> Quarter ending December, 2021              | On or before February 14, 2022 |
| 4 <sup>th</sup> Quarter / year ending March, 2022          | On or before May 30, 2022      |
| Annual General Meeting for the Year 2021-22                | By September, 2022             |

**c) Book Closure:**

|                              |  |
|------------------------------|--|
| <b>Dates of Book Closure</b> | Friday, September 24, 2021 to Thursday, September 30, 2021 (both days inclusive) |
|------------------------------|--|

**d) Listing:**

The Shares of the Company are listed on the BSE Limited (BSE).

**e) Listing Fees to Stock Exchanges:**

The Company has paid the Listing Fees for the year 2021-22 to the BSE Limited.

**f) Custodial Fees to Depositories:**

The Company has paid the custodial fees for the year 2021-22 to National Securities Depository Limited (NSDL) as well as to Central Depository Services Limited.

**g) Stock Code / Symbol:**

|  |                       |
|--|-----------------------|
| Bombay Stock Exchange Ltd. (BSE)   | 539428                |
| International Securities Identification Number (ISIN)                                  | INE030T01019          |
| Corporate Identity Number (CIN)<br>Allotted by the Ministry of Corporate Affairs (MCA) | L85100MH2008PLC179034 |

h) **Stock Market Price Data for the year 2020-21:**

| Month   | BSE Share Price (Rs.) |       |       |       |
|---------|-----------------------|-------|-------|-------|
|         | Open                  | High  | Low   | Close |
| Apr 20  | 36.50                 | 48.75 | 33.25 | 41.75 |
| May 20  | 41.00                 | 45.00 | 37.00 | 45.00 |
| June 20 | 42.75                 | 47.00 | 36.40 | 42.50 |
| July 20 | 43.00                 | 48.00 | 35.50 | 38.30 |
| Aug 20  | 38.40                 | 39.50 | 32.30 | 36.00 |
| Sep 20  | 36.00                 | 36.70 | 27.95 | 28.75 |
| Oct 20  | 28.00                 | 34.45 | 22.95 | 31.50 |
| Nov 20  | 33.05                 | 42.70 | 30.25 | 36.90 |
| Dec 20  | 38.60                 | 54.50 | 35.40 | 54.40 |
| Jan 21  | 56.00                 | 59.80 | 50.35 | 52.75 |
| Feb 21  | 54.50                 | 77.20 | 50.25 | 70.60 |
| Mar 21  | 74.00                 | 85.00 | 60.25 | 72.80 |

Source: www.bseindia.com

i) **Registrar and Share Transfer Agent:**

Share transfers, dividend payment and all other investor related matters are attended to and processed by our Registrar and Share Transfer Agent,

**M/s. Cameo Corporate Services Ltd.**

Submaramanian Building,

1 Club House Road, Chennai – 600 002

Tel No.: +91-44-2846 0390/1989

Fax No.: +91-44-2846 0129

Website: www.cameoindia.com

E-mail ID: investor@cameoindia.com

j) **Share Transfer System:**

Presently, the share transfers received by the Registrar and Share Transfer Agent of the Company are processed and returned within a period of 15 days from the date of its receipt, subject to documents being valid and complete in all respect. The Board has delegated the authority for approving the transfers to the Registrar and Share Transfer Agent subject to approval by Stakeholders Relationship Committee. Shareholders' Grievances and other miscellaneous correspondence on change of address, mandates, etc. received from Members are generally processed by Registrar and Share Transfer Agent of the Company within 15 days. The Company obtains from a Company Secretary in practice half yearly certificate of compliance with the share transfer formalities as required under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and files a copy of the certificate with BSE and NSE.

k) **Distribution of Shareholding as on 31<sup>st</sup> March, 2021:**

| Range of Shareholding (Rs.) | Number of Shareholders | % of Total | Amount (Rs.) | % of Total |
|-----------------------------|------------------------|------------|--------------|------------|
| 10 - 5000                   | 502                    | 67.1122    | 422850       | 0.4163     |
| 5001 - 10000                | 36                     | 4.8128     | 293630       | 0.2890     |
| 10001 - 20000               | 82                     | 10.9625    | 1405740      | 1.3840     |
| 20001 - 30000               | 20                     | 2.6737     | 507220       | 0.4993     |

|                  |            |                 |                  |                 |
|------------------|------------|-----------------|------------------|-----------------|
| 30001 - 40000    | 20         | 2.6737          | 722440           | 0.7112          |
| 40001 - 50000    | 13         | 1.7379          | 583490           | 0.5744          |
| 50001 - 100000   | 23         | 3.0748          | 1696100          | 1.6699          |
| 100001 and above | 52         | 6.9518          | 95936530         | 94.4554         |
| <b>Total</b>     | <b>748</b> | <b>100.0000</b> | <b>101568000</b> | <b>100.0000</b> |

l) **Shareholding pattern (category wise) as on 31<sup>st</sup> March, 2021:**

| Category        | Total Shareholders | Number of Shares held | % of Total Shareholding |
|-----------------|--------------------|-----------------------|-------------------------|
| Resident        | 708                | 2447766               | 24.0997                 |
| NRI             | 12                 | 111695                | 1.0997                  |
| Corporate Body  | 6                  | 80898                 | 0.7964                  |
| Clearing Member | 18                 | 16856                 | 0.1659                  |
| Promoters       | 4                  | 7499585               | 73.8380                 |
| <b>Total</b>    | <b>748</b>         | <b>10156800</b>       | <b>100.0000</b>         |

m) **Dematerialization of shares and liquidity:**

Your Company's shares are traded compulsorily in electronic form and the Company has established connectivity with both the depositories. i.e. National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL).

As on 31<sup>st</sup> March, 2021, 100% of the equity shares have been dematerialized form.

n) **E-voting**

E-voting is a common internet infrastructure that enables investors to vote electronically on resolutions of Companies. The Company will have the E-voting facility for the items to be transacted at this AGM. The MCA has authorized NSDL and CDSL for setting up electronic platform to facilitate casting of votes in electronic form. The Company has entered into agreements with NSDL for providing e-voting facilities to the shareholders.

o) **Outstanding GDR / ADR / Warrants or any convertible instruments, conversion date and its impact on equity: Nil**

p) **Unclaimed Dividend/ Amounts:**

Section 124 of the Companies Act, 2013 is not applicable to the Company.

q) **Unit locations:**

The Company has Corporate Office at Sakri Road, Dhule, Maharashtra, India - 424 001

The Company has acquired Care Point Hospital, Uran, Navi Mumbai on 09.07.2021

r) **Address for correspondence:**

**Registered Office**

A 601, Floor No.6, Kailash Business Park,

Veer Savarkar Marg, Vikroli - West,

Mumbai - 400079

Tel: 022-2754 2311;

Email id - nstituteofurology@gmail.com / cs.tejnaksh@gmail.com

Website: www.tejnaksh.com

s) **List of all credit rating obtained by the entity along with revisions thereto for all debt instruments:**

Since the entity has not issued any debt instruments or any fixed deposit programme or any scheme or any proposal of listed entity involving mobilization of funds whether in india or aborad. There is no requirement to obtain the credit ratings including revision by the entity.

**xiii) Code of Conduct and Ethics for Directors and Senior Management:**

The Company has laid down a code of conduct for all Board members and senior management personnel of the Company. A copy of the Code of conduct is available on the Company's website [www.tejnaksh.com](http://www.tejnaksh.com). The Code has been circulated to all the members of the Board and Senior Management and the compliance of the same has been affirmed by them. A declaration signed by the Managing Director is given below:

**"I hereby confirm that –**

The Company has obtained from all the members of the Board and Senior Management, affirmation that they have complied with the Code of Conduct and Ethics for Directors and Senior Management in respect of the Financial Year 2020-21."

**Sd/-  
Dr. Ashish Vishwas Rawandale  
Managing Director  
DIN: 02005733**

**AUDITORS CERTIFICATE ON CORPORATE GOVERNANCE REPORT**

**To,  
The Members of  
Tejnaksh Healthcare Limited**

We have examined all the relevant records of Tejnaksh Healthcare Limited ("the Company") for the purpose of certifying compliance of the conditions of the Corporate Governance under Chapter IV to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (Listing Regulations) for the period from April 01, 2020 to March 31, 2021. We have obtained all the information and explanation, which are to the best of our knowledge and beliefs were necessary for the purpose of certification.

The compliance of conditions of Corporate Governance is the responsibility of the Management. Our examination was limited to procedures and implementation of processes adopted by the Company for ensuring the compliance of the conditions of the Corporate Governance. This certificate is neither an audit nor an expression of opinion on the financial statements of the Company.

In our opinion and to the best of our information and according to the explanation and information furnished to us, we certify that the Company has complied with all the condition of Corporate Governance as stipulated in the said Listing Regulations.

We further state that such compliances are neither an assurance as to the future viability of the Company nor the efficiency or effectiveness with which the Management has conducted the affairs of the Company.

**For and on behalf of  
P.D.Dalal & Co.  
Chartered Accountants  
Firm Registration No.102047W**

**Sd-  
(Aashish S. Kakaria)  
Partner  
Membership No.102915  
Mumbai, June 29, 2021**

**CEO / CFO CERTIFICATION**

**To**  
**The Board of Directors**  
**Tejnaksh Healthcare Limited**  
A 601, Floor No.6, Kailash Business Park,  
Veer Savarkar Marg,  
Vikroli - West,  
Mumbai - 400079

We, Dr. Ashish Vishwas Rawandale, Managing Director and Mr. Ramesh Kuwar, Chief Financial Officer of Tejnaksh Healthcare Limited, hereby certify to the Board that:

- a) We have reviewed financial statements and the cash flow statement for the year ending 31<sup>st</sup> March, 2021 and that to the best of our knowledge and belief:
  - These statements do not contain any materially untrue statements or omit any material fact or contain statements that might be misleading;
  - These statements together present a true and fair view of the Company's affairs and are in compliance with existing Accounting Standards, applicable Laws and Regulations.
- b) There are, to the best of our knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or violation of the Company's code of conduct.
- c) We are responsible for establishing and maintaining internal controls and we have evaluated the effectiveness of the internal control systems of the Company pertaining to financial reporting. We have disclosed to the Auditors and the Audit Committee, deficiencies in the design or operation of such internal controls, if any, of which we are aware and the steps we have taken or proposed to take to rectify these deficiencies.
- d) We have indicated to the Auditors and the Audit Committee:
  - There have been no significant changes in internal control over financial reporting during the year;
  - There have been no significant changes in Accounting Policies during the year and the same have been disclosed in the notes to the financial statements; and
- e) We certify that there have been no instances of significant frauds of which we have become aware and the involvement therein, of management or any employees having significant role in the Company's internal control systems
- f) We affirm that we have not denied any personnel, access to the Audit Committee of the Company (in respect of matters involving alleged misconduct).

Sd/-  
**Dr. Ashish V. Rawandale**  
Managing Director

Sd/-  
**Mr. Ramesh Kuwar**  
Chief Finance Officer

*Mumbai, June 29, 2021*



**CERTIFICATE OF NON-DISQUALIFICATION OF DIRECTORS**  
(Pursuant to Regulation 34(3) and Schedule V Para C clause (10)(i) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015)

To,  
**The Members of**  
**Tejnaksh Healthcare Limited**  
Lion Tarachand Bapa Hospital,  
Lion Tarachand Bapa Hospital Marg,  
Sion - West, Mumbai - 400022

I have examined the relevant registers, records, forms, returns and disclosures received from the Directors of Tejnaksh Healthcare Limited having CIN - L85100MH2008PLC179034 and having registered office at Lion Tarachand Bapa Hospital, Lion Tarachand Bapa Hospital Marg, Sion - West, Mumbai - 400022 (hereinafter referred to as 'the Company'), produced before me by the Company for the purpose of issuing this Certificate, in accordance with Regulation 34(3) read with Schedule V Para-C Sub clause 10(i) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

In my opinion and to the best of my information and according to the verifications (including Directors Identification Number (DIN) status at the portal [www.mca.gov.in](http://www.mca.gov.in)) as considered necessary and explanations furnished to me by the Company & its officers, I hereby certify that none of the Directors on the Board of the Company as stated below for the Financial Year ending on 31st March, 2021 have been debarred or disqualified from being appointed or continuing as Directors of companies by the Securities and Exchange Board of India, Ministry of Corporate Affairs, Maharashtra, Mumbai or any such other Statutory Authority.

| Sr. No. | Name of Director                   | DIN      | Date of appointment in Company |
|---------|------------------------------------|----------|--------------------------------|
| 1.      | Mr. Ashish Vishwas Rawandale       | 02005733 | 18/02/2008                     |
| 2.      | Mrs. Preeti Ashish Rawandale       | 02021400 | 18/02/2008                     |
| 3.      | Mr. Vikramsinh Satish Khatal Patil | 01979626 | 30/01/2015                     |
| 4.      | Mr. Kiran Madhavrao Pawar          | 07078045 | 30/01/2015                     |
| 5.      | Mr. Sanjay Bhikajirao Khatal       | 06616883 | 13/07/2020                     |
| 6.      | Mr. Pratap Tarachand Patil         | 08765839 | 13/07/2020                     |

Ensuring the eligibility of for the appointment / continuity of every Director on the Board is the responsibility of the management of the Company. Our responsibility is to express an opinion on these based on our verification. This certificate is neither an assurance as to the future viability of the Company nor of the efficiency or effectiveness with which the management has conducted the affairs of the Company.

**Place: Mumbai**  
**Date: 29th June 2021**

For, **Bhuwnesh Bansal & Associates**

**Sd/-**  
**Bhuwnesh Bansal**  
**Proprietor**  
FCS No. - 6526  
CP No. - 9089  
UDIN: F006526C000524758

## Independent Auditor's Report

To  
The Members,  
Tejnaksh Healthcare Limited,  
Mumbai

### Report on the Standalone Financial Statements

#### Opinion

We have audited the accompanying Standalone financial statements of **Tejnaksh Healthcare Limited** (*"the Company"*) which comprises the Balance Sheet as at March 31, 2021, the Statement of Profit and Loss, (statement of changes in equity) and statement of cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies and other explanatory information.

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid standalone financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2021, and profit/loss, (changes in equity) and its cash flows for the year ended on that date.

#### Basis for Opinion

We conducted our audit in accordance with Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Key audit matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined that there are no key audit matters to be communicated in our report *except for*

**Covid Impact - In view of the highly uncertain economic environment, a definitive assessment of the impact on the subsequent periods is highly dependent on the circumstances, as they evolve.**

#### Information Other than the Financial Statements and Auditor's Report Thereon

The Company's Board of Directors is responsible for the other information. The other information comprises the Board's Report including Annexures to the Board's Report but does not include the financial statements and our auditor's report thereon.

Our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information. We are required to report that fact. We have nothing to report in this regard.

### **Management's Responsibility for the Standalone Financial Statements**

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Companies Act, 2013 ("the Act") with respect to the preparation of these standalone financial statements that give a true and fair view of the financial position, financial performance, (changes in equity) and cash flows of the Company in accordance with the accounting principles generally accepted in India, including the accounting Standards specified under section 133 of the Act. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate implementation and maintenance of accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the company's financial reporting process.

### **Auditor's Responsibility for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has an adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management. Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report.

However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the standalone financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the standalone financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the standalone financial statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the standalone financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

#### COVID Impact

Since there are increasing restrictions on travel & meetings, as a result we faced practical issues for access to the audit location in carrying out the audit.

#### Challenges in carrying audit at audit location

During this pandemic, challenges never before faced by auditors in performing audits are emerging. In response we need to be more agile and creative in performing audits and complying with the auditing standards. Now, more than ever, auditors might rely on technology in performing audit procedures. Performing auditing procedures in the middle of this pandemic is troublesome and we as auditor have encountered challenges in:

- Physical verification of inventory, fixed assets etc
- Assessing records
- Understanding and testing internal control
- Account and balance confirmations
- Performing subsequent event procedures

#### Report on Other Legal and Regulatory Requirements

As required by the Companies (Auditor's Report) Order, 2016 ("the Order"), issued by the Central Government of India in terms of sub-section (11) of section 143 of the Companies Act, 2013, we give (in the Annexure A) a statement on the matters specified in paragraphs 3 and 4 of the Order, to the extent applicable.

As required by Section 143(3) of the Act, we report that:

- (a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
- (b) In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.
- (c) The Balance Sheet, the Statement of Profit and Loss, and the Cash Flow Statement dealt with by this Report are in agreement with the books of account.
- (d) In our opinion, the aforesaid standalone financial statements comply with the Accounting Standards specified under Section 133 of the Act, read with Rule 7 of the Companies (Accounts) Rules, 2014.
- (e) On the basis of the written representations received from the directors as on 31st March, 2021 taken on record by the Board of Directors, none of the directors are disqualified as on 31st March, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.
- (f) With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls, refer to our separate Report in "Annexure B".
- (g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

- i. The Company does not have any pending litigations which would impact its financial position;
- ii. The Company has Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.;
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company

For and on behalf of  
**P.D.Dalal & Co.**  
*Chartered Accountants*  
Firm Registration No.102047W

Sd/-  
(Aashish S. Kakaria)  
*Partner*  
Membership No.102915  
UDIN: 21102915AAAAEL9704

*Mumbai*  
*29<sup>th</sup> June, 2021*

## **Annexure A to the Independent Auditors Report**

The Annexure referred to in our Independent Auditors' Report to the members of Tejnakhsh Healthcare Limited on the standalone financial statements for the year ended 31<sup>st</sup> March, 2021, we report that:

- (i)(a) In our opinion the Company has maintained proper records showing full particulars, including quantitative details and situation of fixed assets on the basis of available information.
- (b) As informed to us the Company has a regular programme of physical verification of its fixed assets by which fixed assets are verified in a phased manner over a period of three years. In accordance with this programme, certain fixed assets were verified during the year and no material discrepancies were noticed on such verification. In our opinion, this periodicity of physical verification is reasonable having regard to the size of the Company and the nature of its assets.
- (c) According to the information and explanations given to us the title deeds of the Immovable properties are held in the name of the company.
- (ii) As explained to us the inventory has been physically verified by the management during the year at reasonable intervals. In our opinion the frequency of such verification is reasonable. No material discrepancies noticed on physical verification of inventories as compared to the book record.
- (iii) In our opinion the Company has not granted any loans, secured or unsecured to companies, firms or other parties covered in the register maintained under section 189 of the Companies Act, 2013 ('the Act'). Therefore, sub clauses (a), (b) and (c) are not applicable.
- (iv) In our opinion and according to the information and explanations provided to us, the Company has not granted any loans or provided any guarantees or security to the parties covered under Section 185 and 186 of the Act and therefore, the provisions of clause (iv) of the Order are not applicable to the Company.
- (v) In our opinion and according to the information and explanations given to us the company has not accepted any deposits during the year from the public within the meaning of provisions of section 73 to 76 of the companies act 2013 and the rules framed there under and therefore, the provisions of clause (v) of the Order are not applicable to the company.
- (vi) The maintenance of cost records under sub section(1) of section 148 of the Companies Act, 2013 is not applicable in view of rule 3 of the Companies Act (Cost Records and Audit) Amendment Rules 2014 and therefore, the provisions of clause (vi) of the Order are not applicable to the Company.
- (vii) (a) The Company is generally regular in depositing with appropriate authorities undisputed statutory dues including Provident fund, Employees' State Insurance, Income-tax, Sales-tax, Goods and Services tax, Duty of Custom, Duty of Excise, Value Added Tax, Cess and Other Statutory Dues applicable to it.
- (b) According to the information and explanations provided to us, no undisputed amounts payable in respect of Provident fund, Employees' State Insurance, Income-tax, Sales Tax, Goods and Service tax, Duty of custom, Duty of excise, Value added tax, Cess and Other Statutory Dues were outstanding, at the year end, for a period of more than six months from the date they became payable.
- (c) According to the information and explanations given to us, there are no material dues of income tax, sales tax, wealth tax, service tax, duty of customs, duty of excise, value added tax and cess which have not been deposited with the appropriate authorities on account of any dispute.
- (viii) The Company has not defaulted in repayment of dues to financial institutions or banks. The company did not have borrowings by way of debentures.
- (ix) In our opinion the Company did not raise any money by way of Debt Instruments and term loans during the year.

- (x) Based upon the audit procedures performed for the purpose of reporting the true and fair view of the Financial Statements and according to the information and explanations provided by the management, we report that no fraud by the Company or no material fraud on the Company by the officers and employees of the Company has been noticed or reported during the year.
- (xi) According to the information and explanations provided by the management, the managerial remuneration has been paid/provided in accordance with the requisite approvals mandated by the provisions of Section 197 read with Schedule V to the Act.
- (xii) In our opinion and according to the information and the explanations given to us, the Company is not a Nidhi company and therefore, the provisions of clause (xii) of the order are not applicable to the company.
- (xiii) In our opinion and according to the information and the explanations given to us, and based on our examination of the records of the company, all transactions with the related parties are in compliance with section 177 and 188 of the Act where applicable and the details have been disclosed in the financial statements as required by the applicable accounting standards.
- (xiv) According to the information and explanations provided to us and on an overall examination of the balance sheet, the Company has not made any preferential allotment or private placement of shares or fully or partly convertible debentures during the year under review and hence, reporting requirements under clause 3(xiv) of the Order are not applicable to the Company and, not commented upon.
- (xv) In our opinion and according to the information and explanations given to us, the company has not entered into any non-cash transactions with directors or persons connected with him.
- (xvi) The company is not required to be registered under Section 45-IA of the Reserve Bank of India Act, 1934.

For and on behalf of  
**P.D.Dalal & Co.**  
*Chartered Accountants*  
Firm Registration No.102047W

Sd/-  
(Aashish S. Kakaria)  
*Partner*  
Membership No.102915  
UDIN: 21102915AAAAEL9704

*Mumbai*  
29<sup>th</sup> June, 2021

## **Annexure “B” to the Independent Auditors Report**

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of section 143 of the Companies Act, 2013 (“the Act”)

We have audited the internal financial controls over financial reporting of Tejnakhsh Healthcare Limited as of 31st March, 2021 in conjunction with our audit of the standalone financial statements of the Company for the year ended on that date.

### **Management’s Responsibility for Internal Financial Controls**

The Company’s management is responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls over Financial Reporting issued by the institute of Chartered Accountants of India (“ICAI”). These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Companies Act, 2013.

### **Auditors’ Responsibility**

Our responsibility is to express an opinion on the Company’s internal financial controls over financial reporting based on our audit. We conducted our audit in accordance with the Guidance Note on Audit of Internal Financial Controls over Financial Reporting (the “Guidance Note”) and the Standards on Auditing, issued by ICAI and deemed to be prescribed under section 143 (10) of the Companies Act, 2013 to the extent applicable to an audit of internal financial controls, both applicable to an audit of Internal Financial Controls and, both issued by the Institute of Chartered Accountants of India. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditor’s judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion on the Company’s internal financial controls system over financial reporting.

### **Meaning of Internal Financial Controls over Financial Reporting**

A company’s internal financial control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

### **Inherent Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting to future periods are subject to the risk that the internal financial control over financial reporting may become inadequate because of changes in conditions, or that the degree of compliance with the policies or



procedure may deteriorate.

### **Opinion**

In our opinion, the Company has, in all material respects, adequate internal financial controls over financial reporting with reference to these Standalone Financial Statements and such internal financial controls over financial reporting with reference to these Standalone Financial Statements were operating effectively as at March 31, 2021, based on the internal control over financial reporting criteria established by the Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India.

For and on behalf of

**P.D.Dalal & Co.**

*Chartered Accountants*

Firm Registration No.102047W

Sd/-

(Aashish S. Kakaria)

*Partner*

Membership No.102915

UDIN: 21102915AAAAEL9704

*Mumbai*

*29<sup>th</sup> June, 2021*

**TEJNAKSH HEALTHCARE LIMITED**  
**Balance Sheet as at March 31, 2021**

(Amount in INR, unless otherwise stated)

| Particulars                             | Notes | March 31, 2021      | March 31, 2020      |
|---|-------|---------------------|---------------------|
| <b>ASSETS</b>                           |       |                     |                     |
| <b>Non-Current Assets</b>               |       |                     |                     |
| (a) Property, Plant and Equipment       | 4     | 10,82,37,884        | 12,05,35,467        |
| (b) Capital work-in-progress            |       | 3,90,152            | 3,14,823            |
| (c) Goodwill                            | 5     | 3,50,00,000         | 4,50,00,000         |
| (d) Other Intangible Assets             | 5     | 1,20,762            | 3,79,291            |
| (e) Intangible Assets Under Development |       | 75,12,947           | 62,12,947           |
| (f) Financial Assets                    |       |                     |                     |
| (i) Investments                         | 6     | 1,06,00,600         | 1,06,00,600         |
| (ii) Other Financial Assets             | 6     | 5,05,95,599         | 1,40,728            |
| (g) Other Non-Current Assets            | 10    | 49,12,423           | 21,40,490           |
|   |       | <b>21,73,70,367</b> | <b>18,53,24,347</b> |
| <b>Current assets</b>                   |       |                     |                     |
| (a) Inventories                         | 8     | 41,53,371           | 33,46,296           |
| (b) Financial Assets                    |       |                     |                     |
| (i) Trade Receivables                   | 7     | 36,76,271           | 52,99,250           |
| (ii) Cash and Cash Equivalents          | 9     | 56,19,863           | 1,02,96,421         |
| (iii) Other Financial Assets            | 6     | 11,16,021           | 11,16,021           |
| (c) Other Current Assets                | 10    | 67,93,018           | 3,49,40,584         |
| (d) Current tax asset                   |       | -                   | 25,18,535           |
|   |       | <b>2,13,58,544</b>  | <b>5,75,17,107</b>  |
| <b>TOTAL</b>                            |       | <b>23,87,28,911</b> | <b>24,28,41,453</b> |
| <b>EQUITY AND LIABILITIES</b>           |       |                     |                     |
| <b>Equity</b>                           |       |                     |                     |
| (a) Equity Share capital                | 12    | 10,15,68,000        | 10,15,68,000        |
| (b) Other Equity                        | 13    | 6,86,88,242         | 4,85,47,810         |
|   |       | <b>17,02,56,242</b> | <b>15,01,15,810</b> |
| <b>Liabilities</b>                      |       |                     |                     |
| <b>Non Current Liabilities</b>          |       |                     |                     |
| (a) Financial Liabilities               |       |                     |                     |
| (i) Borrowings                          | 14    | 4,18,21,518         | 6,59,34,377         |
| (ii) Other financial liabilities        | 16    | 38,06,589           | 34,64,589           |
| (b) Deferred Tax liabilities (Net)      | 11    | 72,75,317           | 71,09,988           |
| (c) Other Non Current Liabilities       | 17    | 6,35,412            | 6,35,411            |
| (d) Non Current Provision               | 18    | 10,81,252           | 10,21,728           |
|   |       | <b>5,46,20,088</b>  | <b>7,81,66,093</b>  |
| <b>Current Liabilities</b>              |       |                     |                     |
| (a) Financial Liabilities               |       |                     |                     |
| (i) Borrowings                          | 14    | 4,12,937            | 6,35,559            |
| (ii) Trade Payables                     | 15    |                     |                     |
| Micro and Small Enterprises             |       | -                   | -                   |
| Others                                  |       | 15,94,043           | 26,20,970           |
| (iii) Other financial liabilities       | 16    | 81,17,068           | 90,58,666           |
| (b) Other Current Liabilities           | 17    | 10,50,638           | 19,99,976           |
| (c) Current Provision                   | 18    | 2,81,669            | 2,44,380            |
| (d) Current tax Liability               |       | 23,96,227           | -                   |
|   |       | <b>1,38,52,581</b>  | <b>1,45,59,551</b>  |
| <b>TOTAL</b>                            |       | <b>23,87,28,911</b> | <b>24,28,41,453</b> |

See accompanying notes forming part of the standalone financial statements  
In terms of our report attached.

**For P.D. Dalal & Co**

Chartered Accountants  
Firm Registration No.102047W

1 to 34

**For and on behalf of the Board  
of Directors**

Sd/-  
(Aashish Kakaria)  
Partner  
Membership No.: 102915

Mumbai  
June 29, 2021  
UDIN:21102915AAAAEL9704

Sd/- (Dr. A.V. Rawandale) Sd/- (Dr. P.A. Rawandale)  
Managing Director Director  
DIN : 02005733 DIN : 02005733

Sd/- (Prakash Sogam) Sd/- (Ramesh Kuwar)  
Company Secretary Chief Finance Officer  
Membership No.: ACS42727

**TEJNAKSH HEALTHCARE LIMITED****Statement of Profit and Loss for the year Ended March 31, 2021**

(Amount in INR, unless otherwise stated)

| Particulars                              | Notes | March 31, 2021     | March 31, 2020      |
|--|-------|--------------------|---------------------|
| <b>REVENUE</b>                           |       |                    |                     |
| Revenue from operations (net)            | 19    | 8,55,80,623        | 11,49,76,583        |
| Other income                             | 20    | 15,34,716          | 48,38,051           |
| <b>Total Revenue (I)</b>                 |       | <b>8,71,15,339</b> | <b>11,98,14,634</b> |
| <b>EXPENSES</b>                          |       |                    |                     |
| Purchases of stock-in-trade              | 21    | 52,66,846          | 53,03,637           |
| Changes in inventories of Stock-in-Trade | 22    | (8,07,075)         | 12,85,284           |
| Employee benefits expense                | 23    | 91,53,312          | 1,63,80,122         |
| Finance costs                            | 24    | 53,63,097          | 79,52,471           |
| Depreciation and amortization expense    | 25    | 61,18,917          | 58,59,307           |
| Other expenses                           | 26    | 3,61,19,114        | 5,64,27,960         |
| <b>Total Expenses (II)</b>               |       | <b>6,12,14,211</b> | <b>9,32,08,782</b>  |
| <b>Profit before tax (I) - (II)</b>      |       | <b>2,59,01,128</b> | <b>2,66,05,852</b>  |
| <b>Tax expense:</b>                      |       |                    |                     |
| Current tax                              |       | 57,27,000          | 61,38,400           |
| Deferred tax                             |       | 1,32,200           | 12,32,111           |
| <b>Profit for the year</b>               |       | <b>2,00,41,928</b> | <b>1,92,35,340</b>  |

|  |  |                    |                    |
|--|--|--------------------|--------------------|
| <b>OTHER COMPREHENSIVE INCOME</b>  |  |                    |                    |
| A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods: |  |                    | -                  |
| Actuarial gain / (loss) on liabilities   |  | 1,31,634           | -                  |
| Income tax effect  |  | (33,130)           | -                  |
| B. Other Comprehensive income to be reclassified to profit and loss in subsequent periods:     |  | -                  | -                  |
| Other Comprehensive income for the year, net of tax  |  | 98,504             | -                  |
| <b>TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX</b>                                   |  | <b>2,01,40,432</b> | <b>1,92,35,340</b> |

|   |    |      |      |
|---|----|------|------|
| <b>Basic and Diluted earnings per share (INR)</b> | 27 | 1.97 | 1.89 |
|---|----|------|------|

See accompanying notes forming part of the standalone financial statements

1 to 34

In terms of our report attached.

**For P.D. Dalal & Co**

Chartered Accountants

Firm Registration No.102047W

**For and on behalf of the Board**

Sd/-

(Aashish Kakaria)

Partner

Membership No.: 102915

Sd/-

(Dr. A.V. Rawandale)

Managing Director

DIN : 02005733

Sd/-

(Dr. P.A. Rawandale)

Director

DIN : 02005733

Mumbai

June 29, 2021

UDIN:21102915AAAAEL9704

Sd/-

(Prakash Sogam)

Company Secretary

Membership No.: ACS42727

Sd/-

(Ramesh Kuwar)

Chief Finance Officer

**TEJNAKSH HEALTHCARE LIMITED**  
**STATEMENT OF CASH FLOWS FOR THE PERIOD ENDED March 31, 2021**  
(Amount in INR, unless otherwise stated)

| Particulars  | March 31, 2021       | March 31, 2020       |
|--|----------------------|----------------------|
| <b>Profit before tax</b>   | <b>2,59,01,128</b>   | <b>2,66,05,852</b>   |
| <b>Adjustments for:</b>  |                      |                      |
| Depreciation and amortisation expense  | 61,18,917            | 58,59,307            |
| Interest Income  | (5,58,241)           | (9,00,110)           |
| Finance costs  | 53,63,097            | 79,52,471            |
| (Profit)/loss on sale/disposal property, plant and equipment and Intangibles       | 56,165               | -                    |
| Bad Debts  | 4,30,244             | -                    |
| Provision for Gratuity   | 2,28,447             | 9,66,108             |
| <b>Change in operating assets and liabilities:</b>                                 |                      |                      |
| (Increase)/Decrease in trade receivables   | 11,92,735            | (30,88,664)          |
| (Increase)/Decrease in inventories   | (8,07,075)           | 12,85,284            |
| Increase/(decrease) in trade payables  | (10,26,927)          | (5,37,238)           |
| (Increase) in other financial assets   | (5,04,54,871)        | (10,072)             |
| (Increase)/decrease in other assets  | 1,96,48,633          | (2,33,13,551)        |
| Increase/(decrease) in other financial liabilities                                 | (16,92,762)          | 41,45,247            |
| Increase/(decrease) in other liabilities   | (9,49,337)           | (59,78,712)          |
| <b>Cash generated from operations</b>  | <b>34,50,153</b>     | <b>1,29,85,922</b>   |
| Less: Income taxes paid/(Refund)   | 49,14,762            | (29,68,540)          |
| <b>Net cash inflow from operating activities</b>                                   | <b>83,64,915</b>     | <b>1,00,17,382</b>   |
| <b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>                                       |                      |                      |
| Payments for property, plant and equipment and Intangibles                         | (44,33,800)          | (1,02,02,157)        |
| Proceeds from disposal of property, plant and equipment and Intangibles            | 2,07,39,501          | -                    |
| Intangible asset under development   | (13,00,000)          | (22,75,000)          |
| Interest received  | 5,58,241             | 9,00,110             |
| <b>Net cash outflow from investing activities</b>                                  | <b>1,55,63,942</b>   | <b>(1,15,77,047)</b> |
| <b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>                                       |                      |                      |
| Proceeds from non current borrowings   | -                    | 1,50,02,144          |
| Repayment of non current borrowings  | (2,31,83,087)        | (47,12,036)          |
| Proceeds from current borrowings   | 7,54,815             | 6,35,559             |
| Repayment of current borrowings  | (9,77,437)           | (17,67,441)          |
| Interest paid  | (51,99,705)          | (69,66,750)          |
| Acquisition of non-controlling interests   | -                    | -                    |
| <b>Net cash inflow (outflow) from financing activities</b>                         | <b>(2,86,05,414)</b> | <b>21,91,475</b>     |
| Net increase (decrease) in cash and cash equivalents                               | (46,76,558)          | 6,31,810             |
| Cash and Cash Equivalents at the beginning of the financial year                   | 1,02,96,421          | 96,64,611            |
| <b>Cash and Cash Equivalents at end of the year</b>                                | <b>56,19,863</b>     | <b>1,02,96,421</b>   |
| <b>Reconciliation of cash and cash equivalents as per the cash flow statement:</b> |                      |                      |
| Cash and cash equivalents as per above comprise of the following:                  |                      |                      |
| Balances with banks in current accounts  | 21,70,415            | 31,62,029            |
| Cash on hand   | 34,49,448            | 71,34,391            |
| <b>Balances per statement of cash flows</b>  | <b>56,19,863</b>     | <b>1,02,96,421</b>   |

**Net debt Reconciliation**

This section sets out an analysis of net debt and the movements in net debt for each of the years specified :

| Particulars                          | Liabilities from financing activities |                    |                    |
|--------------------------------------|---------------------------------------|--------------------|--------------------|
|                                      | Non Current Borrowings                | Current Borrowings | Total              |
| <b>Net Debt as at April 1, 2019</b>  | <b>6,15,03,827</b>                    | <b>17,67,441</b>   | <b>6,32,71,268</b> |
| Cash Inflows                         | 1,50,02,144                           | 6,35,559           | 1,56,37,703        |
| Cash Outflows                        | (47,12,036)                           | (17,67,441)        | (64,79,477)        |
|                                      | <b>7,17,93,935</b>                    | <b>6,35,559</b>    | <b>7,24,29,493</b> |
| Interest Expense                     | 70,79,002                             | -                  | 70,79,002          |
| Interest Paid                        | (69,66,750)                           | -                  | (69,66,750)        |
| <b>Net Debt as at March 31, 2020</b> | <b>7,19,06,187</b>                    | <b>6,35,559</b>    | <b>7,25,41,745</b> |
| Cash Inflows                         | -                                     | 7,54,815           | 7,54,815           |
| Cash Outflows                        | (2,31,83,087)                         | (9,77,437)         | (2,41,60,524)      |
|                                      | <b>4,87,23,100</b>                    | <b>4,12,938</b>    | <b>4,91,36,036</b> |
| Interest Expense                     | 53,63,097                             | -                  | 53,63,097          |
| Interest Paid                        | (51,99,705)                           | -                  | (51,99,705)        |
| <b>Net Debt as at March 31, 2021</b> | <b>4,88,86,491</b>                    | <b>4,12,938</b>    | <b>4,92,99,428</b> |

See accompanying notes forming part of the standalone financial statements  
In terms of our report attached.

**For P.D. Dalal & Co**  
Chartered Accountants  
Firm Registration No.102047W

**For and on behalf of the Board**

Sd/-  
(Aashish Kakaria)  
Partner  
Membership No.: 102915

Sd/-  
(Dr. A.V. Rawandale)  
Managing Director  
DIN : 02005733

SD/-  
(Dr. P.A. Rawandale)  
Director  
DIN : 02005733

Mumbai  
June 29, 2021  
UDIN:21102915AAAAEL9704

Sd/-  
(Prakash Sogam)  
Company Secretary  
Membership No.: ACS42727

Sd/-  
(Ramesh Kuwar)  
Chief Finance Officer

**TEJNAKSH HEALTHCARE LIMITED****STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED March 31, 2021**

(Amount in INR, unless otherwise stated)

**A Equity Share Capital**

| Particulars           | Balance at the Beginning of the year | Changes in Equity share capital during the year | Balance at the end of the year |
|-----------------------|--------------------------------------|---|--------------------------------|
| <b>March 31, 2020</b> |                                      |   |                                |
| Numbers               | 1,01,56,800                          | -   | 1,01,56,800                    |
| Amount                | 10,15,68,000                         | -   | 10,15,68,000                   |
| <b>March 31, 2021</b> |                                      |   |                                |
| Numbers               | 1,01,56,800                          | -   | 1,01,56,800                    |
| Amount                | 10,15,68,000                         | -   | 10,15,68,000                   |

**B Other Equity**

| Particulars                                    | Reserves and Surplus       |                    | Total              |
|--|----------------------------|--------------------|--------------------|
|  | Securities Premium Reserve | Retained Earnings  |                    |
| <b>As at April 1, 2019</b>                     | <b>2,12,80,000</b>         | <b>80,32,482</b>   | <b>2,93,12,483</b> |
| Profit for the period                          | -                          | 1,92,35,340        | 1,92,35,340        |
| Other comprehensive income                     | -                          | -                  | -                  |
| <b>Total comprehensive income for the year</b> | <b>-</b>                   | <b>1,92,35,340</b> | <b>1,92,35,340</b> |
| Issue of bonus shares                          |                            | -                  | -                  |
| <b>As at March 31, 2020</b>                    | <b>2,12,80,000</b>         | <b>2,72,67,822</b> | <b>4,85,47,810</b> |
| Profit for the period                          | -                          | 2,00,41,928        | 2,00,41,928        |
| Other comprehensive income                     | -                          | 98,504             | 98,504             |
| <b>Total comprehensive income for the year</b> | <b>-</b>                   | <b>2,01,40,432</b> | <b>2,01,40,432</b> |
| <b>As at March 31, 2021</b>                    | <b>2,12,80,000</b>         | <b>4,74,08,254</b> | <b>6,86,88,242</b> |

See accompanying notes forming part of the standalone financial statements  
In terms of our report attached.

**For P.D. Dalal & Co**

Chartered Accountants

Firm Registration No.102047W

1 to 34

**For and on behalf of the Board**

Sd/-

**(Aashish Kakaria)**

Partner

Membership No.: 102915

Sd/-

(Dr. A.V. Rawandale)

Managing Director

DIN : 02005733

Sd/-

(Dr. P.A. Rawandale)

Director

DIN : 02005733

Mumbai

June 29, 2021

UDIN:21102915AAAAEL9704

Sd/-

(Prakash Soqam)

Company Secretary

Membership No.: ACS42727

Sd/-

(Ramesh Kuwar)

Chief Finance Officer

**TEJNAKSH HEALTHCARE LIMITED**  
**NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED MARCH 31, 2021**

**1 Corporate Information**

These statements comprise financial statements of Tejnakh Healthcare Limited ('the Company')(CIN: L85100MH2008PLC179034) and for the year ended March 31, 2021. The company is a public company domiciled in India and is incorporated under the provisions of the Companies Act applicable in India. Its shares are listed on one recognised stock exchange in India. The registered office of the company is located at A 601 Floor No 6 Kailash Business Park Veer Savarkar Marg. Mumbai - 400079.

The Company is engaged in the provision hospital and healthcare service in Mumbai and other parts of Maharashtra.

The financial statements were authorised for issue in accordance with a resolution of the directors on June 29 2021.

All amounts disclosed in the financial statements and notes have been rounded off to the nearest Lakhs as per the requirement of Schedule III, unless otherwise stated.

**2 Significant Accounting Policies**

**2.1 Statement of Compliance**

The financial statements of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015(as amended).

**2.2 Basis of preparation and presentation**

The financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair values at the end of each reporting period.

Historical Cost is generally based on the fair value of the consideration given in exchange of goods and services.

**2.3 Summary of significant accounting policies**

**(a) Foreign currency translation**

**(i) Functional and presentation currency**

Items included in the financial statements of the entity are measured using the currency of the primary economic environment in which the entity operates ('the functional currency'). The financial statements are presented in Indian rupee (INR), which is entity's functional and presentation currency.

**(ii) Transactions and balances**

Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognised in profit or loss.

**(b) Revenue recognition**

Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue is net of returns, trade allowances, rebates, value added taxes and amounts collected on behalf of third parties. The company recognises revenue when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and specific criteria have been met for each of the company's activities as described below.

**Recognising revenue from major business activities**

**(i) Sale of traded goods – pharmacy items**

Revenue from sale of pharmacy items are recognized on delivery of items to the customers which is when all the significant risks and rewards of ownership of the goods are passed to the customers.

**(ii) Inpatient and Outpatient Revenue**

Inpatient and Outpatient revenue is recognized as and when the related services are rendered.

Estimates of revenues, costs or extent of progress toward completion are revised if circumstances change. Any resulting increases or decreases in estimated revenues or costs are reflected in profit or loss in the period in which the circumstances that give rise to the revision become known by management.

**TEJNAKSH HEALTHCARE LIMITED**  
**NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED MARCH 31, 2021**

**(iii) Interest income**

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

**(iv) Dividend income**

Revenue is recognised when the company's right to receive the payment is established, which is generally when shareholders approve the dividend.

**(c) Government Grants**

Government grants are not recognised until there is reasonable assurance that the Company will comply with the conditions attaching to them and such grants can reasonably have a value placed upon them. Government grants are recognised in the profit or loss on a systematic basis over there periods in which the Company recognises as expense the related costs for which the grant was intended to compensate.

Government grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the Company with no future related costs are recognised in profit or loss in the period they become receivable.

**(d) Taxes**

**(i) Current income tax**

The tax currently payable is based on taxable profit for the year. Taxable profit differs from 'profit before tax' as reported in the statement of profit and loss because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The current tax is calculated using tax rates and tax laws that have been enacted by the end of the reporting period.

Current income-tax is measured at the amount expected to be paid to the tax authorities in accordance with the Income-tax Act, 1961.

**(ii) Deferred tax**

Deferred income tax is recognised using the Balance sheet approach. Deferred income tax assets and liabilities are recognised for deductible and taxable temporary differences arising between the tax base of assets and liabilities and their carrying amount, except when the deferred income tax arises from the initial recognition of an asset or liability in a transaction that is not a business combination and affects neither accounting nor taxable profit or loss at the time of the transaction.

Deferred income tax asset are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forward of unused tax credits and unused tax losses can be utilized.

The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized.

Deferred tax assets and liabilities are measured using substantively enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to be received or settled.

Deferred tax assets and liabilities are offset when they relate to income taxes levied by the same taxation authority and there are legally enforceable right to set off current tax assets and liabilities.

Deferred tax assets include Minimum Alternate Tax (MAT) paid in accordance with the tax laws in India, which is likely to give future economic benefits in the form of availability of set off against future economic tax liability. Accordingly, MAT is recognised as deferred tax asset in the Balance sheet when the asset can be measured reliably and it is probable that the future economic benefit associated with the asset will be realised.

**(e) Leases**

**(i) Company as a lessee**

The Company's lease asset classes primarily consist of leases for land and buildings. The Company assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Company assesses whether: (i) the contract involves the use of an identified asset (ii) the Company has substantially all of the economic benefits from use of the asset through the period of the lease and (iii) the Company has the right to direct the use of the asset. Any lease payments made at or prior to the commencement date of the lease plus any initial direct costs less any lease incentives. They are subsequently measured at cost less accumulated depreciation and impairment losses.

ROU assets are depreciated from the commencement date on a straight-line basis over the shorter of the lease term and useful life of the underlying asset. ROU assets are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. For the purpose of impairment testing, the recoverable amount (i.e. the higher of the fair value less cost to sell and the value-in-use) is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the Cash Generating Unit (CGU) to which the asset belongs.

The lease liability is initially measured at amortized cost at the present value of the future lease payments. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, using the incremental borrowing rates in the country of domicile of these leases. Lease liabilities are remeasured with a corresponding adjustment to the related ROU asset if the Company changes its assessment of whether it will exercise an extension or a termination option.

Lease liability and ROU assets have been separately presented in the Balance Sheet and lease payments have been classified as financing cash flows.

**(ii) Company as a lessor**

Leases for which the Company is a lessor is classified as a finance or operating lease. Whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee, the contract is classified as a finance lease. All other leases are classified as operating leases.

When the Company is an intermediate lessor, it accounts for its interests in the head lease and the sublease separately. The sublease is classified as a finance or operating lease by reference to the ROU asset arising from the head lease.

For operating leases, rental income is recognized on a straight line basis over the term of the relevant lease.

**(f) Impairment of non financial assets**

The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. An impairment loss is recognised immediately in the statement of profit and loss.

**(g) Cash and cash equivalents**

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

**(h) Inventories**

Inventories of medical consumables and drugs are valued at lower of cost or net realisable value. Cost is determined on weighted average basis.

Net realisable value represents the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale.

Due allowance is estimated and made by the Management for slow moving / non-moving items of inventory, wherever necessary, based on the past experience of the Company and such allowances are adjusted against the carrying inventory value.



**TEJNAKSH HEALTHCARE LIMITED**  
**NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED MARCH 31, 2021**

**(i) Non-current assets held for sale**

Non-current assets and disposal groups are classified as held for sale if their carrying amount will be recovered principally through a sale transaction rather than through continuing use. This condition is regarded as met only when the asset (or disposal group) is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such asset (or disposal group) and its sale is highly probable. Management must be committed to the sale, which should be expected to qualify for recognition as a completed sale within one year from the date of classification.

Non-current assets (and disposal groups) classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell.

**(j) Fair value measurement**

The Company measures financial instruments at fair value at each balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities

Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable

Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

**(k) Financial instruments**

**Initial recognition**

The Company recognizes financial assets and financial liabilities when it becomes a party to the contractual provisions of the instrument. All financial assets and liabilities are recognized at fair value on initial recognition. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities that are not at fair value through profit or loss are added to the fair value on initial recognition. Regular way purchase and sale of financial assets are accounted for at trade date.

**Subsequent measurement**

**(i) Financial assets carried at amortised cost**

A financial asset is subsequently measured at amortised cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

**(ii) Financial assets at fair value through other comprehensive income**

A financial asset is subsequently measured at fair value through other comprehensive income if it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

**(iii) Financial assets at fair value through profit or loss**

A financial asset which is not classified in any of the above categories are subsequently fair valued through profit or loss.

**TEJNAKSH HEALTHCARE LIMITED**  
**NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED MARCH 31, 2021**

**(iv) Financial liabilities**

Financial liabilities are subsequently carried at amortized cost using the effective interest method. For trade and other payables maturing within one year from the Balance Sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

**(v) Investment in subsidiaries**

Investment in subsidiaries is carried at cost in the separate financial statements.

**(vi) Equity instruments**

An equity instrument is any contract that evidences a residual interest in the assets of company after deducting all of its liabilities. Equity instruments are recognised at the proceeds received, net of direct issue costs.

**(I) Impairment of financial assets**

The Company measures the loss allowance for a financial instrument at an amount equal to the lifetime expected credit losses if the credit risk on that financial instrument has increased significantly since initial recognition. If the credit risk on a financial instrument has not increased significantly since initial recognition, the Company measures the loss allowance for that financial instrument at an amount equal to 12-month expected credit losses.

However, for trade receivables or any contractual right to receive cash or another financial asset that result from transactions that are within the scope of Ind AS 115, the Company measures the loss allowance at an amount equal to lifetime expected credit losses.

When making the assessment of whether there has been a significant increase in credit risk since initial recognition, the Company uses the change in the risk of a default occurring over the expected life of the financial instrument instead of the change in the amount of expected credit losses. To make that assessment, the Company compares the risk of a default occurring on the financial instrument as at the reporting date with the risk of a default occurring on the financial instrument as at the date of initial recognition and considers reasonable and supportable information, that is available without undue cost or effort, that is indicative of significant increases in credit risk since initial recognition.

**(m) Derecognition of financial assets and financial liabilities**

The Company derecognises a financial asset when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party. If the Company neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the Company recognises its retained interest in the asset and an associated liability for amounts it may have to pay.

The Company derecognises financial liabilities when, and only when, the Company's obligations discharged, cancelled or have expired. An exchange between with a lender of debt instruments substantially different terms is accounted for as an extinguishment of the original financial liability the recognition of a new financial liability. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable is recognised in the statement of profit and loss.

**(n) Property, plant and equipment**

Freehold land is carried at historical cost. All other items of property, plant and equipment are stated at cost less depreciation. The cost of an asset includes the purchase cost including import duties and non-refundable taxes, borrowing costs if capitalization criteria are met and any directly attributable costs of bringing an asset to the location and condition of its intended use.

Subsequent expenditure related to an item of PPE is added to its carrying value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance.

All other expenditure related to existing assets including day-to-day repair and maintenance expenditure and cost of replacing parts, are charged to the statement of profit and loss in the period during which such expenditure is incurred.

Projects under which tangible fixed assets are not yet ready for their intended use are carried at cost, comprising of direct cost, related incidental expenses and attributable interest and such properties are classified to the appropriate categories of PPE when completed and ready to use.

**TEJNAKSH HEALTHCARE LIMITED**  
**NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED MARCH 31, 2021**

The carrying amount of a PPE is de-recognised upon disposal of PPE or when no future economic benefits are expected from its use. Any gain or loss arising on the disposal or retirement of an item of PPE is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognised in the statement of profit and loss.

**Depreciation methods, estimated useful lives and residual value**

Depreciation on Property, Plant and Equipment (PPE) has been provided on the straight-line method as per the useful life prescribed in Schedule II to the Companies Act, 2013.

The property, plant and equipment acquired under finance leases is depreciated over the asset's useful life or over the shorter of the asset's useful life and the lease term if there is no reasonable certainty that the company will obtain ownership at the end of the lease term.

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

**(o) Intangible assets**

Intangible assets acquired separately are measured on initial recognition at cost less accumulated amortisation and accumulated impairment losses, if any.

**Goodwill**

Goodwill arising on an acquisition of a business is carried at cost as established at the date of acquisition of the business less accumulated impairment losses, if any. For the purposes of impairment testing, goodwill is allocated to each of the Company's cash-generating units that is expected to benefit from the synergies of the combination. A cash-generating unit to which goodwill has been allocated is tested for impairment annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than its carrying amount, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro rata based on the carrying amount of each asset in the unit. Any impairment loss for goodwill is recognised directly in profit or loss. An impairment loss recognised for goodwill is not reversed in subsequent periods.

On disposal of the relevant cash-generating unit, the attributable amount of goodwill is included in the determination of the profit or loss on disposal.

**Trade Mark, Patents, copyrights and other rights**

Separately acquired patents and copyrights are shown at cost. They have a finite useful life and are subsequently carried at cost less accumulated amortisation and impairment losses.

**Computer software**

Cost of software and licenses, which are acquired, are capitalised and amortized on a straight line basis over a period of 3 to 6 years or the license period, whichever is lower.

The amortisation period and method are reviewed at the end of each reporting period if the expected useful life of the asset changes from previous estimates, the effect of such change in estimates are accounted for prospectively.

An intangible asset is derecognised on disposal, or when no future economic benefits are expected from use or disposal. Gains and losses arising from de-recognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit and loss when the asset is de-recognised.

**(p) Business combinations and goodwill**

Acquisitions of businesses are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition-date fair values of the assets transferred by the Company, liabilities incurred by the Company to the former owners of the acquiree and the equity interests issued by the Company in exchange of control of the acquiree. Acquisition-related costs are generally recognised in profit or loss as incurred.

**TEJNAKSH HEALTHCARE LIMITED**  
**NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED MARCH 31, 2021**

Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the acquisition-date amounts of the identifiable assets acquired and the liabilities assumed.

**(q) Borrowing costs**

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale.

All other borrowing costs are recognised in the statement of profit and loss in the period in which they are incurred.

**(r) Provisions**

Provisions are recognised when the company has a present obligation (legal or constructive) as a result of a past event, it is probable that the company will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. When a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

**(s) Contingent liabilities**

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize a contingent liability but discloses its existence in the financial statements.

**(t) Employee benefits**

**Short-term obligations**

Liabilities for wages and salaries, including non-monetary benefits that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognised in respect of employees' services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet.

**Post-employment obligations**

**Gratuity**

The Company has an obligation towards gratuity. It provides for a lump sum payment to vested employees at retirement, death while in employment or on termination of employment of an amount based on the respective employee's salary and the tenure of employment. The liability in respect of gratuity is recognised in the books of account based on actuarial valuation by an independent actuary.

**Defined contribution plans**

The company pays provident fund contributions to publicly administered provident funds as per local regulations. The company has no further payment obligations once the contributions have been paid. The contributions are accounted for as defined contribution plans and the contributions are recognised as employee benefit expense when they are due. Prepaid contributions are recognised as an asset to the extent that a cash refund or a reduction in the future payments is available.

**(u) Earnings per share**

The Company presents basic and diluted earnings per share ("EPS") data for its equity shares.

Basic EPS is calculated by dividing the profit or loss attributable to equity shareholders of the Company by the weighted average number of equity shares outstanding during the period.

Diluted EPS is determined by adjusting the profit or loss attributable to equity shareholders and the weighted average number of equity shares outstanding, for the effects of all dilutive potential equity shares.

Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease earning per share. Potential dilutive equity shares are deemed to be converted as at the beginning of the period, unless they have been issued at a later date. Dilutive potential equity shares are determined independently for each period presented.

**(v) Segment Reporting**

Operating segments reflect the Company's management structure and the way the financial information is regularly reviewed by the Company's Chief operating decision maker (CODM). The CODM considers the business from both business and product perspective based on the dominant source, nature of risks and returns and the internal organization and management structure. The operating segments are the segments for which separate financial information is available and for which operating profit / (loss) amounts are evaluated regularly by the executive Management in deciding how to allocate resources and in assessing performance.

The accounting policies adopted for segment reporting are in line with the accounting policies of the Company. Segment revenue, segment expenses, segment assets and segment liabilities have been identified to segments on the basis of their relationship to the operating activities of the segment.

**(w) Operating cycle**

Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realization in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

**3 Critical accounting judgements and key sources of estimation uncertainty**

In the application of the Company's accounting policies, which are described in Note 2, the management of the Company are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

**Critical judgements in applying accounting policies**

The following are the critical judgements, apart from those involving estimations, that the directors have made in the process of applying the Company's accounting policies and that have the most significant effect on the amounts recognised in the financial statements.

**(i) Useful lives of property, plant and equipment**

Management reviews the useful lives of property, plant and equipment at least once a year. Such lives are dependent upon an assessment of both the technical lives of the assets and also their likely economic lives based on various internal and external factors including relative efficiency and operating costs. Accordingly, depreciable lives are reviewed annually using the best information available to the Management.

**TEJNAKSH HEALTHCARE LIMITED**  
**NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED MARCH 31, 2021**

**(ii) Impairment of non financial assets and goodwill**

Determining whether the asset/goodwill is impaired requires an estimation of the value in use of the cash-generating units to which asset/goodwill has been allocated. The value in use calculation requires the Company to estimate the future cash flows expected to arise from the cash-generating unit and a suitable discount rate in order to calculate present value. Where the actual future cash flows are less than expected, a material impairment loss may arise.

**(iii) Valuation of deferred tax assets**

The Company reviews the carrying amount of deferred tax assets at the end of each reporting period.

**(iv) Provisions and Contingent liabilities**

A provision is recognised when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. These are reviewed at each Balance sheet date and adjusted to reflect the current best estimates.

**TEJNAKSH HEALTHCARE LIMITED****Notes to financial statements for the period ended March 31, 2021**

(Amount in INR, unless otherwise stated)

**4. PROPERTY, PLANT AND EQUIPMENT**

| Particulars                                    | Buildings          | Plant and Equipments | Office Equipments | Furniture and Fixtures | Computers       | Vehicles         | Total               |
|--|--------------------|----------------------|-------------------|------------------------|-----------------|------------------|---------------------|
| <b>GROSS CARRYING VALUE</b>                    |                    |                      |                   |                        |                 |                  |                     |
| <b>As at April 1, 2019</b>                     | 7,66,13,929        | 4,27,51,336          | 17,72,146         | 19,70,954              | 6,91,004        | 22,61,188        | 12,60,60,558        |
| Additions                                      | 2,26,071           | 36,08,086            | 2,07,442          | -                      | 30,700          | 57,79,693        | 98,51,992           |
| Disposals                                      | -                  | -                    | -                 | -                      | -               | -                | -                   |
| <b>As at March 31, 2020</b>                    | <b>7,68,40,000</b> | <b>4,63,59,422</b>   | <b>19,79,588</b>  | <b>19,70,954</b>       | <b>7,21,704</b> | <b>80,40,881</b> | <b>13,59,12,550</b> |
| Additions                                      | 2,42,079           | 38,90,488            | 1,65,775          | -                      | 60,130          | -                | 43,58,471           |
| Disposals                                      | 40,45,920          | 77,89,000            | 3,25,688          | -                      | 1,77,174        | -                | 1,23,37,782         |
| <b>As at March 31, 2021</b>                    | <b>7,30,36,159</b> | <b>4,24,60,910</b>   | <b>18,19,675</b>  | <b>19,70,954</b>       | <b>6,04,660</b> | <b>80,40,881</b> | <b>12,79,33,239</b> |
| <b>ACCUMULATED DEPRECIATION/IMPAIRMENT</b>     |                    |                      |                   |                        |                 |                  |                     |
| <b>As at April 1, 2019</b>                     | 23,61,889          | 49,07,880            | 6,40,458          | 2,59,354               | 2,90,605        | 11,22,762        | 95,82,948           |
| Depreciation for the year                      | 12,23,089          | 31,78,265            | 3,91,844          | 2,00,566               | 1,77,502        | 6,22,869         | 57,94,135           |
| Deductions\Adjustments during the period       | -                  | -                    | -                 | -                      | -               | -                | -                   |
| <b>As at March 31, 2020</b>                    | <b>35,84,978</b>   | <b>80,86,145</b>     | <b>10,32,302</b>  | <b>4,59,920</b>        | <b>4,68,107</b> | <b>17,45,630</b> | <b>1,53,77,083</b>  |
| Depreciation for the year                      | 12,15,196          | 33,40,415            | 2,85,052          | 1,87,159               | 1,49,938        | 8,87,027         | 60,64,787           |
| Deductions\Adjustments during the period       | 1,80,718           | 13,11,977            | 1,18,399          | -                      | 1,35,421        | -                | 17,46,515           |
| <b>As at March 31, 2021</b>                    | <b>46,19,456</b>   | <b>1,01,14,583</b>   | <b>11,98,955</b>  | <b>6,47,079</b>        | <b>4,82,625</b> | <b>26,32,657</b> | <b>1,96,95,355</b>  |
| <b>Net Carrying value as at March 31, 2021</b> | <b>6,84,16,703</b> | <b>3,23,46,327</b>   | <b>6,20,720</b>   | <b>13,23,875</b>       | <b>1,22,036</b> | <b>54,08,224</b> | <b>10,82,37,884</b> |
| <b>Net Carrying value as at March 31, 2020</b> | <b>7,32,55,022</b> | <b>3,82,73,277</b>   | <b>9,47,286</b>   | <b>15,11,034</b>       | <b>2,53,597</b> | <b>62,95,251</b> | <b>12,05,35,467</b> |

**Note:**

All the property, plant and equipments are charged as security against the secured borrowings of the Company

**TEJNAKSH HEALTHCARE LIMITED****NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED March 31, 2021***(Amount in INR, unless otherwise stated)***5. INTANGIBLE ASSETS**

| Particulars                                    | Goodwill           | Patents       | Trade Mark    | Software        | Total              |
|--|--------------------|---------------|---------------|-----------------|--------------------|
| <b>GROSS CARRYING VALUE</b>                    |                    |               |               |                 |                    |
| <b>As at April 1, 2019</b>                     | 4,50,00,000        | 19,372        | 66,050        | 3,30,400        | 4,54,15,822        |
| Additions                                      | -                  | 22,840        | 12,500        | -               | 35,340             |
| Deletions                                      | -                  | -             | -             | -               | -                  |
| Acquisition through business combinations      | -                  | -             | -             | -               | -                  |
| <b>As at March 31, 2020</b>                    | <b>4,50,00,000</b> | <b>42,212</b> | <b>78,550</b> | <b>3,30,400</b> | <b>4,54,51,162</b> |
| Additions                                      | -                  | -             | -             | -               | -                  |
| Deletions                                      | 1,00,00,000        | -             | -             | 3,30,400        | 1,03,30,400        |
| <b>As at March 31, 2021</b>                    | <b>3,50,00,000</b> | <b>42,212</b> | <b>78,550</b> | <b>-</b>        | <b>3,51,20,762</b> |
| <b>ACCUMULATED AMORTISATION AND IMPAIRMENT</b> |                    |               |               |                 |                    |
| <b>As at April 1, 2019</b>                     | -                  | -             | -             | 6,699           | 6,699              |
| Amortisation for the year                      | -                  | -             | -             | 65,172          | 65,172             |
| Deductions\Adjustments during the period       | -                  | -             | -             | -               | -                  |
| <b>As at March 31, 2020</b>                    | -                  | -             | -             | 71,871          | 71,871             |
| Amortisation for the year                      | -                  | -             | -             | 54,130          | 54,130             |
| Deductions\Adjustments during the period       | -                  | -             | -             | 1,26,001        | 1,26,001           |
| <b>As at March 31, 2021</b>                    | <b>-</b>           | <b>-</b>      | <b>-</b>      | <b>-</b>        | <b>-</b>           |
| <b>Net Carrying value as at March 31, 2021</b> | <b>3,50,00,000</b> | <b>42,212</b> | <b>78,550</b> | <b>-</b>        | <b>3,51,20,762</b> |
| <b>Net Carrying value as at March 31, 2020</b> | <b>4,50,00,000</b> | <b>42,212</b> | <b>78,550</b> | <b>2,58,529</b> | <b>4,53,79,291</b> |

**Impairment testing of goodwill**

The goodwill is measured as the excess of the sum of the consideration transferred over the net of acquisition date amount of identified assets acquired and liabilities assumed.

For the purpose of impairment testing, goodwill is allocated to the cash generating units (businesses acquired) that is expected to benefit from the synergies of the combination.

The Company tests whether goodwill has suffered any impairment periodically. The recoverable amount of a cash generating unit (CGU) is determined based on fair value less cost to sell of the underlying asset.

Based on the evaluation by the management, the goodwill has not suffered any impairment during the year.

On 1st February, 2021 the company discontinued and disposed off its operations at Lion Tarachand Bapa Hospital, Mumbai. On disposal the attributable amount of goodwill is included in the determination of the profit or loss on disposal.



**6. FINANCIAL ASSETS**

| Particulars   | March 31, 2021     | March 31, 2020     |
|---|--------------------|--------------------|
| <b>(A) INVESTMENTS</b>  |                    |                    |
| <b>Non Current</b>  |                    |                    |
| (1) Investments carried at fair value through Profit and Loss |                    |                    |
| Unquoted  |                    |                    |
| Investments in Equity Instruments                             |                    |                    |
| Marvela Society, Thane  | 600                | 600                |
| (2) Investments carried at Cost                               |                    |                    |
| Unquoted  |                    |                    |
| Investments in Equity Instruments of Subsidiary               |                    |                    |
| Tej Vedaant Healthcare Private Limited                        | 1,06,00,000        | 1,06,00,000        |
| <b>Total</b>  | <b>1,06,00,600</b> | <b>1,06,00,600</b> |
| Aggregate amount of unquoted investments                      | 1,06,00,600        | 1,06,00,600        |
| Aggregate amount of impairment in the value of investments    | -                  | -                  |
| <b>(B) OTHER FINANCIAL ASSETS</b>                             |                    |                    |
| <b>Non Current</b>  |                    |                    |
| Financial assets carried at amortised cost                    |                    |                    |
| Bank Deposits with more than 12 months maturity               | 5,05,95,599        | 1,40,728           |
| <b>Total</b>  | <b>5,05,95,599</b> | <b>1,40,728</b>    |
| <b>Current</b>  |                    |                    |
| Financial assets carried at amortised cost                    |                    |                    |
| Security Deposits   | 11,16,021          | 11,16,021          |
| <b>Total</b>  | <b>11,16,021</b>   | <b>11,16,021</b>   |

**7. TRADE RECEIVABLES**

| Particulars                | March 31, 2021   | March 31, 2020   |
|----------------------------|------------------|------------------|
| <b>Current</b>             |                  |                  |
| <b>Trade Receivables</b>   |                  |                  |
| Secured, considered good   | -                | -                |
| Unsecured, considered good | 36,76,271        | 52,99,250        |
| Doubtful                   | -                | -                |
|                            | <b>36,76,271</b> | <b>52,99,250</b> |

**8. INVENTORIES**

| Particulars   | March 31, 2021   | March 31, 2020   |
|---|------------------|------------------|
| <b>(Valued at lower of Cost and Net Realisable value)</b> |                  |                  |
| Stock-in-trade (Medical consumables and Drugs)            | 41,53,371        | 33,46,296        |
| <b>Total</b>  | <b>41,53,371</b> | <b>33,46,296</b> |

**9. CASH AND CASH EQUIVALENTS**

| Particulars                             | March 31, 2021   | March 31, 2020     |
|---|------------------|--------------------|
| Balances with banks in current accounts | 21,70,415        | 31,62,029          |
| Cash on hand                            | 34,49,448        | 71,34,391          |
|   | <b>56,19,863</b> | <b>1,02,96,421</b> |

**TEJNAKSH HEALTHCARE LIMITED****NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED March 31, 2021**

(Amount in INR, unless otherwise stated)

**10. OTHER ASSETS**

| Particulars                                       | March 31,<br>2021 | March 31,<br>2020  |
|---|-------------------|--------------------|
| <b>Non Current</b>                                |                   |                    |
| Capital advances                                  | 6,12,300          | 5,57,300           |
| Payment of Taxes (Net of Provisions)              | 36,16,122         | 12,41,189          |
| Others  | 6,84,001          | 3,42,001           |
| <b>Total</b>                                      | <b>49,12,423</b>  | <b>21,40,490</b>   |
| <b>Current</b>                                    |                   |                    |
| <b>Advances other than Capital advances</b>       |                   |                    |
| - Advances to vendors                             | 33,72,778         | 1,12,60,053        |
| - Other Advances                                  | 22,17,777         | 2,23,70,166        |
| Prepaid Expenses                                  | 11,72,431         | 12,80,333          |
| Balance with Statutory and Government Authorities | 30,032            | 30,032             |
| <b>Total</b>                                      | <b>67,93,018</b>  | <b>3,49,40,584</b> |

**11. INCOME TAX****Deferred Tax**

| Particulars  | March 31,<br>2021  | March 31,<br>2020  |
|--|--------------------|--------------------|
| <b>Deferred tax relates to the following:</b>                              |                    |                    |
| Temporary differences in carrying amount of Property, plant and equipments | (75,58,212)        | (73,63,929)        |
| Provision for Gratuity   | 3,43,020           | 3,52,231           |
| Financial liability at amortised cost                                      | (60,124)           | (98,290)           |
| <b>Net Deferred Tax Liabilities</b>  | <b>(72,75,317)</b> | <b>(71,09,988)</b> |

**Movement in deferred tax liabilities/assets**

| Particulars   | March 31,<br>2021  | March 31,<br>2020  |
|---|--------------------|--------------------|
| <b>Opening balance as of April 1</b>                                | (71,09,988)        | (58,77,877)        |
| Tax income/(expense) during the period recognised in profit or loss | (1,32,200)         | (12,32,111)        |
| Recognise in OCI  | (33,130)           | -                  |
| <b>Closing balance as at March 31</b>                               | <b>(72,75,317)</b> | <b>(71,09,988)</b> |

The Company offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority

**Major Components of income tax expense for the years ended March 31, 2021 and March 31, 2020 are as follows:**

**Income tax recognised in profit or loss**

|   | 2020-21          | 2019-20          |
|---|------------------|------------------|
| Current income tax charge                                     | 57,27,000        | 61,38,400        |
| Adjustment in respect of current income tax of previous year  | -                | -                |
| <b>Deferred tax</b>   |                  |                  |
| Relating to origination and reversal of temporary differences | 1,32,200         | 12,32,111        |
| <b>Income tax expense recognised in profit or loss</b>        | <b>58,59,200</b> | <b>73,70,511</b> |

**Reconciliation of tax expense and accounting profit multiplied by income tax rate for March 31, 2021 and March 31, 2020**

|   | 2020-21          | 2019-20          |
|---|------------------|------------------|
| Accounting profit before income tax     | 2,59,01,128      | 2,66,05,852      |
| Enacted tax rate in India               | 25.17%           | 27.82%           |
| <b>Income tax on accounting profits</b> | <b>65,18,796</b> | <b>74,01,748</b> |
| <b>Tax effect of</b>                    |                  |                  |
| Other adjustments                       | (6,59,596)       | (31,236)         |
| <b>Tax at effective income tax rate</b> | <b>58,59,200</b> | <b>73,70,512</b> |

## 12. SHARE CAPITAL

### i. Authorised Share Capital

|                                     | Equity Share of INR 10 each |                     |
|-------------------------------------|-----------------------------|---------------------|
|                                     | Number                      | Amount              |
| <b>At April 1, 2019</b>             | 1,05,00,000                 | 10,50,00,000        |
| Increase/(decrease) during the year | -                           | -                   |
| <b>At March 31, 2020</b>            | 1,05,00,000                 | 10,50,00,000        |
| Increase/(decrease) during the year | -                           | -                   |
| <b>At March 31, 2021</b>            | <b>1,05,00,000</b>          | <b>10,50,00,000</b> |

### Terms/rights attached to equity shares

The company has only one class of equity shares having par value of INR 10 per share. Each holder of equity shares is entitled to one vote per share. The company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

### ii. Issued Capital

| Particulars   | Number             | Amount              |
|---|--------------------|---------------------|
| <b>Equity shares of INR 10 each issued, subscribed and fully paid</b> |                    |                     |
| <b>At April 1, 2019</b>   | 1,01,56,800        | <b>10,15,68,000</b> |
| Issued during the period  | -                  | -                   |
| <b>At March 31, 2020</b>  | <b>1,01,56,800</b> | <b>10,15,68,000</b> |
| Issued during the period  | -                  | -                   |
| <b>At March 31, 2021</b>  | <b>1,01,56,800</b> | <b>10,15,68,000</b> |

### iii. Details of shareholders holding more than 5% shares in the company

| Name of the shareholder                        | As at March 31, 2021 |           | As at March 31, 2020 |           |
|--|----------------------|-----------|----------------------|-----------|
|  | Number               | % holding | Number               | % holding |
| <b>Equity shares of INR 10 each fully paid</b> |                      |           |                      |           |
| Dr. Ashish Vishwas Rawandale                   | 38,74,601            | 38.15%    | 38,73,201            | 38.13%    |
| Dr. Preeti Ashish Rawandale                    | 36,08,699            | 35.53%    | 36,08,699            | 35.53%    |

### iv. Aggregate number of equity shares issued as bonus, shares issued for consideration other than cash and shares bought back during the period of five years immediately preceding the reporting date:

The Company has allotted 79,48,800 (March 31, 2017: 11,04,000) fully paid up shares of face value INR 10 each in financial year 2018-19, pursuant to bonus issue approved by the shareholders through postal ballot.

## 13. OTHER EQUITY

| Particulars                             | March 31, 2021     | March 31, 2020     |
|---|--------------------|--------------------|
| <b>i. Reserves and Surplus</b>          |                    |                    |
| Securities Premium Reserve              | 2,12,80,000        | 2,12,80,000        |
| Retained Earnings                       | 4,73,09,738        | 2,72,67,810        |
| <b>ii. Other Comprehensive Income</b>   |                    |                    |
| Re-measurement of defined benefit plans | 98,504             | -                  |
|   | <b>6,86,88,242</b> | <b>4,85,47,810</b> |

### (a) Securities Premium Reserve

|                         | March 31, 2021     | March 31, 2020     |
|-------------------------|--------------------|--------------------|
| Opening balance         | 2,12,80,000        | 2,12,80,000        |
| Changes during the year | -                  | -                  |
| <b>Closing balance</b>  | <b>2,12,80,000</b> | <b>2,12,80,000</b> |

The amount received in excess of face value of the shares is recognised in Share premium reserve. This is not available for distribution of dividend but can be utilised for issuing bonus shares.

### (b) Re-measurement of defined benefit plans

|                         | March 31, 2021 | March 31, 2020 |
|-------------------------|----------------|----------------|
| Opening balance         | -              | -              |
| Changes during the year | 98,504         | -              |
| <b>Closing balance</b>  | <b>98,504</b>  | <b>-</b>       |

**TEJNAKSH HEALTHCARE LIMITED****NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED March 31, 2021***(Amount in INR, unless otherwise stated)***(b) Retained Earnings**

|                                  | <b>March 31,<br/>2021</b> | <b>March 31,<br/>2020</b> |
|----------------------------------|---------------------------|---------------------------|
| Opening balance                  | 2,72,67,810               | 80,32,469                 |
| Net Profit/(Loss) for the period | 2,00,41,928               | 1,92,35,340               |
| <b>Closing balance</b>           | <b>4,73,09,738</b>        | <b>2,72,67,810</b>        |

**14. BORROWINGS**

| <b>Particulars</b>                                | <b>March 31,<br/>2021</b> | <b>March 31,<br/>2020</b> |
|---|---------------------------|---------------------------|
| <b>Non Current Borrowings</b>                     |                           |                           |
| <b>Secured</b>                                    |                           |                           |
| Term Loans  |                           |                           |
| From Banks  | 4,68,42,328               | 6,86,93,337               |
| From Others                                       | 20,44,163                 | 32,12,850                 |
|   | <b>4,88,86,491</b>        | <b>7,19,06,186</b>        |
| <b>Current Maturity of Non Current Borrowings</b> |                           |                           |
| Term Loans  |                           |                           |
| From Banks  | 57,00,321                 | 47,05,267                 |
| From Others                                       | 13,64,652                 | 12,66,542                 |
|   | <b>70,64,973</b>          | <b>59,71,810</b>          |
| <b>Total (A)-(B)</b>                              | <b>4,18,21,518</b>        | <b>6,59,34,377</b>        |
| <b>Current Borrowings</b>                         |                           |                           |
| <b>Unsecured - Repayable on demand</b>            |                           |                           |
| Loans from Related Parties (Refer Note:29)        | 4,12,937                  | 6,35,559                  |
| <b>Total</b>                                      | <b>4,12,937</b>           | <b>6,35,559</b>           |

**TEJNAKSH HEALTHCARE LIMITED****NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED March 31, 2021**

(Amount in INR, unless otherwise stated)

| Particulars  | Terms of Repayment  | March 31, 2021     | March 31, 2020     |
|--|---|--------------------|--------------------|
| <b>Non Current Borrowings</b>                            |   |                    |                    |
| <b>Secured</b>   |   |                    |                    |
| <b>Term Loan from Banks</b>                              |   |                    |                    |
| Kotak Mahindra Bank Limited                              | In the year 2018-19, the company borrowed INR 2,74,00,000 which was repayable in 96 equated monthly installments of INR 4,15,773 starting from February 10, 2019. During the year company has made a lumpsum repayment of Rs. 57,00,000 towards principal amount. Outstanding amount as on 31.03.2021 is repayable in 66 equated monthly installments of INR 3,15,576. The same is secured against the immovable properties of the company. | 1,62,97,181        | 2,44,36,293        |
| Standard Chartered Bank Limited                          | In the year 2017-18, the company borrowed INR 3,50,30,805 , which is repayable in 48 equated monthly installments of INR 3,79,131 starting from March 2019. During the year company has made a lumpsum repayment of Rs. 84,10,771 towards principal amount. Outstanding amount as on 31.03.2021 is repayable in 26 equated monthly installments of INR 3,79,131. The loan is secured against company's immovable properties.                | 2,30,84,840        | 3,35,91,453        |
| Kotak Mahindra Bank Limited                              | In the year 2019-20, the company borrowed INR 1,13,00,000 which is repayable in 120 equated monthly installments of INR 1,49,018 starting from May 3rd, 2019. During the year company has made a lumpsum repayment of Rs. 25,00,000 towards principal amount. Outstanding amount as on 31.03.2021 is repayable in 89 equated monthly installments of INR 1,13,080. The same is secured against the immovable properties of the company.     | 74,60,307          | 1,06,65,590        |
| <b>Term Loan from Others</b>                             |   |                    |                    |
| Daimler Financial Services                               | During the year 2019-20, the company borrowed INR 37,02,144 which is repayable in 36 equated monthly installments of INR 97,909 starting from November 14th, 2019. The same is secured against the vehicle of the company.  | 20,44,163          | 32,12,850          |
| <b>Gross Non Current Borrowings</b>                      |   | <b>4,88,86,491</b> | <b>7,19,06,186</b> |
| Less: Current maturity                                   |   | 70,64,973          | 59,71,810          |
| <b>Net Non Current Borrowings (as per Balance sheet)</b> |   | <b>4,18,21,518</b> | <b>6,59,34,376</b> |

| Particulars                | Terms of Repayment  | March 31, 2021 | March 31, 2020 |
|----------------------------|---------------------|----------------|----------------|
| <b>Current Borrowings</b>  |                     |                |                |
| <b>Unsecured</b>           |                     |                |                |
| Loans from Related Parties | Repayable on demand | 4,12,937       | 6,35,559       |

The property, plant and equipments are charged as security against secured borrowings of the Company

The secured borrowings are guaranteed by promoter director

**15. TRADE PAYABLES**

| Particulars   | March 31, 2021   | March 31, 2020   |
|---|------------------|------------------|
| <b>Current</b>  |                  |                  |
| Trade Payables to Micro, Small and Medium Enterprises | -                | -                |
| Trade Payables to Others                              | 15,94,043        | 26,20,970        |
| <b>Total</b>  | <b>15,94,043</b> | <b>26,20,970</b> |

**Details Of Dues To Micro And Small Enterprises As Defined Under Micro, Small And Medium Enterprises Development Act, 2006 (MSMED Act, 2006)**

The company does not possess information as to which of its suppliers are covered under the Micro, Small and Medium Enterprise Development Act, 2006. However the company is regular in making payments to its suppliers and has not received any claim in respect of interest for delayed payment.

**16. OTHER FINANCIAL LIABILITIES**

| Particulars                                  | March 31, 2021   | March 31, 2020   |
|--|------------------|------------------|
| <b>Non - Current</b>                         |                  |                  |
| Deposit Payable                              | 38,06,589        | 34,64,589        |
| <b>Total</b>                                 | <b>38,06,589</b> | <b>34,64,589</b> |
| <b>Current</b>                               |                  |                  |
| Current maturities of non current borrowings | 70,64,973        | 59,71,810        |
| Interest Accrued but not due                 | 2,91,286         | 5,04,106         |
| Payable for expenses                         | 7,60,808         | 25,82,750        |
| <b>Total</b>                                 | <b>81,17,068</b> | <b>90,58,666</b> |

**17. OTHER LIABILITIES**

| Particulars           | March 31, 2021   | March 31, 2020   |
|-----------------------|------------------|------------------|
| <b>Non - Current</b>  |                  |                  |
| Others                | 6,35,412         | 6,35,411         |
| <b>Total</b>          | <b>6,35,412</b>  | <b>6,35,411</b>  |
| <b>Current</b>        |                  |                  |
| Advances received     | 1,00,000         | 4,55,318         |
| Statutory Liabilities | 6,08,638         | 12,02,657        |
| Other                 | 3,42,000         | 3,42,001         |
| <b>Total</b>          | <b>10,50,638</b> | <b>19,99,976</b> |

**18. PROVISION**

| Particulars          | March 31, 2021   | March 31, 2020   |
|----------------------|------------------|------------------|
| <b>Non - Current</b> |                  |                  |
| Gratuity             | 10,81,252        | 10,21,728        |
| <b>Total</b>         | <b>10,81,252</b> | <b>10,21,728</b> |
| <b>Current</b>       |                  |                  |
| Gratuity             | 2,81,669         | 2,44,380         |
| <b>Total</b>         | <b>2,81,669</b>  | <b>2,44,380</b>  |

**19. REVENUE FROM OPERATIONS**

| Particulars                     | March 31, 2021     | March 31, 2020      |
|---------------------------------|--------------------|---------------------|
| <b>Sale of products</b>         |                    |                     |
| Traded Goods                    | 1,01,63,246        | 1,36,30,657         |
| <b>Sale of services</b>         |                    |                     |
| Consultation Fee                | 63,44,038          | 81,48,976           |
| Operation & Surgery             | 5,29,68,055        | 7,52,13,140         |
| Pathology                       | 95,43,883          | 1,20,23,101         |
| <b>Other Operating Revenues</b> | 65,61,400          | 59,60,710           |
|                                 | <b>8,55,80,623</b> | <b>11,49,76,583</b> |

**20. OTHER INCOME**

| Particulars                            | March 31, 2021   | March 31, 2020   |
|--|------------------|------------------|
| Interest income on Bank fixed deposits | 5,58,241         | 9,00,110         |
| Miscellaneous Income                   | 9,76,475         | 39,37,941        |
|  | <b>15,34,716</b> | <b>48,38,051</b> |

**TEJNAKSH HEALTHCARE LIMITED****NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED March 31, 2021**

(Amount in INR, unless otherwise stated)

**21. PURCHASES OF STOCK-IN-TRADE**

| Particulars                   | March 31, 2021   | March 31, 2020   |
|-------------------------------|------------------|------------------|
| Medical consumables and Drugs | 52,66,846        | 53,03,637        |
|                               | <b>52,66,846</b> | <b>53,03,637</b> |

**22. CHANGES IN INVENTORIES OF STOCK-IN-TRADE**

| Particulars   | March 31, 2021    | March 31, 2020   |
|---|-------------------|------------------|
| <b>Inventories as at the beginning of the year</b><br>Stock-in-trade  | 33,46,296         | 46,31,580        |
| <b>Less : Inventories as at the end of the year</b><br>Stock-in-trade | 41,53,371         | 33,46,296        |
| <b>Net decrease / (increase) in inventories</b>                       | <b>(8,07,075)</b> | <b>12,85,284</b> |

**23. EMPLOYEE BENEFITS EXPENSE**

| Particulars                                | March 31, 2021   | March 31, 2020     |
|--|------------------|--------------------|
| Salaries, wages and bonus                  | 86,32,952        | 1,51,38,944        |
| Contributions to provident and other funds | 2,91,913         | 2,75,070           |
| Gratuity Expense                           | 2,28,447         | 9,66,108           |
|  | <b>91,53,312</b> | <b>1,63,80,122</b> |

**24. FINANCE COST**

| Particulars                              | March 31, 2021   | March 31, 2020   |
|--|------------------|------------------|
| Interest expense on debts and borrowings | 51,97,983        | 79,28,281        |
| Other borrowing cost                     | 1,65,114         | 24,190           |
|  | <b>53,63,097</b> | <b>79,52,471</b> |

**25. DEPRECIATION AND AMORTISATION EXPENSE**

| Particulars                       | March 31, 2021   | March 31, 2020   |
|-----------------------------------|------------------|------------------|
| Depreciation on tangible assets   | 60,64,787        | 57,94,135        |
| Amortisation of intangible assets | 54,130           | 65,172           |
|                                   | <b>61,18,917</b> | <b>58,59,307</b> |



**TEJNAKSH HEALTHCARE LIMITED****NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED March 31, 2021***(Amount in INR, unless otherwise stated)***26. OTHER EXPENSES**

| Particulars   | March 31, 2021     | March 31, 2020     |
|---|--------------------|--------------------|
| Hospital Expenses                                     | 68,97,345          | 1,46,41,762        |
| Pathology Expenses                                    | 21,43,287          | 21,00,354          |
| Oxygen Cylinder                                       | 4,66,480           | 5,79,434           |
| Net Consumption of X Ray Film                         | 3,23,608           | 4,41,140           |
| Legal and professional fees                           | 1,86,95,648        | 2,83,71,448        |
| House Keeping Expenses                                | 11,23,977          | 20,84,118          |
| Electricity and power expense                         | 17,95,519          | 23,72,824          |
| Printing and Stationery                               | 4,13,903           | 5,85,693           |
| Repairs and maintenance                               | 13,79,795          | 14,38,539          |
| Rent  | -                  | 39,150             |
| Bad Debts   | 4,30,244           | 27,163             |
| Advertisement   | 1,21,682           | 1,10,869           |
| Payments to auditors (Refer note below)               | 1,06,200           | 2,12,200           |
| Insurance   | 3,23,915           | 2,93,100           |
| Telephone and internet expenses                       | 53,412             | 1,03,468           |
| Travelling and conveyance expenses                    | 1,84,378           | 14,18,673          |
| Net loss on disposal of property, plant and equipment | 56,165             | -                  |
| Miscellaneous expenses                                | 16,03,557          | 16,08,025          |
| <b>Total</b>  | <b>3,61,19,114</b> | <b>5,64,27,960</b> |

**Details of Payments to auditors**

|                   | March 31, 2021  | March 31, 2020  |
|-------------------|-----------------|-----------------|
| <b>As auditor</b> |                 |                 |
| Audit Fee         | 1,06,200        | 2,12,200        |
|                   | <b>1,06,200</b> | <b>2,12,200</b> |

**27. EARNINGS PER SHARE**

| Particulars   | 2020-21     | 2019-20     |
|---|-------------|-------------|
| <b>Basic and Diluted earnings per share (INR)</b>   | 1.97        | 1.89        |
| <b>Nominal value per share (INR)</b>  | 10.00       | 10.00       |
| Profit attributable to the equity holders of the company used in calculating basic and diluted earnings per share   | 2,00,41,928 | 1,92,35,340 |
| Weighted average number of equity shares used as the denominator in calculating basic and diluted earnings per share (including the impact of bonus shares) | 1,01,56,800 | 1,01,56,800 |

The weighted average number of shares takes into account the weighted average effect of changes in share transactions during the year. There have been no other transactions involving Equity shares or potential Equity shares between the reporting date and the date of authorisation of these financial statements.

**TEJNAKSH HEALTHCARE LIMITED****NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED March 31, 2021***(Amount in INR, unless otherwise stated)***28. Employee Benefit Plan****Gratuity**

The Company has a defined benefit gratuity plan, where under employee who has completed five years or more of service gets a gratuity on departure at 15 days salary (last drawn basic salary) for each completed year of service subject. Vesting occurs upon completion of 5 years of service. The Gratuity is unfunded.

The following table summarizes the components of net benefit expenses recognised in the Statement of Profit and Loss and the amounts recognized in the Balance Sheet.

| <b>Assumptions</b>  | <b>March 31, 2021</b> | <b>March 31, 2020</b> |
|---|-----------------------|-----------------------|
| Discount Rate   | 5.79% p.a.            | 5.66% p.a.            |
| Rate of Increase in Compensation Level                        | 5.00% p.a.            | 5.00% p.a.            |
| Rate of Return on Plan Assets                                 | NA                    | NA                    |
| Average Future Services (in Years)                            | 26.34 Years           | 27.19 Years           |
| <b>Service Cost</b>   | <b>March 31, 2021</b> | <b>March 31, 2020</b> |
| Current Service Cost  | 1,56,785              | 2,08,069              |
| Past Service Cost (including curtailment Gain/Loss)           | -                     | 7,36,889              |
| Gain or Loss on Non Routine settlements                       | -                     | -                     |
| <b>Total</b>  | <b>1,56,785</b>       | <b>9,44,958</b>       |
| <b>Net Interest Cost</b>                                      | <b>March 31, 2021</b> | <b>March 31, 2020</b> |
| Interest Cost on Defined Benefit Obligation                   | 71,662                | 21,150                |
| Interest Income on Plan Assets                                | -                     | -                     |
| <b>Net Interest Cost (Income)</b>                             | <b>71,662</b>         | <b>21,150</b>         |
| <b>Change in Present Value of Obligations</b>                 | <b>March 31, 2021</b> | <b>March 31, 2020</b> |
| Opening of defined benefit obligation                         | 12,66,108             | 3,00,000              |
| Service Cost  | 1,56,785              | 9,44,958              |
| Interest Cost   | 71,662                | 21,150                |
| Benefit Paid  | -                     | -                     |
| <b>Actuarial Gain/Loss on Total Liabilities</b>               | <b>(1,31,634)</b>     | <b>NA</b>             |
| - due to change in financial assumption                       | (5,174)               | NA                    |
| - due to change in demographic assumption                     | -                     | NA                    |
| - due to experience variance                                  | (1,26,460)            | NA                    |
| <b>Closing of defined benefit obligation</b>                  | <b>13,62,921</b>      | <b>12,66,108</b>      |
| <b>Reconciliation of expense in Profit and loss Statement</b> | <b>March 31, 2021</b> | <b>March 31, 2020</b> |
| Present value of Obligation at the end of the year            | 13,62,921             | 12,66,108             |
| Present value of Obligation at the end beginning of the year  | (12,66,108)           | (3,00,000)            |
| Benefit Paid  | -                     | -                     |
| Actual return on asset  | -                     | -                     |
| OCI   | 1,31,634              | -                     |
| <b>Expense recognised in Statement of Profit and Loss</b>     | <b>2,28,447</b>       | <b>9,66,108</b>       |
| <b>Reconciliation of Liability in Balance Sheet</b>           | <b>March 31, 2021</b> | <b>March 31, 2020</b> |
| Opening net defined benefit liability / (asset)               | 12,66,108             | 3,00,000              |
| Expense charged to profit and loss account                    | 2,28,447              | 9,66,108              |
| Amount recognised outside profit and loss account             | -                     | -                     |
| Employer contributions  | -                     | -                     |
| OCI   | (1,31,634)            | -                     |
| <b>Closing net defined benefit liability / (asset)</b>        | <b>13,62,921</b>      | <b>12,66,108</b>      |

**TEJNAKSH HEALTHCARE LIMITED****NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED March 31, 2021***(Amount in INR, unless otherwise stated)*

| <b>Bifurcation of Present Value of obligation as the end of the year</b>                 | <b>March 31, 2021</b> | <b>March 31, 2020</b> |
|--|-----------------------|-----------------------|
| Current Liability  | 2,81,669              | 2,44,380              |
| Non - Current Liability  | 10,81,252             | 10,21,728             |
| <b>Total Liability</b>   | <b>13,62,921</b>      | <b>12,66,108</b>      |
|  |                       |                       |
| <b>Sensitivity Analysis</b>  | <b>March 31, 2021</b> | <b>Impact %</b>       |
| Base Liability   | 13,62,921             |                       |
| Increase Discount Rate by 0.50%  | 13,43,453             | -1.43%                |
| Decrease Discount Rate by 0.50%  | 13,83,084             | 1.48%                 |
| Increase Salary Inflation Rate by 1.00%  | 14,03,901             | 3.01%                 |
| Decrease Salary Inflation Rate by 1.00%  | 13,24,011             | -2.85%                |
| Increase withdrawal Rate by 5.00%  | 13,37,192             | -1.89%                |
| Decrease withdrawal Rate by 5.00%  | 13,88,185             | 1.85%                 |
|  |                       |                       |
| <b>Maturity Profile of Defined Benefit Obligation<br/>(Valued on undiscounted basis)</b> | <b>March 31, 2021</b> | <b>March 31, 2020</b> |
| Year 1   | 2,81,669              | 2,44,380              |
| Year 2   | 2,45,624              | 2,05,707              |
| Year 3   | 2,36,952              | 1,80,983              |
| Year 4   | 2,48,575              | 1,97,475              |
| Year 5   | 1,41,270              | 2,03,214              |
| After 5th Year   | 4,96,697              | 5,45,752              |
| <b>Total</b>   | <b>16,50,787</b>      | <b>15,77,511</b>      |

**TEJNAKSH HEALTHCARE LIMITED**  
**FINANCIAL STATEMENTS FOR THE PERIOD ENDED MARCH 31, 2021**

(Amount in INR, unless otherwise stated)

**29 RELATED PARTY TRANSACTIONS**

**(i) List of related parties as per the requirements of Ind-AS 24 - Related Party Disclosures**

**(1) Subsidiary**

Tej Vedaant Healthcare Private Limited

**(2) Key Management Personnel (KMP)**

Dr. Ashish Rawandale - Chairman and Managing Director

Dr. Preeti Rawandale - Director

Kiran Pawar - Director

Vikramsinh Patil - Director

Ramesh Kuwar - Chief Financial Officer

Prakash Soqam - Company Secretary

**(3) Enterprise that have a member of key management in common with the reporting enterprise.**

Tejnaksh Healthcare Foundation

**(ii) Transactions with related parties**

**The following transactions occurred with related parties**

| Name                                   | 2020-21   | 2019-20   |
|--|-----------|-----------|
| <b>(a) Sale of Products</b>            |           |           |
| Tej Vedaant Healthcare Private Limited | 3,29,707  | 6,66,847  |
| <b>(b) Services rendered</b>           |           |           |
| Tej Vedaant Healthcare Private Limited | 41,40,000 | 36,00,000 |
| Tejnaksh Healthcare Foundation         | 54,00,000 | -         |
| <b>(c) Deposit Return</b>              |           |           |
| Prakash Soqam                          | -         | 35,000    |
| <b>(d) Professional fees</b>           |           |           |
| Dr. Ashish Rawandale                   | 7,00,000  | 15,00,000 |
| Dr. Preeti Rawandale                   | 6,00,000  | 6,00,000  |
| <b>(e) Interest Expense</b>            |           |           |
| Tej Vedaant Healthcare Private Limited | 3,42,000  | -         |
| <b>(f) Other Income</b>                |           |           |
| Tej Vedaant Healthcare Private Limited | 3,42,000  | -         |

**(iii) Outstanding balances**

| Name                                   | March 31, 2021 | March 31, 2020 |
|--|----------------|----------------|
| <b>Trade Receivables</b>               |                |                |
| Tej Vedaant Healthcare Private Limited | 1,42,351       | 9,78,881       |
| <b>Trade Payables</b>                  |                |                |
| Tejnaksh Healthcare Foundation         | 6,47,500       | -              |
| <b>Professional fees Payable</b>       |                |                |
| Dr. Ashish Rawandale                   | -              | 3,37,500       |
| Dr. Preeti Rawandale                   | -              | 2,25,000       |
| <b>Deposit Refundable</b>              |                |                |
| Tej Vedaant Healthcare Private Limited | 38,06,589      | -              |

**TEJNAKSH HEALTHCARE LIMITED**  
**FINANCIAL STATEMENTS FOR THE PERIOD ENDED MARCH 31, 2021**

**(iv) Loans from related parties**

| Name                                   | Particulars            | March 31, 2021 | March 31, 2020 |
|--|------------------------|----------------|----------------|
| <b>Loans from related parties</b>      |                        |                |                |
| Dr. Ashish Rawandale                   | Beginning of the year  | -              | 17,67,441      |
|  | Loans received         | -              | -              |
|  | Loan repayments made   | -              | (17,67,441)    |
|  | <b>End of the year</b> | -              | -              |
| Tej Vedaant Healthcare Private Limited | Beginning of the year  | 6,35,559       | -              |
|  | Loans received         | 7,14,815       | 8,97,959       |
|  | Loan repayments made   | (9,77,437)     | (2,62,400)     |
|  | <b>End of the year</b> | 3,72,937       | 6,35,559       |
| Tejnaksh Healthcare Foundation         | Beginning of the year  | -              | -              |
|  | Loans received         | 40,000         | -              |
|  | Loan repayments made   | -              | -              |
|  | <b>End of the year</b> | 40,000         | -              |

**(v) Key management personnel compensation**

|                              | 2020-21         | 2019-20         |
|------------------------------|-----------------|-----------------|
| Short term employee benefits | 8,23,699        | 5,97,688        |
| Post-employment benefits     | 24,040          | 1,87,700        |
|                              | <b>8,47,739</b> | <b>7,85,388</b> |

**(vi) Terms and conditions of transactions with related parties**

The sales to and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions. Outstanding balances at the year end are unsecured and interest free and settlement occurs in cash. For the year ended March 31, 2021, the group has not recorded any impairment of receivables relating to amount owed by related parties (March 31, 2020: NIL). This assessment is undertaken each financial year through examining the financial position of the related party and market in which the related party operates.

### 30. SEGMENT REPORTING

The Company has a single operating segment, namely, health care services and the information reported to the chief operating decision maker (CODM) for the purposes of resource allocation and assessment of performance focusses on this operating segment. Further the company does not have any separate geographic segment other than India. Accordingly, the amounts appearing in these financial statements relate to this operating segment.

### 31. FAIR VALUE MEASUREMENTS

#### i. Financial Instruments by Category

| Particulars                      | Carrying Amount    |                    | Fair Value         |                    |
|----------------------------------|--------------------|--------------------|--------------------|--------------------|
|                                  | March 31, 2021     | March 31, 2020     | March 31, 2021     | March 31, 2020     |
| <b>FINANCIAL ASSETS</b>          |                    |                    |                    |                    |
| <b>Amortised cost</b>            |                    |                    |                    |                    |
| Cash and Cash Equivalents        | 56,19,863          | 1,02,96,421        | 56,19,863          | 1,02,96,421        |
| Other Financial Assets           | 5,17,11,620        | 12,56,749          | 5,17,11,620        | 12,56,749          |
| <b>FVTPL</b>                     |                    |                    |                    |                    |
| Investment in Equity Instruments | 600                | 600                | 600                | 600                |
| <b>Total</b>                     | <b>5,73,32,083</b> | <b>1,15,53,770</b> | <b>5,73,32,083</b> | <b>1,15,53,770</b> |
| <b>FINANCIAL LIABILITIES</b>     |                    |                    |                    |                    |
| <b>Amortised cost</b>            |                    |                    |                    |                    |
| Borrowings                       | 4,18,21,518        | 6,59,34,377        | 4,18,21,518        | 6,59,34,377        |
| Trade Payables                   | 15,94,043          | 26,20,970          | 15,94,043          | 26,20,970          |
| Deposit Payable                  | 38,06,589          | 34,64,589          | 38,06,589          | 34,64,589          |
| <b>Total</b>                     | <b>4,72,22,150</b> | <b>7,20,19,935</b> | <b>4,72,22,150</b> | <b>7,20,19,935</b> |

The management assessed that the fair value of cash and cash equivalent, trade receivables, trade payables, and other current financial assets and liabilities approximate their carrying amounts largely due to the short term maturities of these instruments.

The fair values for security deposits were calculated based on cash flows discounted using a current lending rate. They are classified as level 3 fair values in the Fair value hierarchy due to the inclusion of unobservable inputs including counterparty credit risk.

The fair values of non current borrowings are based on discounted cash flows using a current borrowing rate. They are classified as level 3 fair values in the fair value hierarchy due to the use of unobservable inputs, including own credit risk.

#### ii. Fair Value Hierarchy

The company has classified its financial instruments into three levels prescribed under the accounting standard as follows:

##### Assets and liabilities measured at fair value

| Assets and liabilities measured at fair value |   |   |   |       |   |   |   |       |
|---|---|---|---|-------|---|---|---|-------|
| Particulars                                   | March 31, 2021                            |   |   | Total | March 31, 2020                            |   |   | Total |
|   | Fair value measurement using              |   |   |       | Fair value measurement using              |   |   |       |
|   | Quoted prices in active markets (Level 1) | Significant Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) |       | Quoted prices in active markets (Level 1) | Significant Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) |       |
| Financial Assets                              |   |   |   |       |   |   |   |       |
| Investment in Equity Instruments              |   | 600                                     |   | 600   |   | 600                                     |   | 600   |
| Total Assets                                  | -   | 600                                     | -   | 600   | -   | -                                       | -   | 600   |

There have been no transfers among Level 1, Level 2 and Level 3 during the period

### 32. BUSINESS COMBINATIONS

#### (1) Discontinued operations

On 1st february,2021 the company discontinued and disposed off its operations at Lion Tarachand Bapa Hospital, Mumbai.

##### The details of disposal of unit :

| Particulars                   | Amount Rs.    |
|-------------------------------|---------------|
| Consideration Received        | 3,14,00,000   |
| Carring Amount of Assets Sold | 3,14,56,165   |
| Loss on disposal              | <u>56,165</u> |

The carring amount of assets and liabilities as at the date of sale (01 February 2021) were as follows:

| Particulars                   | Amount Rs.         |
|-------------------------------|--------------------|
| Property, plant and equipment | 1,05,91,267        |
| Intangible Assets             | 1,02,04,399        |
| Trade Receivable              | 8,35,825           |
| Other current Assets          | 1,01,99,686        |
| <b>Total Assets</b>           | <u>3,18,31,177</u> |
| Other current liabilities     | 3,75,012           |
| <b>Total Liabilities</b>      | <u>3,75,012</u>    |
| <b>Net Assets</b>             | <u>3,14,56,165</u> |

**33. FINANCIAL RISK MANAGEMENT**

The Company manages financial risk relating to the operations through internal risk reports which analyse exposure by degree and magnitude of risk. These risks include market risk (including interest rate risk and other price risk), credit risk and liquidity risk. The focus of the chief operating decision maker (CODM) is to assess the unpredictability of the financial environment and to mitigate potential adverse effects, if any, on the financial performance of the Company.

The Company does not enter into or trade financial instruments including derivative financial instruments for speculative purpose.

**(A) Credit risk**

Credit risk is the risk that counterparty will default on its contractual obligation resulting in a financial loss to the company. The credit risk arises primarily on trade receivables and deposits with banks and other financial instruments.

The Company's hospital and healthcare services and sale of medical goods are on the counter sale i.e. on cash basis and as such no credit risk arises.

Exposures to customers outstanding at the end of each reporting period are reviewed by the Company to determine expected credit losses. Historical trends of impairment of trade receivables do not reflect any credit losses. Given that there is no substantial change in the economic environment affecting customers of the Company, the Company expects the historical trend of immaterial credit losses to continue.

Credit risk on cash and bank balances is limited as company counterparties are banks with high credit ratings assigned credit rating agencies.

**(B) Liquidity risk**

Liquidity risk refers to the risk that the Company cannot meet its financial obligations. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements. The Company consistently generated sufficient cash flows from operations to meet its financial obligations as and when they fall due.

The following tables detail the Company's remaining contractual maturity for its financial liabilities with agreed repayment periods. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based. It include both interest and principal cash flows. The contractual maturity is based on the earliest date on which the Company may be required to pay.

**Contractual maturities of financial liabilities**

| Particulars                 | Carrying amount    | Within 1 year      | 1-5 years          | More than 5 years  | Total              |
|-----------------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| <b>As at March 31, 2021</b> |                    |                    |                    |                    |                    |
| Borrowing                   | 4,88,86,491        | 70,64,973          | 4,03,13,813        | 15,07,706          | 4,88,86,491        |
| Trade payable               | 15,94,043          | 15,94,043          | -                  | -                  | 15,94,043          |
| Other financial liabilities | 10,52,094          | 10,52,094          | -                  | -                  | 10,52,094          |
| Deposit Payable             | 38,06,589          | -                  | 38,06,589          | -                  | 38,06,589          |
|                             | <b>5,53,39,218</b> | <b>97,11,110</b>   | <b>4,41,20,402</b> | <b>15,07,706</b>   | <b>5,53,39,218</b> |
| <b>As at March 31, 2020</b> |                    |                    |                    |                    |                    |
| Borrowing                   | 7,19,06,186        | 59,71,810          | 5,18,27,796        | 1,41,06,580        | 7,19,06,186        |
| Trade payable               | 26,20,970          | 26,20,970          | -                  | -                  | 26,20,970          |
| Other financial liabilities | 30,86,856          | 30,86,856          | -                  | -                  | 30,86,856          |
| Deposit Payable             | 34,64,589          | -                  | 34,64,589          | -                  | 34,64,589          |
|                             | <b>8,10,78,602</b> | <b>1,16,79,636</b> | <b>5,52,92,385</b> | <b>1,41,06,580</b> | <b>8,10,78,602</b> |

**(C) Market risk**

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in the market prices. The Company is exposed in the ordinary course of its business to risks related to changes in foreign currency exchange rates. The Company's exposure to foreign currency risk and other price risk is not significant.

**Interest rate risk**

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in the market interest rates. The Company's exposure to the risk of changes in the market interest rates relates primarily to the Company's debt obligations with floating interest rates.

However, the company does not expect any material change in the interest rates in the foreseeable future and therefore does not expects any significantly risk on account of change in interest rate as at the respective reporting dates.

**Interest rate sensitivity**

The following table demonstrates the sensitivity to a reasonably possible change in interest rates on that portion of loans and borrowings taken at floating rates. With all other variables held constant, the Company's profit/ (loss) before tax is affected through the impact on floating rate borrowings, as follows:

| Particulars                                   | Impact on profit before tax |            |
|---|-----------------------------|------------|
|   | 2020-21                     | 2019-20    |
| Interest rates - increase by 50 basis points* | (2,35,406)                  | (3,45,233) |
| Interest rates - decrease by 50 basis points* | 2,35,406                    | 3,45,233   |

**TEJNAKSH HEALTHCARE LIMITED****NOTES TO FINANCIAL STATEMENTS FOR THE PERIOD ENDED March 31, 2021**

(Amount in INR, unless otherwise stated)

**34. CAPITAL MANAGEMENT**

For the purpose of the company's capital management, capital includes issued equity capital, equity instruments, share premium and all other equity reserves attributable to the equity holders. The primary objective of the Company's capital management is to maximise the shareholder value.

The Company manages its capital to ensure that it will be able to continue as going concerns through the optimization of the debt and equity balance. The capital structure of the Company consists of net debt (i.e. borrowings offset by cash and bank balances) and equity of the Company (comprising issued capital, reserves and retained earnings). The Company monitors capital using a ratio of 'net debt' to equity. The Company's net debt to equity ratio is as follows.

| Particulars                     | March 31, 2021      | March 31, 2020      |
|---------------------------------|---------------------|---------------------|
| Borrowings                      | 4,18,21,518         | 6,59,34,377         |
| Less: cash and cash equivalents | (56,19,863)         | (1,02,96,421)       |
| <b>Net Debt</b>                 | <b>3,62,01,655</b>  | <b>5,56,37,956</b>  |
| Equity                          | 17,02,56,242        | 15,01,15,810        |
| <b>Total Capital</b>            | <b>17,02,56,242</b> | <b>15,01,15,810</b> |
| <b>Capital and net debt</b>     | <b>20,64,57,897</b> | <b>20,57,53,765</b> |
| <b>Net debt to equity ratio</b> | <b>0.18</b>         | <b>0.27</b>         |

See accompanying notes forming part of the standalone financial statements

1 to 34

In terms of our report attached.

**For P.D. Dalal & Co**

Chartered Accountants

Firm Registration No.102047W

**For and on behalf of the Board  
of Directors**

Sd/-  
(Aashish Kakaria)  
Partner  
Membership No.: 102915

Sd/-  
(Dr. A.V. Rawandale)  
Managing Director  
DIN : 02005733

Sd/-  
(Dr. P.A. Rawandale)  
Director  
DIN : 02005733

Mumbai  
29-Jun-21  
UDIN:21102915AAAAEL9704

Sd/-  
(Prakash Sogam)  
Company Secretary  
Membership No.: ACS42727

Sd/-  
(Ramesh Kuwar)  
Chief Finance Officer



## Independent Auditor's Report

To  
The Members,  
Tejnaksh Healthcare Limited,  
Mumbai

### Report on the Audit of the Consolidated Financial Statements

#### Opinion

We have audited the accompanying consolidated financial statements of **Tejnaksh Healthcare Limited** (hereinafter referred to as the 'Holding Company') and its subsidiary **TejVedaant Healthcare Private Limited** (Holding Company and its subsidiaries together referred to as "the Group"), which comprise the consolidated Balance Sheet as at March 31, 2021, and the consolidated statement of Profit and Loss, (the consolidated statement of changes in equity) and the consolidated cash flows Statement for the year then ended, and notes to the consolidated financial statements, including a summary of significant accounting policies (hereinafter referred to as "the consolidated financial statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid consolidated financial statements give the information required by the Act in the manner so required and give a true and fair view in conformity with the accounting principles generally accepted in India, of their consolidated state of affairs of the Company as at March 31, 2021, of consolidated profit/loss, (consolidated changes in equity) and its consolidated cash flows for the year then ended.

#### Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Statements section of our report. We are independent of the Group in accordance with the Code of Ethics issued by ICAI, and we have fulfilled our other ethical responsibilities in accordance with the provisions of the Companies Act, 2013. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the consolidated financial statements of the current period. These matters were addressed in the context of our audit of the consolidated financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. We have determined that there are no key audit matters to be communicated in our report *except for*

Covid Impact - In view of the highly uncertain economic environment, a definitive assessment of the impact on the subsequent periods is highly dependent on the circumstances, as they evolve.

#### Information Other than the Financial Statements and Auditor's Report thereon

The Company's Board of Directors is responsible for the preparation of the other information. The other information comprises the information included in the Management Discussion and Analysis, Board's Report including Annexures to Board's Report, Business Responsibility Report, Corporate Governance and Shareholder's Information, but does not include the consolidated financial statements, standalone financial statements and our auditor's report thereon.

Our opinion on the consolidated financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the consolidated financial statements, our responsibility is to read the other information and in doing so, consider whether the other information is materially inconsistent with the consolidated financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information; we are required to report that fact. We have nothing to report in this regard.

### **Management's Responsibilities for the Consolidated Financial Statements**

The Holding Company's Board of Directors is responsible for the preparation and presentation of these consolidated financial statements in term of the requirements of the Companies Act, 2013 that give a true and fair view of the consolidated financial position, consolidated financial performance and consolidated cash flows of the Group in accordance with the accounting principles generally accepted in India, including the Accounting Standards specified under section 133 of the Act. The respective Board of Directors of the companies included in the Group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Group and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statements that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the consolidated financial statements by the Directors of the Holding Company, as aforesaid.

In preparing the consolidated financial statements, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are responsible for overseeing the financial reporting process of the Group.

### **Auditor's Responsibility for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company and its subsidiary companies which are companies incorporated in India, has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities within the Group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the audit of the financial statements of such entities included in the consolidated financial statements of which we are the independent auditors.

Materiality is the magnitude of misstatements in the consolidated financial statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the consolidated financial statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the consolidated financial statements.

We communicate with those charged with governance of the Company and such other entities included in the consolidated financial statements of which we are the independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the consolidated financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

## COVID Impact

Since there are increasing restrictions on travel & meetings, as a result we faced practical issues for access to the audit location in carrying out the audit.

### Challenges in carrying audit at audit location

During this pandemic, challenges never before faced by auditors in performing audits are emerging. In response we need to be more agile and creative in performing audits and complying with the auditing standards. Now, more than ever, auditors might rely on technology in performing audit procedures. Performing auditing procedures in the middle of this pandemic is troublesome and we as auditor have encountered challenges in:

- Physical verification of inventory, fixed assets etc
- Assessing records
- Understanding and testing internal control
- Account and balance confirmations
- Performing subsequent event procedures

### Report on Other Legal and Regulatory Requirements

As required by Section 143(3) of the Act, we report that:

(a) We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit of the aforesaid consolidated financial statements.

(b) In our opinion, proper books of account as required by law relating to preparation of the aforesaid consolidated financial statements have been kept so far as it appears from our examination of those books and the reports of the other auditors.

(c) The Consolidated Balance Sheet, the Consolidated Statement of Profit and Loss, and the Consolidated Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account maintained for the purpose of preparation of the consolidated financial statements.

(d) In our opinion, the aforesaid consolidated financial statements comply with the Accounting Standards specified under Section 133 of the Act..

(e) On the basis of the written representations received from the directors of the Holding Company as on 31st March, 2021 taken on record by the Board of Directors of the Holding Company and the reports of subsidiary companies incorporated in India, none of the directors of Group company incorporated in India are disqualified as on 31st March, 2021 from being appointed as a director in terms of Section 164 (2) of the Act.

(f) With respect to the adequacy of internal financial controls over financial reporting of the Group and the operating effectiveness of such controls, refer to our separate report in Annexure A.

(g) With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, in our opinion and to the best of our information and according to the explanations given to us:

- i. There were no pending litigations which would impact the consolidated financial position of the Group.
- ii. The Group, did not have any material foreseeable losses on long-term contracts including derivative contracts.
- iii. There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Holding Company, and its subsidiary companies incorporated in India

For and on behalf of  
**P.D.Dalal & Co.**  
*Chartered Accountants*  
Firm Registration No.102047W

Sd/-  
(Aashish S. Kakaria)  
*Partner*  
Membership No.102915  
UDIN : 21102915AAAAEM6989

*Mumbai*  
*29<sup>th</sup> June, 2021*

## **Annexure “A” to the Independent Auditors Report**

Report on the Internal Financial Controls under Clause (i) of Sub-section 3 of section 143 of the Companies Act, 2013 (“the Act”)

In conjunction with our audit of the Consolidated Financial Statements of **Tejnaksh Healthcare Limited** we have audited the internal financial controls over financial reporting of **Tejnaksh Healthcare Limited** (hereinafter referred to as the “Holding Company”) and its subsidiary **Tej Vedaant Healthcare Limited** which are companies incorporated in India, as of that date.

### **Management’s Responsibility for Internal Financial Controls**

The respective Board of Directors of the Holding Company and its subsidiaries, which are companies incorporated in India, are responsible for establishing and maintaining internal financial controls based on the internal control over financial reporting criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting (the “Guidance Note”) issued by the Institute of Chartered Accountants of India. These responsibilities include the design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the orderly and efficient conduct of its business, including adherence to the respective company’s policies, the safeguarding of its assets, the prevention and detection of frauds and errors, the accuracy and completeness of the accounting records, and the timely preparation of reliable financial information, as required under the Act.

### **Auditors’ Responsibility**

Our responsibility is to express an opinion on the Holding Company and its subsidiaries, which are companies incorporated in India, internal financial controls over financial reporting with reference to these Consolidated Financial Statements based on our audit. We conducted our audit in accordance with the Guidance Note and the Standards on Auditing, both, issued by Institute of Chartered Accountants of India, and deemed to be prescribed under Section 143(10) of the Act, to the extent applicable to an audit of internal financial controls. Those Standards and the Guidance Note require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether adequate internal financial controls over financial reporting with reference to these Consolidated Financial Statements was established and maintained and if such controls operated effectively in all material respects.

Our audit involves performing procedures to obtain audit evidence about the adequacy of the internal financial controls system over financial reporting with reference to these Consolidated Financial Statements and their operating effectiveness. Our audit of internal financial controls over financial reporting included obtaining an understanding of internal financial controls over financial reporting with reference to these Consolidated Financial Statements, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. The procedures selected depend on the auditors’ judgement, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error.

We believe that the audit evidence we have obtained and the audit evidence obtained by the other auditors in terms of their reports is sufficient and appropriate to provide a basis for our audit opinion on the internal financial controls system over financial reporting with reference to these Consolidated Financial Statements.

### **Meaning of Internal Financial Controls over Financial Reporting**

A company’s internal financial control over financial reporting with reference to these Consolidated Financial Statements is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company’s internal financial control over financial reporting with reference to these Consolidated Financial Statements includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorisation of management and directors of the Company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorised acquisition, use, or disposition of the Company’s assets that could have a material effect on the financial statements.

### **Inherent Limitations of Internal Financial Controls over Financial Reporting**

Because of the inherent limitations of internal financial controls over financial reporting with reference to these Consolidated Financial Statements, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may occur and not be detected. Also, projections of any evaluation of the internal financial controls over financial reporting with reference to these Consolidated Financial Statements to future periods are subject to the risk that the internal financial control over financial reporting with reference to these Consolidated Financial Statements may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

### **Opinion**

In our opinion, to the best of our information and according to the explanations given to us and based on the consideration of reports of other auditors, the Holding Company and its subsidiary, which are companies incorporated in India, have, maintained in all material respects, adequate internal financial controls over financial reporting with reference to these Consolidated Financial Statements and such internal financial controls over financial reporting with reference to these Consolidated Financial Statements were operating effectively as at March 31, 2021 based on the internal control over financial reporting criteria established by the Holding Company considering the essential components of internal control stated in the Guidance Note on Audit of Internal Financial Controls Over Financial Reporting issued by the Institute of Chartered Accountants of India

For and on behalf of

**P.D.Dalal & Co.**

*Chartered Accountants*

Firm Registration No.102047W

Sd/-

(Aashish S. Kakaria)

*Partner*

Membership No.102915

UDIN : 21102915AAAAEM6989

*Mumbai*

*29<sup>th</sup> June, 2021*

**TEJNAKSH HEALTHCARE LIMITED**
**CONSOLIDATED BALANCE SHEET AS AT MARCH 31, 2021**
*(Amount in INR, unless otherwise stated)*

| Particulars  | Notes | March 31, 2021      | March 31, 2020      |
|--|-------|---------------------|---------------------|
| <b>ASSETS</b>  |       |                     |                     |
| <b>Non-Current Assets</b>                                  |       |                     |                     |
| (a) Property, Plant and Equipment                          | 4     | 11,52,92,747        | 12,82,76,561        |
| (b) Capital work-in-progress                               |       | 3,90,152            | 3,14,823            |
| (c) Goodwill   | 5     | 3,50,00,000         | 4,50,00,000         |
| (d) Other Intangible Assets                                | 5     | 1,20,762            | 3,79,291            |
| (e) Intangible Assets Under Development                    |       | 75,12,947           | 62,12,947           |
| (f) Financial Assets                                       |       |                     |                     |
| (i) Investments  | 6     | 600                 | 600                 |
| (ii) Other Financial Assets                                | 6     | 5,05,95,599         | 1,40,728            |
| (g) Other Non-Current Assets                               | 10    | 46,58,275           | 30,42,470           |
|  |       | <b>21,35,71,082</b> | <b>18,33,67,421</b> |
| <b>Current assets</b>                                      |       |                     |                     |
| (a) Inventories  | 8     | 69,68,832           | 63,52,021           |
| (b) Financial Assets                                       |       |                     |                     |
| (i) Trade Receivables                                      |       | 46,55,687           | 52,68,215           |
| (ii) Cash and Cash Equivalents                             | 9     | 1,23,29,734         | 1,29,39,866         |
| (iii) Other Financial Assets                               | 6     | 12,87,021           | 12,51,021           |
| (c) Other Current Assets                                   | 10    | 69,06,598           | 3,53,99,930         |
| (d) Current tax Asset                                      |       | -                   | 45,11,410           |
|  |       | <b>3,21,47,872</b>  | <b>6,57,22,464</b>  |
| <b>TOTAL</b>   |       | <b>24,57,18,954</b> | <b>24,90,89,885</b> |
| <b>EQUITY AND LIABILITIES</b>                              |       |                     |                     |
| <b>Equity</b>  |       |                     |                     |
| (a) Equity Share capital                                   | 12    | 10,15,68,000        | 10,15,68,000        |
| (b) Other Equity   | 13    | 7,15,75,834         | 5,09,41,740         |
| <b>Equity attributable to equity holders of the parent</b> |       | <b>17,31,43,834</b> | <b>15,25,09,740</b> |
| Non Controlling Interest                                   |       | 44,95,864           | 43,31,310           |
| <b>Total Equity</b>  |       | <b>17,76,39,699</b> | <b>15,68,41,051</b> |
| <b>Liabilities</b>   |       |                     |                     |
| <b>Non Current Liabilities</b>                             |       |                     |                     |
| (a) Financial Liabilities                                  |       |                     |                     |
| Borrowings   | 14    | 4,18,21,518         | 6,59,34,377         |
| (b) Deferred Tax liabilities (Net)                         | 11    | 75,68,303           | 74,59,591           |
| (c) Other Non Current Liabilities                          |       | -                   | -                   |
| (c) Non Current Provision                                  | 18    | 16,75,792           | 14,30,681           |
|  |       | <b>5,10,65,613</b>  | <b>7,48,24,649</b>  |
| <b>Current Liabilities</b>                                 |       |                     |                     |
| (a) Financial Liabilities                                  |       |                     |                     |
| (i) Borrowings   | 14    | 40,000              | -                   |
| (ii) Trade Payables  | 15    |                     |                     |
| Micro and Small Enterprises                                |       | -                   | -                   |
| Others   |       | 46,64,462           | 54,31,416           |
| (iii) Other financial liabilities                          | 16    | 89,04,074           | 99,89,737           |
| (b) Other Current Liabilities                              | 17    | 5,12,776            | 17,57,369           |
| (c) Current Provision                                      |       | 3,08,104            | 2,45,664            |
| (d) Current tax Liability                                  |       | 25,84,227           | -                   |
|  |       | <b>1,70,13,643</b>  | <b>1,74,24,186</b>  |
| <b>TOTAL</b>   |       | <b>24,57,18,954</b> | <b>24,90,89,885</b> |

See accompanying notes forming part of the consolidated financial statements

1 to 36

In terms of our report attached.

**For P.D. Dalal & Co**

Chartered Accountants

Firm Registration No.102047W

Sd/-

**Aashish Kakaria**

Partner

Membership No.: 102915

Place: Mumbai

Date: June 29, 2021

UDIN:21102915AAAAEM6989

**For and on behalf of the Board of Directors**

Sd/-

**(Dr. A.V. Rawandale)**

Managing Director

Sd/-

**(Dr. P.A. Rawandale)**

Director

Sd/-

**(Prakash Sogam)**

Company Secretary

Membership No.: ACS42727

Sd/-

**(Ramesh Kuwar)**

Chief Finance Officer



**TEJNAKSH HEALTHCARE LIMITED**
**CONSOLIDATED STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2021**
*(Amount in INR, unless otherwise stated)*

| Particulars                                   | Notes | 2020-21             | 2019-20             |
|---|-------|---------------------|---------------------|
| <b>REVENUE</b>                                |       |                     |                     |
| Revenue from operations (net)                 | 19    | 11,96,00,649        | 17,11,65,215        |
| Other income                                  | 20    | 13,84,906           | 34,10,617           |
| <b>Total Revenue (I)</b>                      |       | <b>12,09,85,555</b> | <b>17,45,75,832</b> |
| <b>EXPENSES</b>                               |       |                     |                     |
| Purchases of stock-in-trade                   | 21    | 95,67,371           | 1,09,74,875         |
| Changes in inventories of Stock-in-Trade      | 22    | (6,16,811)          | 19,97,358           |
| Employee benefits expense                     | 23    | 1,38,75,047         | 2,55,42,093         |
| Finance costs                                 | 24    | 50,21,097           | 76,10,470           |
| Depreciation and amortization expense         | 25    | 68,05,149           | 65,44,119           |
| Other expenses                                | 26    | 5,96,53,308         | 9,22,51,464         |
| <b>Total Expenses (II)</b>                    |       | <b>9,43,05,160</b>  | <b>14,49,20,380</b> |
| <b>Profit before tax (I) - (II)</b>           |       | <b>2,66,80,395</b>  | <b>2,96,55,453</b>  |
| <b>Tax expense:</b>                           |       |                     |                     |
| Current tax                                   |       | 59,15,000           | 69,30,100           |
| Adjustment of tax relating to earlier periods |       | -                   | -                   |
| Deferred tax                                  |       | 72,983              | 12,68,997           |
| <b>Profit for the year</b>                    |       | <b>2,06,92,412</b>  | <b>2,14,56,355</b>  |

|   |  |                    |                    |
|---|--|--------------------|--------------------|
| <b>OTHER COMPREHENSIVE INCOME</b>   |  |                    |                    |
| <b>A. Other Comprehensive income not to be reclassified to profit and loss in subsequent periods:</b> |  | -                  | -                  |
| Actuarial gain / (loss) on liabilities  |  | 1,41,965           |                    |
| Income tax effect   |  | (35,730)           |                    |
| <b>B. Other Comprehensive income to be reclassified to profit and loss in subsequent periods:</b>     |  | -                  | -                  |
| <b>Other Comprehensive income for the year, net of tax</b>  |  | <b>1,06,235</b>    | <b>-</b>           |
| <b>TOTAL COMPREHENSIVE INCOME FOR THE PERIOD, NET OF TAX</b>  |  | <b>2,07,98,647</b> | <b>2,14,56,355</b> |

|   |  |             |             |
|---|--|-------------|-------------|
| <b>Profit for the year attributable to:</b>                     |  |             |             |
| Equity holders of the parent                                    |  | 2,05,29,791 | 2,09,01,102 |
| Non-controlling interests                                       |  | 1,62,621    | 5,55,254    |
| <b>Other comprehensive income for the year attributable to:</b> |  |             |             |
| Equity holders of the parent                                    |  | 1,04,302    | -           |
| Non-controlling interests                                       |  | 1,933       | -           |
| <b>Total comprehensive income for the year attributable to:</b> |  |             |             |
| Equity holders of the parent                                    |  | 2,06,34,093 | 2,09,01,102 |
| Non-controlling interests                                       |  | 1,64,554    | 5,55,254    |

|   |    |      |      |
|---|----|------|------|
| <b>Basic and Diluted earnings per share (INR)</b> | 27 | 2.02 | 2.06 |
|---|----|------|------|

See accompanying notes forming part of the consolidated financial statements

In terms of our report attached.

**For P.D. Dalal & Co**

Chartered Accountants

Firm Registration No.102047W

Sd/-

**Aashish Kakaria**

Partner

Membership No.: 102915

Place: Mumbai

Date: June 29, 2021

UDIN:21102915AAAEM6989

1 to 36

**For and on behalf of the Board of Directors**

Sd/-

**(Dr. A.V. Rawandale)**

Managing Director

Sd/-

**(Prakash Sogam)**

Company Secretary

Membership No.: ACS42727

Sd/-

**(Dr. P.A. Rawandale)**

Director

Sd/-

**(Ramesh Kuwar)**

Chief Finance Officer

**TEJNAKSH HEALTHCARE LIMITED**
**CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED MARCH 31, 2021**
*(Amount in INR, unless otherwise stated)*

| Particulars  | 2020-21            | 2019-20              |
|--|--------------------|----------------------|
| <b>Profit before tax</b>   | <b>2,66,80,395</b> | <b>2,96,55,453</b>   |
| <b>Adjustments for:</b>  |                    |                      |
| Depreciation and amortisation expense  | 68,05,149          | 65,44,119            |
| Interest income  | (5,58,241)         | (9,67,396)           |
| Finance costs  | 50,21,097          | 76,10,470            |
| (Profit)/loss on sale/disposal property, plant and equipment and Intangibles | 56,165             | -                    |
| Bad Debts  | 4,30,244           | -                    |
| Provision for Gratuity   | 4,49,516           | 13,76,345            |
| <b>Change in operating assets and liabilities:</b>                           |                    |                      |
| (Increase)/Decrease in trade receivables                                     | 1,82,284           | (33,66,465)          |
| (Increase)/Decrease in inventories   | (6,16,811)         | 19,97,358            |
| Increase/(decrease) in trade payables  | (7,66,953)         | (5,26,504)           |
| (Increase) in other financial assets   | (5,15,84,035)      | 24,26,572            |
| (Increase)/decrease in other assets  | 2,09,62,527        | (2,28,41,921)        |
| Increase/(decrease) in other financial liabilities                           | (10,85,664)        | 12,93,540            |
| Increase/(decrease) in other liabilities                                     | (12,44,593)        | (67,09,967)          |
| <b>Cash generated from operations</b>  | <b>47,31,080</b>   | <b>1,64,91,604</b>   |
| Less: Income taxes paid/(refund)   | 70,95,637          | (48,77,915)          |
| <b>Net cash inflow from operating activities</b>                             | <b>1,18,26,717</b> | <b>1,16,13,689</b>   |
| <b>CASH FLOWS FROM INVESTING ACTIVITIES:</b>                                 |                    |                      |
| Payments for property, plant and equipment and intangibles                   | (44,33,800)        | (1,07,90,359)        |
| Proceeds from disposal of property, plant and equipment and Intangibles      | 2,07,39,501        | -                    |
| Intangible asset under development   | (13,00,000)        | (22,75,000)          |
| Interest received  | 5,58,241           | 9,67,396             |
| <b>Net cash outflow from investing activities</b>                            | <b>1,55,63,942</b> | <b>(1,20,97,963)</b> |

|  |                      |                    |
|--|----------------------|--------------------|
| <b>CASH FLOWS FROM FINANCING ACTIVITIES:</b>                                       |                      |                    |
| Proceeds from non current borrowings   | -                    | 1,50,02,146        |
| Repayment of non current borrowings  | (2,31,83,087)        | (47,12,036)        |
| Proceeds from current borrowings   | 40,000               | -                  |
| Repayment of current borrowings  | -                    | (17,67,441)        |
| Interest paid  | (48,57,705)          | (74,98,221)        |
| Acquisition of non-controlling interests   | -                    | -                  |
| <b>Net cash inflow (outflow) from financing activities</b>                         | <b>(2,80,00,792)</b> | <b>10,24,447</b>   |
| Net increase (decrease) in cash and cash equivalents                               | (6,10,133)           | 5,40,173           |
| Cash and Cash Equivalents at the beginning of the financial year                   | 1,29,39,866          | 1,23,99,693        |
| <b>Cash and Cash Equivalents at end of the year</b>                                | <b>1,23,29,734</b>   | <b>1,29,39,866</b> |
| <b>Reconciliation of cash and cash equivalents as per the cash flow statement:</b> |                      |                    |
| Cash and cash equivalents as per above comprise of the following:                  |                      |                    |
| Balances with banks in current accounts  | 74,85,160            | 50,35,255          |
| Cash on hand   | 48,44,573            | 79,04,612          |
| <b>Balances per statement of cash flows</b>  | <b>1,23,29,734</b>   | <b>1,29,39,866</b> |

**Net debt Reconciliation**

This section sets out an analysis of net debt and the movements in net debt for each of the years specified :

| Particulars                          | Liabilities from financing activities |                    |                    |
|--------------------------------------|---------------------------------------|--------------------|--------------------|
|                                      | Non Current Borrowings                | Current Borrowings | Total              |
| <b>Net Debt as at April 1, 2019</b>  | <b>6,15,03,827</b>                    | <b>17,67,441</b>   | <b>6,32,71,268</b> |
| Cash Inflows                         | 1,50,02,146                           | -                  | 1,50,02,146        |
| Cash Outflows                        | (47,12,036)                           | (17,67,441)        | (64,79,477)        |
|                                      | <b>7,17,93,937</b>                    | <b>-</b>           | <b>7,17,93,937</b> |
| Interest Expense                     | 76,10,470                             | -                  | 76,10,470          |
| Interest Paid                        | (74,98,221)                           | -                  | (74,98,221)        |
| <b>Net Debt as at March 31, 2020</b> | <b>7,19,06,186</b>                    | <b>-</b>           | <b>7,19,06,186</b> |
| Cash Inflows                         | -                                     | 40,000             | 40,000             |
| Cash Outflows                        | (2,31,83,087)                         | -                  | (2,31,83,087)      |
|                                      | <b>4,87,23,099</b>                    | <b>40,000</b>      | <b>4,87,63,099</b> |
| Interest Expense                     | 50,21,097                             | -                  | 50,21,097          |
| Interest Paid                        | (48,57,705)                           | -                  | (48,57,705)        |
| <b>Net Debt as at March 31, 2021</b> | <b>4,88,86,491</b>                    | <b>-</b>           | <b>4,88,86,491</b> |

See accompanying notes forming part of the consolidated financial statements

1 to 36

In terms of our report attached.

**For P.D. Dalal & Co**

Chartered Accountants

Firm Registration No.102047W

**For and on behalf of the Board of Directors**

Sd/-

**Aashish Kakaria**

Partner

Membership No.: 102915

Sd/-

**(Dr. A.V. Rawandale)**

Managing Director

Sd/-

**(Dr. P.A. Rawandale)**

Director

Place: Mumbai

Date: June 29, 2021

UDIN:21102915AAAAEM6989

Sd/-

**(Prakash Sogam)**

Company Secretary

Membership No.: ACS42727

Sd/-

**(Ramesh Kuwar)**

Chief Finance Officer

**TEJNAKSH HEALTHCARE LIMITED****CONSOLIDATED STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED MARCH 31, 2021***(Amount in INR, unless otherwise stated)***A Equity Share Capital**

| Particulars           | Balance at the Beginning of the year | Changes in Equity share capital during the year | Balance at the end of the year |
|-----------------------|--------------------------------------|---|--------------------------------|
| <b>March 31, 2020</b> |                                      |   |                                |
| Numbers               | 1,01,56,800                          | -   | <b>1,01,56,800</b>             |
| Amount                | 10,15,68,000                         | -   | <b>10,15,68,000</b>            |
| <b>March 31, 2021</b> |                                      |   |                                |
| Numbers               | 1,01,56,800                          | -   | <b>1,01,56,800</b>             |
| Amount                | 10,15,68,000                         | -   | <b>10,15,68,000</b>            |

**B Other Equity**

| Particulars                                    | Reserves and Surplus       |                    | Total other equity attributable to parent | Non Controlling Interest | Total other equity |
|--|----------------------------|--------------------|---|--------------------------|--------------------|
|  | Securities Premium Reserve | Retained Earnings  |   |                          |                    |
| <b>As at April 1, 2019</b>                     | <b>2,12,80,000</b>         | <b>87,60,651</b>   | <b>3,00,40,639</b>                        | <b>37,76,057</b>         | <b>3,38,16,696</b> |
| Profit for the period                          | -                          | 2,09,01,102        | 2,09,01,102                               | 5,55,254                 | 2,14,56,356        |
| Other comprehensive income                     | -                          | -                  | -   | -                        | -                  |
| <b>Total comprehensive income for the year</b> | <b>-</b>                   | <b>2,09,01,102</b> | <b>2,09,01,102</b>                        | <b>5,55,254</b>          | <b>2,14,56,356</b> |
| <b>As at March 31, 2020</b>                    | <b>2,12,80,000</b>         | <b>2,96,61,753</b> | <b>5,09,41,741</b>                        | <b>43,31,311</b>         | <b>5,52,73,051</b> |
| Profit for the period                          | -                          | 2,05,29,791        | 2,05,29,791                               | 1,62,621                 | 2,06,92,412        |
| Other comprehensive income                     | -                          | 1,04,302           | 1,04,302                                  | 1,933                    | 1,06,235           |
| <b>Total comprehensive income for the year</b> | <b>-</b>                   | <b>2,06,34,093</b> | <b>2,06,34,093</b>                        | <b>1,64,554</b>          | <b>2,07,98,648</b> |
| <b>As at March 31, 2021</b>                    | <b>2,12,80,000</b>         | <b>5,02,95,846</b> | <b>7,15,75,834</b>                        | <b>44,95,865</b>         | <b>7,60,71,699</b> |

See accompanying notes forming part of the consolidated financial statements  
In terms of our report attached.

**For P.D. Dalal & Co**  
Chartered Accountants  
Firm Registration No.102047W

**For and on behalf of the Board of Directors**

Sd/-  
**Aashish Kakaria**  
Partner  
Membership No.: 102915

Place: Mumbai  
Date: June 29, 2021  
UDIN:21102915AAAAEM6989

Sd/-  
**(Dr. A.V. Rawandale)**  
Managing Director

Sd/-  
**(Prakash Sogam)**  
Company Secretary  
Membership No.: ACS42727

Sd/-  
**(Dr. P.A. Rawandale)**  
Director

Sd/-  
**(Ramesh Kuwar)**  
Chief Finance Officer

## **TEJNAKSH HEALTHCARE LIMITED**

### **NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021**

#### **1 Corporate Information**

These statements comprise consolidated financial statements of Tejnakh Healthcare Limited ('the Holding Company')(CIN: L85100MH2008PLC179034) and its subsidiary (collectively, 'the Company' or 'the Group') for the year ended March 31, 2021. The company is a public company domiciled in India and is incorporated under the provisions of the Companies Act applicable in India. Its shares are listed on one recognised stock exchange in India. The registered office of the company is located at A 601 Floor No 6 Kailash Business Park Veer Savarkar Marg. Mumbai - 400079.

The Group is engaged in the provision hospital and healthcare service in Mumbai and other parts of Maharashtra.

The financial statements were authorised for issue in accordance with a resolution of the directors on June 29 2021.

All amounts disclosed in the financial statements and notes have been rounded off to the nearest Lakhs as per the requirement of Schedule III, unless otherwise stated.

#### **2 Significant Accounting Policies**

##### **2.1 Statement of Compliance**

The financial statements of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the Companies (Indian Accounting Standards) Rules, 2015(as amended).

##### **2.2 Basis of preparation and presentation**

The financial statements have been prepared on the historical cost basis except for certain financial instruments that are measured at fair values at the end of each reporting period.

Historical Cost is generally based on the fair value of the consideration given in exchange of goods and services.

##### **2.3 Principles of consolidation**

###### **Subsidiaries**

Subsidiaries are all entities over which the group has control. The group controls an entity when the group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the relevant activities of the entity. Subsidiaries are fully consolidated from the date on which control is transferred to the group. They are deconsolidated from the date that control ceases.

Generally, there is a presumption that a majority of voting rights results in control. to support this presumption and when the group has less than a majority of voting or similar rights of an investee, the Group considers all relevant facts and circumstances in assessing whether it has power over and investee.

The Group re-assess whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the elements of control.

A change in the ownership interest of a subsidiary, without a loss of control, is accounted for as an equity transaction.

The acquisition method of accounting is used to account for business combinations by the group.

The group combines the financial statements of the parent and its subsidiaries line by line adding together like items of assets, liabilities, equity, income and expenses. Intercompany transactions, balances and unrealised gains on transactions between group companies are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the transferred asset. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the group.

The financial statements of all entities used for the purpose of consolidation are drawn up to same reporting date as that of the parent company, i.e., year ended on March 31. When the end of the reporting period of the parent is different from that of a subsidiary, the subsidiary prepares, for consolidation purposes, additional financial information as of the same date as the financial statements of the parent to enable the parent to consolidate the financial information of the subsidiary, unless it is impracticable to do so.

## **TEJNAKSH HEALTHCARE LIMITED**

### **NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021**

Non-controlling interests in the results and equity of subsidiaries are shown separately in the consolidated statement of profit and loss, consolidated statement of changes in equity and balance sheet respectively.

Profit or loss and each component of other comprehensive income (the 'OCI') are attributed to the equity holders of the parent of the Group and to the non controlling interests, even if this results in the non controlling interest having a deficit balance. When necessary, adjustments are made to the financial statements of subsidiaries to bring there accounting policies into line with the Group's accounting policies.

#### **2.4 Summary of significant accounting policies**

##### **(a) Foreign currency translation**

###### **(i) Functional and presentation currency**

Items included in the financial statements of the entity are measured using the currency of the primary economic environment in which the entity operates ('the functional currency'). The financial statements are presented in Indian rupee (INR), which is entity's functional and presentation currency.

###### **(ii) Transactions and balances**

Foreign currency transactions are translated into the functional currency using the exchange rates at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation of monetary assets and liabilities denominated in foreign currencies at year end exchange rates are generally recognised in profit or loss.

##### **(b) Revenue recognition**

Revenue is measured at the fair value of the consideration received or receivable. Amounts disclosed as revenue is net of returns, trade allowances, rebates, value added taxes and amounts collected on behalf of third parties. The company recognises revenue when the amount of revenue can be reliably measured, it is probable that future economic benefits will flow to the entity and specific criteria have been met for each of the company's activities as described below.

###### **Recognising revenue from major business activities**

###### **(i) Sale of traded goods – pharmacy items**

Revenue from sale of pharmacy items are recognized on delivery of items to the customers which is when all the significant risks and rewards of ownership of the goods are passed to the customers.

###### **(ii) Inpatient and Outpatient Revenue**

Inpatient and Outpatient revenue is recognized as and when the related services are rendered.

Estimates of revenues, costs or extent of progress toward completion are revised if circumstances change. Any resulting increases or decreases in estimated revenues or costs are reflected in profit or loss in the period in which the circumstances that give rise to the revision become known by management.

###### **(iii) Interest income**

Interest income from a financial asset is recognised when it is probable that the economic benefits will flow to the Company and the amount of income can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

###### **(iv) Dividend income**

Revenue is recognised when the company's right to receive the payment is established, which is generally when shareholders approve the dividend.

## **TEJNAKSH HEALTHCARE LIMITED**

### **NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021**

#### **(c) Government Grants**

Government grants are not recognised until there is reasonable assurance that the Company will comply with the conditions attaching to them and such grants can reasonably have a value placed upon them. Government grants are recognised in the profit or loss on a systematic basis over there periods in which the Company recognises as expense the related costs for which the grant was intended to compensate.

Government grants that are receivable as compensation for expenses or losses already incurred or for the purpose of giving immediate financial support to the Company with no future related costs are recognised in profit or loss in the period they become receivable.

#### **(d) Taxes**

##### **(i) Current income tax**

The tax currently payable is based on taxable profit for the year. Taxable profit differs from 'profit before tax' as reported in the statement of profit and loss because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The current tax is calculated using tax rates and tax laws that have been enacted by the end of the reporting period.

Current income-tax is measured at the amount expected to be paid to the tax authorities in accordance with the Income-tax Act, 1961.

##### **(ii) Deferred tax**

Deferred income tax is recognised using the Balance sheet approach. Deferred income tax assets and liabilities are recognised for deductible and taxable temporary differences arising between the tax base of assets and liabilities and their carrying amount, except when the deferred income tax arises from the initial recognition of an asset or liability in a transaction that is not a business combination and affects neither accounting nor taxable profit or loss at the time of the transaction.

Deferred income tax asset are recognised to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and the carry forward of unused tax credits and unused tax losses can be utilized.

The carrying amount of deferred income tax assets is reviewed at each reporting date and reduced to the extent that it is no longer probable that sufficient taxable profit will be available to allow all or part of the deferred income tax asset to be utilized.

Deferred tax assets and liabilities are measured using substantively enacted tax rates expected to apply to taxable income in the years in which the temporary differences are expected to be received or settled.

Deferred tax assets and liabilities are offset when they relate to income taxes levied by the same taxation authority and there are legally enforceable right to set off current tax assets and liabilities.

Deferred tax assets include Minimum Alternate Tax (MAT) paid in accordance with the tax laws in India, which is likely to give future economic benefits in the form of availability of set off against future economic tax liability. Accordingly, MAT is recognised as deferred tax asset in the Balance sheet when the asset can be measured reliably and it is probable that the future economic benefit associated with the asset will be realised.

## **TEJNAKSH HEALTHCARE LIMITED**

### **NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021**

#### **(e) Leases**

##### **(i) Company as a lessee**

The Company's lease asset classes primarily consist of leases for land and buildings. The Company assesses whether a contract contains a lease, at inception of a contract. A contract is, or contains, a lease if the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. To assess whether a contract conveys the right to control the use of an identified asset, the Company assesses whether: (i) the contract involves the use of an identified asset (ii) the Company has substantially all of the economic benefits from use of the asset through the period of the lease and (iii) the Company has the right to direct the use of the asset. Any lease payments made at or prior to the commencement date of the lease plus any initial direct costs less any lease incentives. They are subsequently measured at cost less accumulated depreciation and impairment losses.

ROU assets are depreciated from the commencement date on a straight-line basis over the shorter of the lease term and useful life of the underlying asset. ROU assets are evaluated for recoverability whenever events or changes in circumstances indicate that their carrying amounts may not be recoverable. For the purpose of impairment testing, the recoverable amount (i.e. the higher of the fair value less cost to sell and the value-in-use) is determined on an individual asset basis unless the asset does not generate cash flows that are largely independent of those from other assets. In such cases, the recoverable amount is determined for the Cash Generating Unit (CGU) to which the asset belongs.

The lease liability is initially measured at amortized cost at the present value of the future lease payments. The lease payments are discounted using the interest rate implicit in the lease or, if not readily determinable, using the incremental borrowing rates in the country of domicile of these leases. Lease liabilities are remeasured with a corresponding adjustment to the related ROU asset if the Company changes its assessment of whether it will exercise an extension or a termination option.

Lease liability and ROU assets have been separately presented in the Balance Sheet and lease payments have been classified as financing cash flows.

##### **(ii) Company as a lessor**

Leases for which the Company is a lessor is classified as a finance or operating lease. Whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee, the contract is classified as a finance lease. All other leases are classified as operating leases.

When the Company is an intermediate lessor, it accounts for its interests in the head lease and the sublease separately. The sublease is classified as a finance or operating lease by reference to the ROU asset arising from the head lease.

For operating leases, rental income is recognized on a straight line basis over the term of the relevant lease.

#### **(f) Impairment of non financial assets**

The Company assesses, at each reporting date, whether there is an indication that an asset may be impaired. If any indication exists, or when annual impairment testing for an asset is required, the Company estimates the asset's recoverable amount. An asset's recoverable amount is the higher of an asset's or cash-generating unit's (CGU) fair value less costs of disposal and its value in use. Recoverable amount is determined for an individual asset, unless the asset does not generate cash inflows that are largely independent of those from other assets or groups of assets. When the carrying amount of an asset or CGU exceeds its recoverable amount, the asset is considered impaired and is written down to its recoverable amount. An impairment loss is recognised immediately in the statement of profit and loss.

#### **(g) Cash and cash equivalents**

Cash and cash equivalent in the balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three months or less, which are subject to an insignificant risk of changes in value.

#### **(h) Inventories**

Inventories of medical consumables and drugs are valued at lower of cost or net realisable value. Cost is determined on weighted average basis.

Net realisable value represents the estimated selling price in the ordinary course of business, less estimated costs of completion and estimated costs necessary to make the sale.

## **TEJNAKSH HEALTHCARE LIMITED**

### **NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021**

Due allowance is estimated and made by the Management for slow moving / non-moving items of inventory, wherever necessary, based on the past experience of the Company and such allowances are adjusted against the carrying inventory value.

#### **(i) Non-current assets held for sale**

Non-current assets and disposal groups are classified as held for sale if their carrying amount will be recovered principally through a sale transaction rather than through continuing use. This condition is regarded as met only when the asset (or disposal group) is available for immediate sale in its present condition subject only to terms that are usual and customary for sales of such asset (or disposal group) and its sale is highly probable. Management must be committed to the sale, which should be expected to qualify for recognition as a completed sale within one year from the date of classification.

Non-current assets (and disposal groups) classified as held for sale are measured at the lower of their carrying amount and fair value less costs to sell.

#### **(j) Fair value measurement**

The Company measures financial instruments at fair value at each balance sheet date.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value measurement is based on the presumption that the transaction to sell the asset or transfer the liability takes place either:

- In the principal market for the asset or liability, or
- In the absence of a principal market, in the most advantageous market for the asset or liability

The principal or the most advantageous market must be accessible by the Company.

The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy, described as follows, based on the lowest level input that is significant to the fair value measurement as a whole:

Level 1 — Quoted (unadjusted) market prices in active markets for identical assets or liabilities

Level 2 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is directly or indirectly observable

Level 3 — Valuation techniques for which the lowest level input that is significant to the fair value measurement is unobservable.

#### **(k) Financial instruments**

##### **Initial recognition**

The Company recognizes financial assets and financial liabilities when it becomes a party to the contractual provisions of the instrument. All financial assets and liabilities are recognized at fair value on initial recognition. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities that are not at fair value through profit or loss are added to the fair value on initial recognition. Regular way purchase and sale of financial assets are accounted for at trade date.

##### **Subsequent measurement**

##### **(i) Financial assets carried at amortised cost**

A financial asset is subsequently measured at amortised cost if it is held within a business model whose objective is to hold the asset in order to collect contractual cash flows and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

##### **(ii) Financial assets at fair value through other comprehensive income**

A financial asset is subsequently measured at fair value through other comprehensive income if it is held within a business model whose objective is achieved by both collecting contractual cash flows and selling financial assets and the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.



## **TEJNAKSH HEALTHCARE LIMITED**

### **NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021**

#### **(iii) Financial assets at fair value through profit or loss**

A financial asset which is not classified in any of the above categories are subsequently fair valued through profit or loss.

#### **(iv) Financial liabilities**

Financial liabilities are subsequently carried at amortized cost using the effective interest method. For trade and other payables maturing within one year from the Balance Sheet date, the carrying amounts approximate fair value due to the short maturity of these instruments.

#### **(v) Investment in subsidiaries**

Investment in subsidiaries is carried at cost in the separate financial statements.

#### **(vi) Equity instruments**

An equity instrument is any contract that evidences a residual interest in the assets of company after deducting all of its liabilities. Equity instruments are recognised at the proceeds received, net of direct issue costs.

#### **(l) Impairment of financial assets**

The Company measures the loss allowance for a financial instrument at an amount equal to the lifetime expected credit losses if the credit risk on that financial instrument has increased significantly since initial recognition. If the credit risk on a financial instrument has not increased significantly since initial recognition, the Company measures the loss allowance for that financial instrument at an amount equal to 12-month expected credit losses.

However, for trade receivables or any contractual right to receive cash or another financial asset that result from transactions that are within the scope of Ind AS 115, the Company measures the loss allowance at an amount equal to lifetime expected credit losses.

When making the assessment of whether there has been a significant increase in credit risk since initial recognition, the Company uses the change in the risk of a default occurring over the expected life of the financial instrument instead of the change in the amount of expected credit losses. To make that assessment, the Company compares the risk of a default occurring on the financial instrument as at the reporting date with the risk of a default occurring on the financial instrument as at the date of initial recognition and considers reasonable and supportable information, that is available without undue cost or effort, that is indicative of significant increases in credit risk since initial recognition.

#### **(m) Derecognition of financial assets and financial liabilities**

The Company derecognises a financial asset when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party. If the Company neither transfers nor retains substantially all the risks and rewards of ownership and continues to control the transferred asset, the Company recognises its retained interest in the asset and an associated liability for amounts it may have to pay.

The Company derecognises financial liabilities when, and only when, the Company's obligations discharged, cancelled or have expired. An exchange between with a lender of debt instruments substantially different terms is accounted for as an extinguishment of the original financial liability the recognition of a new financial liability. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable is recognised in the statement of profit and loss.

#### **(n) Property, plant and equipment**

Freehold land is carried at historical cost. All other items of property, plant and equipment are stated at cost less depreciation. The cost of an asset includes the purchase cost including import duties and non-refundable taxes, borrowing costs if capitalization criteria are met and any directly attributable costs of bringing an asset to the location and condition of its intended use.

Subsequent expenditure related to an item of PPE is added to its carrying value only if it increases the future benefits from the existing asset beyond its previously assessed standard of performance.

All other expenditure related to existing assets including day-to-day repair and maintenance expenditure and cost of replacing parts, are charged to the statement of profit and loss in the period during which such expenditure is incurred.

## **TEJNAKSH HEALTHCARE LIMITED**

### **NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021**

Projects under which tangible fixed assets are not yet ready for their intended use are carried at cost, comprising of direct cost, related incidental expenses and attributable interest and such properties are classified to the appropriate categories of PPE when completed and ready to use.

The carrying amount of a PPE is de-recognised upon disposal of PPE or when no future economic benefits are expected from its use. Any gain or loss arising on the disposal or retirement of an item of PPE is determined as the difference between the sales proceeds and the carrying amount of the asset and is recognised in the statement of profit and loss.

#### **Depreciation methods, estimated useful lives and residual value**

Depreciation on Property, Plant and Equipment (PPE) has been provided on the straight-line method as per the useful life prescribed in Schedule II to the Companies Act, 2013.

The property, plant and equipment acquired under finance leases is depreciated over the asset's useful life or over the shorter of the asset's useful life and the lease term if there is no reasonable certainty that the company will obtain ownership at the end of the lease term.

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount.

#### **(o) Intangible assets**

Intangible assets acquired separately are measured on initial recognition at cost less accumulated amortisation and accumulated impairment losses, if any.

##### **Goodwill**

Goodwill arising on an acquisition of a business is carried at cost as established at the date of acquisition of the business less accumulated impairment losses, if any. For the purposes of impairment testing, goodwill is allocated to each of the Company's cash-generating units that is expected to benefit from the synergies of the combination. A cash-generating unit to which goodwill has been allocated is tested for impairment annually, or more frequently when there is an indication that the unit may be impaired. If the recoverable amount of the cash-generating unit is less than its carrying amount, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro rata based on the carrying amount of each asset in the unit. Any impairment loss for goodwill is recognised directly in profit or loss. An impairment loss recognised for goodwill is not reversed in subsequent periods.

On disposal of the relevant cash-generating unit, the attributable amount of goodwill is included in the determination of the profit or loss on disposal.

##### **Trade Mark, Patents, copyrights and other rights**

Separately acquired patents and copyrights are shown at cost. They have a finite useful life and are subsequently carried at cost less accumulated amortisation and impairment losses.

##### **Computer software**

Cost of software and licenses, which are acquired, are capitalised and amortized on a straight line basis over a period of 3 to 6 years or the license period, whichever is lower.

The amortisation period and method are reviewed at the end of each reporting period if the expected useful life of the asset changes from previous estimates, the effect of such change in estimates are accounted for prospectively.

An intangible asset is derecognised on disposal, or when no future economic benefits are expected from use or disposal. Gains and losses arising from de-recognition of an intangible asset are measured as the difference between the net disposal proceeds and the carrying amount of the asset and are recognised in the statement of profit and loss when the asset is de-recognised.

## **TEJNAKSH HEALTHCARE LIMITED**

### **NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021**

#### **(p) Business combinations and goodwill**

Acquisitions of businesses are accounted for using the acquisition method. The consideration transferred in a business combination is measured at fair value, which is calculated as the sum of the acquisition-date fair values of the assets transferred by the Company, liabilities incurred by the Company to the former owners of the acquiree and the equity interests issued by the Company in exchange of control of the acquiree. Acquisition-related costs are generally recognised in profit or loss as incurred.

Goodwill is measured as the excess of the sum of the consideration transferred, the amount of any non-controlling interests in the acquiree, and the fair value of the acquirer's previously held equity interest in the acquiree (if any) over the net of the acquisition-date amounts of the identifiable assets acquired and the liabilities assumed.

#### **(q) Borrowing costs**

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale.

All other borrowing costs are recognised in the statement of profit and loss in the period in which they are incurred.

#### **(r) Provisions**

Provisions are recognised when the company has a present obligation (legal or constructive) as a result of a past event, it is probable that the company will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. When a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows (when the effect of the time value of money is material).

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, a receivable is recognised as an asset if it is virtually certain that reimbursement will be received and the amount of the receivable can be measured reliably.

#### **(s) Contingent liabilities**

A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Company or a present obligation that is not recognized because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in extremely rare cases where there is a liability that cannot be recognized because it cannot be measured reliably. The Company does not recognize a contingent liability but discloses its existence in the financial statements.

#### **(t) Employee benefits**

##### **Short-term obligations**

Liabilities for wages and salaries, including non-monetary benefits that are expected to be settled wholly within 12 months after the end of the period in which the employees render the related service are recognised in respect of employees' services up to the end of the reporting period and are measured at the amounts expected to be paid when the liabilities are settled. The liabilities are presented as current employee benefit obligations in the balance sheet.

##### **Post-employment obligations**

The Company has not provided for obligations towards gratuity as required under applicable laws in India.

##### **Gratuity**

The Company has an obligation towards gratuity. It provides for a lump sum payment to vested employees at retirement, death while in employment or on termination of employment of an amount based on the respective employee's salary and the tenure of employment. The liability in respect of gratuity is recognised in the books of account based on actuarial valuation by an independent actuary.

## **TEJNAKSH HEALTHCARE LIMITED**

### **NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021**

#### **Defined contribution plans**

The company pays provident fund contributions to publicly administered provident funds as per local regulations. The company has no further payment obligations once the contributions have been paid. The contributions are accounted for as defined contribution plans and the contributions are recognised as employee benefit expense when they are due. Prepaid contributions are recognised as an asset to the extent that a cash refund or a reduction in the future payments is available.

#### **(u) Earnings per share**

The Company presents basic and diluted earnings per share ("EPS") data for its equity shares.

Basic EPS is calculated by dividing the profit or loss attributable to equity shareholders of the Company by the weighted average number of equity shares outstanding during the period.

Diluted EPS is determined by adjusting the profit or loss attributable to equity shareholders and the weighted average number of equity shares outstanding, for the effects of all dilutive potential equity shares.

Potential equity shares are deemed to be dilutive only if their conversion to equity shares would decrease earning per share. Potential dilutive equity shares are deemed to be converted as at the beginning of the period, unless they have been issued at a later date. Dilutive potential equity shares are determined independently for each period presented.

#### **(v) Segment Reporting**

Operating segments reflect the Company's management structure and the way the financial information is regularly reviewed by the Company's Chief operating decision maker (CODM). The CODM considers the business from both business and product perspective based on the dominant source, nature of risks and returns and the internal organization and management structure. The operating segments are the segments for which separate financial information is available and for which operating profit / (loss) amounts are evaluated regularly by the executive Management in deciding how to allocate resources and in assessing performance.

The accounting policies adopted for segment reporting are in line with the accounting policies of the Company. Segment revenue, segment expenses, segment assets and segment liabilities have been identified to segments on the basis of their relationship to the operating activities of the segment.

#### **(w) Operating cycle**

Based on the nature of products / activities of the Company and the normal time between acquisition of assets and their realization in cash or cash equivalents, the Company has determined its operating cycle as 12 months for the purpose of classification of its assets and liabilities as current and non-current.

### **3 Critical accounting judgements and key sources of estimation uncertainty**

In the application of the Company's accounting policies, which are described in Note 2, the management of the Company are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

#### **Critical judgements in applying accounting policies**

The following are the critical judgements, apart from those involving estimations, that the directors have made in the process of applying the Company's accounting policies and that have the most significant effect on the amounts recognised in the financial statements.

#### **(i) Useful lives of property, plant and equipment**

Management reviews the useful lives of property, plant and equipment at least once a year. Such lives are dependent upon an assessment of both the technical lives of the assets and also their likely economic lives based on various internal and external factors including relative efficiency and operating costs. Accordingly, depreciable lives are reviewed annually using the best information available to the Management.

**TEJNAKSH HEALTHCARE LIMITED****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021****(ii) Impairment of non financial assets and goodwill**

Determining whether the asset/goodwill is impaired requires an estimation of the value in use of the cash-generating units to which asset/goodwill has been allocated. The value in use calculation requires the Company to estimate the future cash flows expected to arise from the cash-generating unit and a suitable discount rate in order to calculate present value. Where the actual future cash flows are less than expected, a material impairment loss may arise.

**(iii) Valuation of deferred tax assets**

The Company reviews the carrying amount of deferred tax assets at the end of each reporting period.

**(iv) Provisions and Contingent liabilities**

A provision is recognised when the Company has a present obligation as a result of past event and it is probable that an outflow of resources will be required to settle the obligation, in respect of which a reliable estimate can be made. These are reviewed at each Balance sheet date and adjusted to reflect the current best estimates.

**TEJNAKSH HEALTHCARE LIMITED****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021***(Amount in INR, unless otherwise stated)***4. PROPERTY, PLANT AND EQUIPMENT**

| Particulars                                    | Buildings          | Plant and Equipments | Office Equipments | Furniture and Fixtures | Computers       | Vehicles         | Total               |
|--|--------------------|----------------------|-------------------|------------------------|-----------------|------------------|---------------------|
| <b>GROSS CARRYING VALUE</b>                    |                    |                      |                   |                        |                 |                  |                     |
| <b>As at April 1, 2019</b>                     | 7,66,13,929        | 5,08,38,761          | 23,21,598         | 19,98,945              | 8,11,242        | 22,61,188        | 13,48,45,664        |
| Additions                                      | 2,26,071           | 40,89,506            | 3,03,842          | -                      | 41,084          | 57,79,693        | 1,04,40,196         |
| Disposals                                      | -                  | -                    | -                 | -                      | -               | -                | -                   |
| <b>As at March 31, 2020</b>                    | <b>7,68,40,000</b> | <b>5,49,28,267</b>   | <b>26,25,440</b>  | <b>19,98,945</b>       | <b>8,52,326</b> | <b>80,40,881</b> | <b>14,52,85,860</b> |
| Additions                                      | 2,42,079           | 38,90,488            | 1,65,775          | -                      | 60,130          | -                | 43,58,471           |
| Disposals                                      | 40,45,920          | 77,89,000            | 3,25,688          | -                      | 1,77,174        | -                | 1,23,37,782         |
| <b>As at March 31, 2021</b>                    | <b>7,30,36,159</b> | <b>5,10,29,755</b>   | <b>24,65,527</b>  | <b>19,98,945</b>       | <b>7,35,282</b> | <b>80,40,881</b> | <b>13,73,06,549</b> |
| <b>ACCUMULATED DEPRECIATION/IMPAIRMENT</b>     |                    |                      |                   |                        |                 |                  |                     |
| <b>As at April 1, 2019</b>                     | 23,61,890          | 56,16,919            | 8,07,383          | 2,64,464               | 3,56,933        | 11,22,762        | 1,05,30,351         |
| Depreciation for the year                      | 12,23,089          | 37,10,285            | 5,05,021          | 2,03,251               | 2,14,432        | 6,22,869         | 64,78,947           |
| Deductions\Adjustments during the period       | -                  | -                    | -                 | -                      | -               | -                | -                   |
| <b>As at March 31, 2020</b>                    | <b>35,84,979</b>   | <b>93,27,204</b>     | <b>13,12,404</b>  | <b>4,67,715</b>        | <b>5,71,365</b> | <b>17,45,631</b> | <b>1,70,09,298</b>  |
| Depreciation for the year                      | 12,15,196          | 38,85,822            | 4,06,952          | 1,89,844               | 1,66,178        | 8,87,027         | 67,51,019           |
| Deductions\Adjustments during the period       | 1,80,718           | 13,11,977            | 1,18,399          | -                      | 1,35,421        | -                | 17,46,515           |
| <b>As at March 31, 2021</b>                    | <b>46,19,457</b>   | <b>1,19,01,048</b>   | <b>16,00,957</b>  | <b>6,57,560</b>        | <b>6,02,123</b> | <b>26,32,658</b> | <b>2,20,13,802</b>  |
| <b>Net Carrying value as at March 31, 2021</b> | <b>6,84,16,702</b> | <b>3,91,28,707</b>   | <b>8,64,570</b>   | <b>13,41,385</b>       | <b>1,33,159</b> | <b>54,08,223</b> | <b>11,52,92,747</b> |
| <b>Net Carrying value as at March 31, 2020</b> | <b>7,32,55,021</b> | <b>4,56,01,064</b>   | <b>13,13,036</b>  | <b>15,31,230</b>       | <b>2,80,961</b> | <b>62,95,250</b> | <b>12,82,76,561</b> |

**Note:**

All the property, plant and equipments are charged as security against the secured borrowings of the Company

**TEJNAKSH HEALTHCARE LIMITED****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021***(Amount in INR, unless otherwise stated)***5. INTANGIBLE ASSETS**

| Particulars                                    | Goodwill           | Patents       | Trade Mark    | Software        | Total              |
|--|--------------------|---------------|---------------|-----------------|--------------------|
| <b>GROSS CARRYING VALUE</b>                    |                    |               |               |                 |                    |
| <b>As at April 1, 2019</b>                     | 4,50,00,000        | 19,372        | 66,050        | 3,30,400        | 4,54,15,822        |
| Additions                                      | -                  | 22,840        | 12,500        | -               | 35,340             |
| Deletions                                      | -                  | -             | -             | -               | -                  |
| Acquisition through business combinations      | -                  | -             | -             | -               | -                  |
| <b>As at March 31, 2020</b>                    | <b>4,50,00,000</b> | <b>42,212</b> | <b>78,550</b> | <b>3,30,400</b> | <b>4,54,51,162</b> |
| Additions                                      | -                  | -             | -             | -               | -                  |
| Deletions                                      | 1,00,00,000        | -             | -             | 3,30,400        | 1,03,30,400        |
| <b>As at March 31, 2021</b>                    | <b>3,50,00,000</b> | <b>42,212</b> | <b>78,550</b> | <b>-</b>        | <b>3,51,20,762</b> |
| <b>ACCUMULATED AMORTISATION AND IMPAIRMENT</b> |                    |               |               |                 |                    |
| <b>As at April 1, 2019</b>                     | -                  | -             | -             | 6,699           | 6,699              |
| Amortisation for the year                      | -                  | -             | -             | 65,172          | 65,172             |
| Deductions\Adjustments during the period       | -                  | -             | -             | -               | -                  |
| <b>As at March 31, 2020</b>                    | -                  | -             | -             | 71,871          | 71,871             |
| Amortisation for the year                      | -                  | -             | -             | 54,130          | 54,130             |
| Deductions\Adjustments during the period       | -                  | -             | -             | 1,26,001        | 1,26,001           |
| <b>As at March 31, 2021</b>                    | -                  | -             | -             | -               | -                  |
| <b>Net Carrying value as at March 31, 2021</b> | <b>3,50,00,000</b> | <b>42,212</b> | <b>78,550</b> | <b>-</b>        | <b>3,51,20,762</b> |
| <b>Net Carrying value as at March 31, 2020</b> | <b>4,50,00,000</b> | <b>42,212</b> | <b>78,550</b> | <b>2,58,529</b> | <b>4,53,79,291</b> |

**Impairment testing of goodwill**

The goodwill is measured as the excess of the sum of the consideration transferred over the net of acquisition date amount of identified assets acquired and liabilities assumed.

For the purpose of impairment testing, goodwill is allocated to the cash generating units (businesses acquired) that is expected to benefit from the synergies of the combination.

The Group tests whether goodwill has suffered any impairment periodically. The recoverable amount of a cash generating unit (CGU) is determined based on fair value less cost to sell of the underlying asset.

Based on the evaluation by the management, the goodwill has not suffered any impairment during the year.

On 1st February, 2021 the Group discontinued and disposed off its operations at Lion Tarachand Bapa Hospital, Mumbai. On disposal the attributable amount of goodwill is included in the determination of the profit or loss on disposal.

**TEJNAKSH HEALTHCARE LIMITED**
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021**
*(Amount in INR, unless otherwise stated)*
**6. FINANCIAL ASSETS**

| Particulars  | March 31, 2021     | March 31, 2020   |
|--|--------------------|------------------|
| <b>(A) INVESTMENTS</b>                                     |                    |                  |
| <b>Non Current</b>   |                    |                  |
| Investments carried at fair value through Profit and Loss  |                    |                  |
| <b>Unquoted</b>  |                    |                  |
| Investments in Equity Instruments                          |                    |                  |
| Marvela Society, Thane                                     | 600                | 600              |
| <b>(2) Investments carried at Cost</b>                     |                    |                  |
| <b>Unquoted</b>  |                    |                  |
| Investments in Equity Instruments of Subsidiary            |                    |                  |
| Tej Vedaant Healthcare Private Limited                     | -                  | -                |
| <b>Total</b>   | <b>600</b>         | <b>600</b>       |
| Aggregate amount of unquoted investments                   | 600                | 600              |
| Aggregate amount of impairment in the value of investments | -                  | -                |
| <b>(B) OTHER FINANCIAL ASSETS</b>                          |                    |                  |
| <b>Non Current</b>   |                    |                  |
| Financial assets carried at amortised cost                 |                    |                  |
| Bank Deposits with more than 12 months maturity            | 5,05,95,599        | 1,40,728         |
| <b>Total</b>   | <b>5,05,95,599</b> | <b>1,40,728</b>  |
| <b>Current</b>   |                    |                  |
| Financial assets carried at amortised cost                 |                    |                  |
| Security Deposits  | 12,87,021          | 12,51,021        |
| <b>Total</b>   | <b>12,87,021</b>   | <b>12,51,021</b> |

**7. TRADE RECEIVABLES**

| Particulars                | March 31, 2021   | March 31, 2020   |
|----------------------------|------------------|------------------|
| <b>Current</b>             |                  |                  |
| <b>Trade Receivables</b>   |                  |                  |
| Secured, considered good   | -                | -                |
| Unsecured, considered good | 46,55,687        | 52,68,215        |
| Doubtful                   | -                | -                |
|                            | <b>46,55,687</b> | <b>52,68,215</b> |

**8. INVENTORIES**

| Particulars   | March 31, 2021   | March 31, 2020   |
|---|------------------|------------------|
| <b>(Valued at lower of Cost and Net Realisable value)</b> |                  |                  |
| Stock-in-trade (Medical consumables and Drugs)            | 69,68,832        | 63,52,021        |
| <b>Total</b>  | <b>69,68,832</b> | <b>63,52,021</b> |

**9. CASH AND CASH EQUIVALENTS**

| Particulars                             | March 31, 2021     | March 31, 2020     |
|---|--------------------|--------------------|
| Balances with banks in current accounts | 74,85,160          | 50,35,255          |
| Cash on hand                            | 48,44,573          | 79,04,612          |
|   | <b>1,23,29,734</b> | <b>1,29,39,866</b> |



**TEJNAKSH HEALTHCARE LIMITED**
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021**
*(Amount in INR, unless otherwise stated)*
**10. OTHER ASSETS**

| Particulars  | March 31, 2021   | March 31, 2020     |
|--|------------------|--------------------|
| <b>Non Current</b>                                 |                  |                    |
| Capital advances                                   | 6,12,300         | 5,57,300           |
| Payment of Taxes (Net of Provisions)               | 40,45,975        | 24,85,170          |
| <b>Total</b>                                       | <b>46,58,275</b> | <b>30,42,470</b>   |
| <b>Current</b>                                     |                  |                    |
| <b>Advances other than Capital advances</b>        |                  |                    |
| - Advances to vendors                              | 22,70,935        | 2,24,04,166        |
| - Other Advances                                   | 34,19,742        | 1,16,85,399        |
| Prepaid expenses                                   | 11,85,889        | 12,80,333          |
| Balances with Statutory and Government Authorities | 30,032           | 30,032             |
| <b>Total</b>                                       | <b>69,06,598</b> | <b>3,53,99,930</b> |

**11. INCOME TAX**
**Deferred Tax**

| Particulars  | March 31, 2021     | March 31, 2020     |
|--|--------------------|--------------------|
| <b>Deferred tax relates to the following:</b>                              |                    |                    |
| Temporary differences in carrying amount of Property, plant and equipments | (80,07,485)        | (78,27,660)        |
| Provision for Gratuity   | 4,99,307           | 4,66,359           |
| Financial liability at amortised cost                                      | (60,124)           | (98,290)           |
| <b>Net Deferred Tax Liabilities</b>  | <b>(75,68,303)</b> | <b>(74,59,591)</b> |

**Movement in deferred tax liabilities/assets**

| Particulars   | March 31, 2021     | March 31, 2020     |
|---|--------------------|--------------------|
| <b>Opening balance as of April 1</b>                                | (74,59,591)        | (61,90,594)        |
| Tax income/(expense) during the period recognised in profit or loss | (72,983)           | (12,68,997)        |
| Recognise in OCI  | (35,730)           | -                  |
| <b>Closing balance as at March 31</b>                               | <b>(75,68,303)</b> | <b>(74,59,591)</b> |

The Company offsets tax assets and liabilities if and only if it has a legally enforceable right to set off current tax assets and current tax liabilities and the deferred tax assets and deferred tax liabilities relate to income taxes levied by the same tax authority

**Major Components of income tax expense for the years ended March 31, 2021 and March 31, 2020 are as follows:**

**Income tax recognised in profit or loss**

|   | 2020-21          | 2020-19          |
|---|------------------|------------------|
| Current income tax charge                                     | 59,15,000        | 69,30,100        |
| Adjustment in respect of current income tax of previous year  | -                | -                |
| <b>Deferred tax</b>   |                  |                  |
| Relating to origination and reversal of temporary differences | 72,983           | 12,37,641        |
| <b>Income tax expense recognised in profit or loss</b>        | <b>59,87,983</b> | <b>81,67,741</b> |

**Reconciliation of tax expense and accounting profit multiplied by income tax rate for March 31, 2021 and March 31, 2020**

|   | 2020-21          | 2019-20          |
|---|------------------|------------------|
| Accounting profit before income tax     | 2,66,80,395      | 2,96,55,453      |
| Enacted tax rate in India               | 25.17%           | 27.82%           |
| <b>Income tax on accounting profits</b> | <b>67,14,922</b> | <b>82,50,147</b> |
| <b>Tax effect of</b>                    |                  |                  |
| Other adjustments                       | (7,26,939)       | (82,406)         |
| <b>Tax at effective income tax rate</b> | <b>59,87,983</b> | <b>81,67,741</b> |

**TEJNAKSH HEALTHCARE LIMITED**
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021**

(Amount in INR, unless otherwise stated)

**12. SHARE CAPITAL**
**i. Authorised Share Capital**

|                                     | Equity Share of INR 10 each |                     |
|-------------------------------------|-----------------------------|---------------------|
|                                     | Number                      | Amount              |
| <b>At April 1, 2019</b>             | 1,05,00,000                 | 10,50,00,000        |
| Increase/(decrease) during the year | -                           | -                   |
| <b>At March 31, 2020</b>            | 1,05,00,000                 | 10,50,00,000        |
| Increase/(decrease) during the year | -                           | -                   |
| <b>At March 31, 2021</b>            | <b>1,05,00,000</b>          | <b>10,50,00,000</b> |

**Terms/rights attached to equity shares**

The company has only one class of equity shares having par value of INR 10 per share. Each holder of equity shares is entitled to one vote per share. The company declares and pays dividends in Indian rupees. The dividend proposed by the Board of Directors is subject to the approval of the shareholders in the ensuing Annual General Meeting.

In the event of liquidation of the company, the holders of equity shares will be entitled to receive remaining assets of the company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the shareholders.

**ii. Issued Capital**

| Particulars   | Number             | Amount              |
|---|--------------------|---------------------|
| <b>Equity shares of INR 10 each issued, subscribed and fully paid</b> |                    |                     |
| <b>At April 1, 2019</b>   | <b>1,01,56,800</b> | <b>10,15,68,000</b> |
| Issued during the period  | -                  | -                   |
| <b>At March 31, 2020</b>  | <b>1,01,56,800</b> | <b>10,15,68,000</b> |
| Issued during the period  | -                  | -                   |
| <b>At March 31, 2021</b>  | <b>1,01,56,800</b> | <b>10,15,68,000</b> |

**iii. Details of shareholders holding more than 5% shares in the company**

| Name of the shareholder                        | As at March 31, 2021 |           | As at March 31, 2020 |           |
|--|----------------------|-----------|----------------------|-----------|
|  | Number               | % holding | Number               | % holding |
| <b>Equity shares of INR 10 each fully paid</b> |                      |           |                      |           |
| Dr. Ashish Vishwas Rawandale                   | 38,74,601            | 38.15%    | 38,73,201            | 38.13%    |
| Dr. Preeti Ashish Rawandale                    | 36,08,699            | 35.53%    | 36,08,699            | 35.53%    |

**iv. Aggregate number of equity shares issued as bonus, shares issued for consideration other than cash and shares bought back during the period of five years immediately preceding the reporting date:**

The Company has allotted 79,48,800 (March 31, 2017: 11,04,000) fully paid up shares of face value INR 10 each in financial year 2018-19, pursuant to bonus issue approved by the shareholders through postal ballot.

**13. OTHER EQUITY**

| Particulars                            | March 31, 2021     | March 31, 2020     |
|--|--------------------|--------------------|
| <b>i. Reserves and Surplus</b>         |                    |                    |
| Securities Premium Reserve             | 2,12,80,000        | 2,12,80,000        |
| Retained Earnings                      | 5,01,89,599        | 2,96,61,740        |
| <b>ii. Other Comprehensive Income</b>  |                    |                    |
| Actuarial gain / (loss) on liabilities | 1,06,235           | -                  |
|  | <b>7,15,75,834</b> | <b>5,09,41,740</b> |

**(a) Securities Premium Reserve**

|                         | March 31, 2021     | March 31, 2020     |
|-------------------------|--------------------|--------------------|
| Opening balance         | 2,12,80,000        | 2,12,80,000        |
| Changes during the year | -                  | -                  |
| <b>Closing balance</b>  | <b>2,12,80,000</b> | <b>2,12,80,000</b> |

The amount received in excess of face value of the shares is recognised in Share premium reserve. This is not available for distribution of dividend but can be utilised for issuing bonus shares.

**(b) Re-measurement of defined benefit plans**

|                         | March 31, 2021  | March 31, 2020 |
|-------------------------|-----------------|----------------|
| Opening balance         | -               | -              |
| Changes during the year | 1,06,235        | -              |
| <b>Closing balance</b>  | <b>1,06,235</b> | <b>-</b>       |

**TEJNAKSH HEALTHCARE LIMITED****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021***(Amount in INR, unless otherwise stated)***(b) Retained Earnings**

|                                  | March 31, 2021     | March 31, 2020     |
|----------------------------------|--------------------|--------------------|
| Opening balance                  | 2,96,61,740        | 87,60,638          |
| Net Profit/(Loss) for the period | 2,05,29,791        | 2,09,01,102        |
| Change in ownership interest     | -                  | -                  |
| <b>Closing balance</b>           | <b>5,01,91,531</b> | <b>2,96,61,740</b> |

**14. BORROWINGS**

| Particulars                                       | March 31, 2021     | March 31, 2020     |
|---|--------------------|--------------------|
| <b>Non Current Borrowings</b>                     |                    |                    |
| <b>Secured</b>                                    |                    |                    |
| Term Loans  |                    |                    |
| From Banks  | 4,68,42,328        | 6,86,93,337        |
| From Others                                       | 20,44,163          | 32,12,850          |
|   | <b>(A)</b>         | <b>7,19,06,186</b> |
| <b>Current Maturity of Non Current Borrowings</b> |                    |                    |
| Term Loans  |                    |                    |
| From Banks  | 57,00,321          | 47,05,267          |
| From Others                                       | 13,64,652          | 12,66,542          |
|   | <b>(B)</b>         | <b>59,71,810</b>   |
| <b>Total (A)-(B)</b>                              | <b>4,18,21,518</b> | <b>6,59,34,377</b> |
| <b>Current Borrowings</b>                         |                    |                    |
| <b>Unsecured - Repayable on demand</b>            |                    |                    |
| Loans from Related Parties (Refer Note:29)        | 40,000             | -                  |
| <b>Total</b>                                      | <b>40,000</b>      | <b>-</b>           |

**TEJNAKSH HEALTHCARE LIMITED****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021***(Amount in INR, unless otherwise stated)*

| Particulars  | Terms of Repayment  | March 31, 2021     | March 31, 2020     |
|--|---|--------------------|--------------------|
| <b>Non Current Borrowings</b>                            |   |                    |                    |
| <b>Secured</b>   |   |                    |                    |
| <b>Term Loan from Banks</b>                              |   |                    |                    |
| Kotak Mahindra Bank Limited                              | In the year 2018-19, the company borrowed INR 2,74,00,000 which was repayable in 96 equated monthly installments of INR 4,15,773 starting from February 10, 2019. During the year company has made a lumpsum repayment of Rs. 57,00,000 towards principal amount. Outstanding amount as on 31.03.2021 is repayable in 66 equated monthly installments of INR 3,15,576. The same is secured against the immovable properties of the company. | 1,62,97,181        | 2,44,36,293        |
| Standard Chartered Bank Limited                          | In the year 2017-18, the company borrowed INR 3,50,30,805 , which is repayable in 48 equated monthly installments of INR 3,79,131 starting from March 2019. During the year company has made a lumpsum repayment of Rs. 84,10,771 towards principal amount. Outstanding amount as on 31.03.2021 is repayable in 26 equated monthly installments of INR 3,79,131. The loan is secured against company's immovable properties.                | 2,30,84,840        | 3,35,91,453        |
| Kotak Mahindra Bank Limited                              | In the year 2019-20, the company borrowed INR 1,13,00,000 which is repayable in 120 equated monthly installments of INR 1,49,018 starting from May 3rd, 2019. During the year company has made a lumpsum repayment of Rs. 25,00,000 towards principal amount. Outstanding amount as on 31.03.2021 is repayable in 89 equated monthly installments of INR 1,13,080. The same is secured against the immovable properties of the company.     | 74,60,307          | 1,06,65,590        |
| <b>Term Loan from Others</b>                             |   |                    |                    |
| Daimler Financial Services                               | During the year 2019-20, the company borrowed INR 37,02,144 which is repayable in 36 equated monthly installments of INR 97,909 starting from November 14th, 2019. The same is secured against the vehicle of the company.  | 20,44,163          | 32,12,850          |
| <b>Gross Non Current Borrowings</b>                      |   | <b>4,88,86,491</b> | <b>7,19,06,186</b> |
| Less: Current maturity                                   |   | 70,64,973          | 59,71,810          |
| <b>Net Non Current Borrowings (as per Balance sheet)</b> |   | <b>4,18,21,518</b> | <b>6,59,34,377</b> |
| <b>Current Borrowings</b>                                |   |                    |                    |
| <b>Unsecured</b>   |   |                    |                    |
| Loans from Related Parties                               | Repayable on demand   | 40,000             | -                  |

The property, plant and equipments are charged as security against secured borrowings of the Company

The secured borrowings are guaranteed by promoter director

**TEJNAKSH HEALTHCARE LIMITED****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021***(Amount in INR, unless otherwise stated)***15. TRADE PAYABLES**

| Particulars   | March 31, 2021   | March 31, 2020   |
|---|------------------|------------------|
| <b>Current</b>  |                  |                  |
| Trade Payables to Micro, Small and Medium Enterprises | -                | -                |
| Trade Payables to Others                              | 46,64,462        | 54,31,416        |
| <b>Total</b>  | <b>46,64,462</b> | <b>54,31,416</b> |

**Details Of Dues To Micro And Small Enterprises As Defined Under Micro, Small And Medium Enterprises Development Act, 2006 (MSMED Act, 2006)**

The company does not possess information as to which of its suppliers are covered under the Micro, Small and Medium Enterprise Development Act, 2006. However the company is regular in making payments to its suppliers and has not received any claim in respect of interest for delayed payment.

**16. OTHER FINANCIAL LIABILITIES**

| Particulars                                  | March 31, 2021   | March 31, 2020   |
|--|------------------|------------------|
| <b>Current</b>                               |                  |                  |
| Current maturities of non current borrowings | 70,64,973        | 59,71,810        |
| Interest Accrued but not due                 | 2,91,286         | 5,04,106         |
| Payable for expenses                         | 15,47,814        | 35,13,821        |
| <b>Total</b>                                 | <b>89,04,074</b> | <b>99,89,737</b> |

**17. OTHER LIABILITIES**

| Particulars           | March 31, 2021  | March 31, 2020   |
|-----------------------|-----------------|------------------|
| <b>Current</b>        |                 |                  |
| Advances received     | 1,70,385        | 6,67,524         |
| Statutory Liabilities | 3,42,394        | 10,89,848        |
| Others                | -               | -                |
| <b>Total</b>          | <b>5,12,779</b> | <b>17,57,372</b> |

**18. OTHER PROVISIONS**

| Particulars        | March 31, 2021   | March 31, 2020   |
|--------------------|------------------|------------------|
| <b>Non Current</b> |                  |                  |
| Gratuity           | 16,75,792        | 14,30,681        |
| <b>Total</b>       | <b>16,75,792</b> | <b>14,30,681</b> |
| <b>Current</b>     |                  |                  |
| Gratuity           | 3,08,104         | 2,45,664         |
| <b>Total</b>       | <b>3,08,104</b>  | <b>2,45,664</b>  |

**19. REVENUE FROM OPERATIONS**

| Particulars                     | 2020-21             | 2019-20             |
|---------------------------------|---------------------|---------------------|
| <b>Sale of products</b>         |                     |                     |
| Traded Goods                    | 1,77,97,542         | 2,43,24,044         |
| <b>Sale of services</b>         |                     |                     |
| Consultation Fee                | 1,21,55,027         | 1,50,23,800         |
| Operation & Surgery             | 7,25,03,113         | 10,69,17,335        |
| Pathology                       | 1,47,23,566         | 1,89,39,326         |
| <b>Other Operating Revenues</b> | 24,21,400           | 59,60,710           |
|                                 | <b>11,96,00,649</b> | <b>17,11,65,215</b> |

**20. OTHER INCOME**

| Particulars                            | 2020-21          | 2019-20          |
|--|------------------|------------------|
| Interest income on Bank fixed deposits | 5,58,241         | 9,67,396         |
| Rent received                          | 1,12,000         | 56,000           |
| Miscellaneous Income                   | 7,14,665         | 23,87,221        |
|  | <b>13,84,906</b> | <b>34,10,617</b> |

**TEJNAKSH HEALTHCARE LIMITED****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021***(Amount in INR, unless otherwise stated)***21. PURCHASES OF STOCK-IN-TRADE**

| Particulars                   | 2020-21          | 2019-20            |
|-------------------------------|------------------|--------------------|
| Medical consumables and Drugs | 95,67,371        | 1,09,74,875        |
|                               | <b>95,67,371</b> | <b>1,09,74,875</b> |

**22. CHANGES IN INVENTORIES OF STOCK-IN-TRADE**

| Particulars  | 2020-21           | 2019-20          |
|--|-------------------|------------------|
| Inventories as at the beginning of the year<br>Stock-in-trade  | 63,52,021         | 83,49,379        |
| Less : Inventories as at the end of the year<br>Stock-in-trade | 69,68,832         | 63,52,021        |
| Net decrease / (increase) in inventories                       | <b>(6,16,811)</b> | <b>19,97,358</b> |

**23. EMPLOYEE BENEFITS EXPENSE**

| Particulars                                | 2020-21            | 2019-20            |
|--|--------------------|--------------------|
| Salaries, wages and bonus                  | 1,30,54,680        | 2,28,89,937        |
| Contributions to provident and other funds | 3,70,851           | 12,75,811          |
| Gratuity Expense                           | 4,49,516           | 13,76,345          |
|  | <b>1,38,75,047</b> | <b>2,55,42,093</b> |

**24. FINANCE COST**

| Particulars                              | 2020-21          | 2019-20          |
|--|------------------|------------------|
| Interest expense on debts and borrowings | 48,55,983        | 75,86,280        |
| Other borrowing cost                     | 1,65,114         | 24,190           |
|  | <b>50,21,097</b> | <b>76,10,470</b> |

**25. DEPRECIATION AND AMORTISATION EXPENSE**

| Particulars                       | 2020-21          | 2019-20          |
|-----------------------------------|------------------|------------------|
| Depreciation on tangible assets   | 67,51,019        | 64,78,947        |
| Amortisation of intangible assets | 54,130           | 65,172           |
|                                   | <b>68,05,149</b> | <b>65,44,119</b> |

**TEJNAKSH HEALTHCARE LIMITED**
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021**
*(Amount in INR, unless otherwise stated)*
**26. OTHER EXPENSES**

| Particulars   | 2020-21            | 2019-20            |
|---|--------------------|--------------------|
| Hospital Expenses                                     | 99,57,621          | 1,97,94,616        |
| Pathology Expenses                                    | 35,31,307          | 44,65,128          |
| Oxygen Cylinder                                       | 5,41,899           | 6,50,884           |
| Net Consumption of X Ray Film                         | 3,70,614           | 6,13,169           |
| Legal and professional fees                           | 3,50,71,713        | 5,26,84,919        |
| House Keeping Expenses                                | 20,07,374          | 29,34,630          |
| Electricity and power expense                         | 25,02,399          | 33,41,794          |
| Printing and Stationery                               | 5,13,224           | 8,90,839           |
| Repairs and maintenance                               | 15,75,382          | 16,39,194          |
| Rent  | -                  | 2,53,050           |
| Bad Debts   | 4,30,244           | 27,163             |
| Advertisement   | 1,21,682           | 1,11,169           |
| Payments to auditors (Refer note below)               | 3,12,700           | 5,95,700           |
| Insurance   | 3,45,796           | 3,28,439           |
| Telephone and internet expenses                       | 81,520             | 1,44,728           |
| Travelling and conveyance expenses                    | 2,66,965           | 15,41,317          |
| Net loss on disposal of property, plant and equipment | 56,165             | -                  |
| Miscellaneous expenses                                | 19,66,703          | 22,34,725          |
| <b>Total</b>  | <b>5,96,53,308</b> | <b>9,22,51,464</b> |

**Details of Payments to auditors**

|                   | 2020-21         | 2019-20         |
|-------------------|-----------------|-----------------|
| <b>As auditor</b> |                 |                 |
| Audit Fee         | 3,12,700        | 5,95,700        |
|                   | <b>3,12,700</b> | <b>5,95,700</b> |

**27. EARNINGS PER SHARE**

| Particulars   | 2020-21     | 2019-20     |
|---|-------------|-------------|
| <b>Basic and Diluted earnings per share (INR)</b>   | 2.02        | 2.06        |
| <b>Nominal value per share (INR)</b>  | 10.00       | 10.00       |
| Profit attributable to the equity holders of the company used in calculating basic and diluted earnings per share   | 2,05,29,791 | 2,09,01,102 |
| Weighted average number of equity shares used as the denominator in calculating basic and diluted earnings per share (including the impact of bonus shares) | 1,01,56,800 | 1,01,56,800 |

The weighted average number of shares takes into account the weighted average effect of changes in share transactions during the year. There have been no other transactions involving Equity shares or potential Equity shares between the reporting date and the date of authorisation of these financial statements.

**28. Employee Benefit Plan**
**Gratuity**

The Company has a defined benefit gratuity plan, where under employee who has completed five years or more of service gets a gratuity on departure at 15 days salary (last drawn basic salary) for each completed year of service subject. Vesting occurs upon completion of 5 years of service. The Gratuity is unfunded.

The following table summarizes the components of net benefit expenses recognised in the Statement of Profit and Loss and the amounts recognized in the Balance Sheet.

| Service Cost  | March 31, 2021  | March 31, 2020   |
|---|-----------------|------------------|
| Current Service Cost                                | 3,50,655        | 3,92,236         |
| Past Service Cost (including curtailment Gain/Loss) | -               | 9,62,959         |
| Gain or Loss on Non Routine settlements             | -               | -                |
| <b>Total</b>  | <b>3,50,655</b> | <b>13,55,195</b> |

**TEJNAKSH HEALTHCARE LIMITED**
**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021**
*(Amount in INR, unless otherwise stated)*

| <b>Net Interest Cost</b>   | <b>March 31, 2021</b> | <b>March 31, 2020</b> |
|--|-----------------------|-----------------------|
| Interest Cost on Defined Benefit Obligation  | 98,861                | 21,150                |
| Interest Income on Plan Assets   | -                     | -                     |
| <b>Net Interest Cost (Income)</b>  | <b>98,861</b>         | <b>21,150</b>         |
|  |                       |                       |
| <b>Change in Present Value of Obligations</b>  | <b>March 31, 2021</b> | <b>March 31, 2020</b> |
| Opening of defined benefit obligation  | 16,76,345             | 3,00,000              |
| Service Cost   | 3,50,655              | 13,55,195             |
| Interest Cost  | 98,861                | 21,150                |
| Benefit Paid   | -                     | -                     |
| <b>Actuarial Gain/Loss on Total Liabilities</b>  | <b>(1,41,965)</b>     | <b>NA</b>             |
| - due to change in financial assumption  | 2,203                 | NA                    |
| - due to change in demographic assumption  | -                     | NA                    |
| - due to experience variance   | (1,44,168)            | NA                    |
| <b>Closing of defined benefit obligation</b>   | <b>19,83,896</b>      | <b>16,76,345</b>      |
|  |                       |                       |
| <b>Reconciliation of expense in Profit and loss Statement</b>                            | <b>March 31, 2021</b> | <b>March 31, 2020</b> |
| Present value of Obligation at the end of the year                                       | 19,83,896             | 16,76,345             |
| Present value of Obligation at the end beginning of the year                             | (16,76,345)           | (3,00,000)            |
| Benefit Paid   | -                     | -                     |
| Actual return on asset   | -                     | -                     |
| OCI  | 1,41,965              | -                     |
| <b>Expense recognised in Statement of Profit and Loss</b>                                | <b>4,49,516</b>       | <b>13,76,345</b>      |
|  |                       |                       |
| <b>Reconciliation of Liability in Balance Sheet</b>                                      | <b>March 31, 2021</b> | <b>March 31, 2020</b> |
| Opening net defined benefit liability / (asset)  | 16,76,345             | 3,00,000              |
| Expense charged to profit and loss account   | 4,49,516              | 13,76,345             |
| Amount recognised outside profit and loss account  | -                     | -                     |
| Employer contributions   | -                     | -                     |
| OCI  | (1,41,965)            | -                     |
| <b>Closing net defined benefit liability / (asset)</b>                                   | <b>19,83,896</b>      | <b>16,76,345</b>      |
|  |                       |                       |
| <b>Bifurcation of Present Value of obligation as the end of the year</b>                 | <b>March 31, 2021</b> | <b>March 31, 2020</b> |
| Current Liability  | 3,08,104              | 2,45,664              |
| Non - Current Liability  | 16,75,792             | 14,30,681             |
| <b>Total Liability</b>   | <b>19,83,896</b>      | <b>16,76,345</b>      |
|  |                       |                       |
| <b>Sensitivity Analysis</b>  | <b>March 31, 2021</b> | <b>March 31, 2020</b> |
| Base Liability   | 19,83,896             | 16,76,345             |
|  | -                     | -                     |
| Increase Discount Rate by 0.50%  | 19,46,285             | 16,42,317             |
| Decrease Discount Rate by 0.50%  | 20,23,231             | 17,11,936             |
|  | -                     | -                     |
| Increase Salary Inflation Rate by 1.00%  | 20,64,501             | 17,49,400             |
| Decrease Salary Inflation Rate by 1.00%  | 19,08,872             | 16,08,374             |
|  | -                     | -                     |
| Increase withdrawal Rate by 5.00%  | 19,12,411             | 15,79,315             |
| Decrease withdrawal Rate by 5.00%  | 20,47,095             | 17,73,051             |
|  |                       |                       |
| <b>Maturity Profile of Defined Benefit Obligation<br/>(Valued on undiscounted basis)</b> | <b>March 31, 2021</b> | <b>March 31, 2020</b> |
| Year 1   | 3,09,715              | 2,45,664              |
| Year 2   | 2,96,258              | 2,06,507              |
| Year 3   | 3,29,533              | 2,16,085              |
| Year 4   | 3,37,200              | 2,68,183              |
| Year 5   | 2,22,894              | 2,70,800              |
| After 5th Year   | 11,41,791             | 10,81,282             |
| <b>Total</b>   | <b>26,37,391</b>      | <b>22,88,521</b>      |



**TEJNAKSH HEALTHCARE LIMITED****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021***(Amount in INR, unless otherwise stated)***29. RELATED PARTY TRANSACTIONS****(i) List of related parties as per the requirements of Ind-AS 24 - Related Party Disclosures****(1) Key Management Personnel (KMP)**

Dr. Ashish Rawandale - Chairman and Managing Director  
 Dr. Preeti Rawandale - Director  
 Kiran Pawar - Director  
 Vikramsinh Patil - Director  
 Dr. Subhash Chavan - Director  
 Ramesh Kuwar - Chief Financial Officer  
 Prakash Sogam - Company Secretary

**(2) Enterprise that have a member of key management in common with the reporting enterprise.**

Tejnaksh Healthcare Foundation

**(ii) Transactions with related parties**

The following transactions occurred with related parties

| Name                           | 2020-21   | 2019-20   |
|--------------------------------|-----------|-----------|
| <b>(a) Professional Fees</b>   |           |           |
| Dr. Ashish Rawandale           | 7,00,000  | 15,00,000 |
| Dr. Preeti Rawandale           | 6,00,000  | 6,00,000  |
| Dr. Subhash Chavan             | 24,60,137 | 38,73,629 |
| <b>(b) Deposit Return</b>      |           |           |
| Prakash Sogam                  | -         | 35,000    |
| <b>(c) Services rendered</b>   |           |           |
| Tejnaksh Healthcare Foundation | 54,00,000 | -         |

**(iii) Outstanding balances**

| Name                             | March 31, 2021 | March 31, 2020 |
|----------------------------------|----------------|----------------|
| <b>Professional Fees Payable</b> |                |                |
| Dr. Ashish Rawandale             | -              | 3,37,500       |
| Dr. Preeti Rawandale             | -              | 2,25,000       |
| Dr. Subhash Chavan               | 3,03,132       | 2,74,262       |

**(iv) Loans from related parties**

| Name                              | Particulars            | March 31, 2021 | March 31, 2020 |
|-----------------------------------|------------------------|----------------|----------------|
| <b>Loans from related parties</b> |                        |                |                |
| Dr. Ashish Rawandale              | Beginning of the year  | -              | 17,67,441      |
|                                   | Loans received         | -              | -              |
|                                   | Loan repayments made   | -              | (17,67,441)    |
|                                   | <b>End of the year</b> | -              | -              |
| Tejnaksh Healthcare Foundation    | Beginning of the year  | -              | -              |
|                                   | Loans received         | 40,000         | -              |
|                                   | Loan repayments made   | -              | -              |
|                                   | <b>End of the year</b> | <b>40,000</b>  | -              |

**(v) Key management personnel compensation**

|                              | 2020-21         | 2019-20         |
|------------------------------|-----------------|-----------------|
| Short term employee benefits | 8,23,699        | 7,63,788        |
| Post-employment benefits     | 24,040          | 1,87,700        |
|                              | <b>8,47,739</b> | <b>9,51,488</b> |

**(vi) Terms and conditions of transactions with related parties**

The sales to and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions. Outstanding balances at the year end are unsecured and interest free and settlement occurs in cash. For the year ended March 31, 2021, the group has not recorded any impairment of receivables relating to amount owed by related parties (March 31, 2020: NIL). This assessment is undertaken each financial year through examining the financial position of the related party and market in which the related party operates.

**TEJNAKSH HEALTHCARE LIMITED****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021**

(Amount in INR, unless otherwise stated)

**30. SEGMENT REPORTING**

The Company has a single operating segment, namely, health care services and the information reported to the chief operating decision maker (CODM) for the purposes of resource allocation and assessment of performance focusses on this operating segment. Further the company does not have any separate geographic segment other than India. Accordingly, the amounts appearing in these financial statements relate to this operating segment.

**31. FAIR VALUE MEASUREMENTS****i. Financial Instruments by Category**

| Particulars                      | Carrying Amount    |                    | Fair Value         |                    |
|----------------------------------|--------------------|--------------------|--------------------|--------------------|
|                                  | March 31, 2021     | March 31, 2020     | March 31, 2021     | March 31, 2020     |
| <b>FINANCIAL ASSETS</b>          |                    |                    |                    |                    |
| <b>Amortised cost</b>            |                    |                    |                    |                    |
| Cash and Cash Equivalents        | 1,23,29,734        | 1,29,39,866        | 1,23,29,734        | 1,29,39,866        |
| Other Financial Assets           | 5,18,82,620        | 13,91,749          | 5,18,82,620        | 13,91,749          |
| <b>FVTPL</b>                     |                    |                    |                    |                    |
| Investment in Equity Instruments | 600                | 600                | 600                | 600                |
| <b>Total</b>                     | <b>6,42,12,954</b> | <b>1,43,32,215</b> | <b>6,42,12,954</b> | <b>1,43,32,215</b> |

|                              |                    |                    |                    |                    |
|------------------------------|--------------------|--------------------|--------------------|--------------------|
| <b>FINANCIAL LIABILITIES</b> |                    |                    |                    |                    |
| <b>Amortised cost</b>        |                    |                    |                    |                    |
| Borrowings                   | 4,18,21,518        | 6,59,34,377        | 4,18,21,518        | 6,59,34,377        |
| Trade Payables               | 46,64,462          | 54,31,416          | 46,64,462          | 54,31,416          |
| <b>Total</b>                 | <b>4,64,85,980</b> | <b>7,13,65,792</b> | <b>4,64,85,980</b> | <b>7,13,65,792</b> |

The management assessed that the fair value of cash and cash equivalent, trade receivables, trade payables, and other current financial assets and liabilities approximate their carrying amounts largely due to the short term maturities of these instruments.

The fair values for security deposits were calculated based on cash flows discounted using a current lending rate. They are classified as level 3 fair values in the Fair value hierarchy due to the inclusion of unobservable inputs including counterparty credit risk.

The fair values of non current borrowings are based on discounted cash flows using a current borrowing rate. They are classified as level 3 fair values in the fair value hierarchy due to the use of unobservable inputs, including own credit risk.

**ii. Fair Value Hierarchy**

The company has classified its financial instruments into three levels prescribed under the accounting standard as follows:

**Assets and liabilities measured at fair value**

| Assets and liabilities measured at fair value |   |   |   |       |   |   |   |       |
|---|---|---|---|-------|---|---|---|-------|
| Particulars                                   | March 31, 2021                            |   |   | Total | March 31, 2020                            |   |   | Total |
|   | Fair value measurement using              |   |   |       | Fair value measurement using              |   |   |       |
|   | Quoted prices in active markets (Level 1) | Significant Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) |       | Quoted prices in active markets (Level 1) | Significant Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) |       |
| Financial Assets                              |   |   |   |       |   |   |   |       |
| Investment in Equity Instruments              |   | 600                                     |   | 600   |   | 600                                     |   | 600   |
| Total Assets                                  | -   | 600                                     | -   | 600   | -   | 600                                     | -   | 600   |

There have been no transfers among Level 1, Level 2 and Level 3 during the period

**TEJNAKSH HEALTHCARE LIMITED****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021****32. BUSINESS COMBINATIONS****(1) Discontinued operations**

On 1st february,2021 the Group discontinued and disposed off its operations at Lion Tarachand Bapa Hospital, Mumbai.

The details of disposal of unit :

| Particulars                   | Amount Rs.  |
|-------------------------------|-------------|
| Consideration Received        | 3,14,00,000 |
| Carring Amount of Assets Sold | 3,14,56,165 |
| Loss on disposal              | 56,165      |

The carrying amount of assets and liabilities as at the date of sale (01 February 2021) were as follows:

| Particulars                   | Amount Rs.         |
|-------------------------------|--------------------|
| Property, plant and equipment | 1,05,91,267        |
| Intangible Assets             | 1,02,04,399        |
| Trade Receivable              | 8,35,825           |
| Other current Assets          | 1,01,99,686        |
| <b>Total Assets</b>           | <b>3,18,31,177</b> |
| Other current liabilities     | 3,75,012           |
| <b>Total Liabilities</b>      | <b>3,75,012</b>    |
| <b>Net Assets</b>             | <b>3,14,56,165</b> |

**33. INTEREST IN OTHER ENTITIES****Subsidiaries**

| Name of entity                       | Place of business | Principal activities | Ownership interest held by the group |                | Ownership interest held by non controlling interest |                |
|--------------------------------------|-------------------|----------------------|--------------------------------------|----------------|---|----------------|
|                                      |                   |                      | March 31, 2021                       | March 31, 2020 | March 31, 2021                                      | March 31, 2020 |
| Tejvedant Healthcare Private Limited | India             | Healthcare Services  | 75%                                  | 75%            | 25%   | 25%            |

**34. DISCLOSURES REQUIRED BY SCHEDULE III**

| Name of the Entity in the Group             | Net Assets, i.e. total assets minus total liabilities |                     | Share in profit or loss             |                    | Share in other comprehensive income |                 | Share in total comprehensive income |                    |
|---|---|---------------------|-------------------------------------|--------------------|-------------------------------------|-----------------|-------------------------------------|--------------------|
|   | As % of consolidated net assets                       | Amount              | As % of consolidated profit or loss | Amount             | As % of consolidated OCI            | Amount          | As % of total comprehensive income  | Amount             |
| <b>Tejnaksh Healthcare Limited - Parent</b> | 96  | 17,02,56,242        | 97                                  | 2,00,41,928        | 93                                  | 98,504          | 97                                  | 2,01,40,432        |
| <b>Subsidiaries</b>                         |   |                     |                                     |                    |                                     |                 |                                     |                    |
| <b>Indian</b>                               |   |                     |                                     |                    |                                     |                 |                                     |                    |
| Tejvedant Healthcare Private Limited        | 2   | 28,87,592           | 2                                   | 4,87,863           | 5                                   | 5,798           | 2                                   | 4,93,661           |
| Non-controlling Interests                   | 3   | 44,95,864           | 1                                   | 1,62,621           | 2                                   | 1,933           | 1                                   | 1,64,554           |
| <b>Total</b>                                | <b>100</b>  | <b>17,76,39,698</b> | <b>100</b>                          | <b>2,06,92,412</b> | <b>100</b>                          | <b>1,06,236</b> | <b>100</b>                          | <b>2,07,98,647</b> |

**35. FINANCIAL RISK MANAGEMENT**

The Company manages financial risk relating to the operations through internal risk reports which analyse exposure by degree and magnitude of risk. These risks include market risk (including interest rate risk and other price risk), credit risk and liquidity risk. The focus of the chief operating decision maker (CODM) is to assess the unpredictability of the financial environment and to mitigate potential adverse effects, if any, on the financial performance of the Company.

The Company does not enter into or trade financial instruments including derivative financial instruments for speculative purpose.

**(A) Credit risk**

Credit risk is the risk that counterparty will default on its contractual obligation resulting in a financial loss to the company. The credit risk arises primarily on trade receivables and deposits with banks and other financial instruments.

The Company's hospital and healthcare services and sale of medical goods are on the counter sale i.e. on cash basis and as such no credit risk arises.

Exposures to customers outstanding at the end of each reporting period are reviewed by the Company to determine expected credit losses. Historical trends of impairment of trade receivables do not reflect any credit losses. Given that there is no substantial change in the economic environment affecting customers of the Company, the Company expects the historical trend of immaterial credit losses to continue.

Credit risk on cash and bank balances is limited as company counterparties are banks with high credit ratings assigned credit rating agencies.

**(B) Liquidity risk**

Liquidity risk refers to the risk that the Company cannot meet its financial obligations. The objective of liquidity risk management is to maintain sufficient liquidity and ensure that funds are available for use as per requirements. The Company consistently generated sufficient cash flows from operations to meet its financial obligations as and when they fall due.

The following tables detail the Company's remaining contractual maturity for its financial liabilities with agreed repayment periods. The tables have been drawn up based on the undiscounted cash flows of financial liabilities based. It include both interest and principal cash flows. The contractual maturity is based on the earliest date on which the Company may be required to pay.

**Contractual maturities of financial liabilities**

| Particulars                 | Carrying amount    | Within 1 year      | 1-5 years          | More than 5 years  | Total              |
|-----------------------------|--------------------|--------------------|--------------------|--------------------|--------------------|
| <b>As at March 31, 2020</b> |                    |                    |                    |                    |                    |
| Borrowing                   | 4,88,86,491        | 70,64,973          | 4,03,13,813        | 15,07,706          | 4,88,86,491        |
| Trade payable               | 46,64,462          | 46,64,462          |                    |                    | 46,64,462          |
| Other financial liabilities | 18,39,100          | 18,39,100          |                    |                    | 18,39,100          |
|                             | <b>5,53,90,054</b> | <b>1,35,68,535</b> | <b>4,03,13,813</b> | <b>15,07,706</b>   | <b>5,53,90,054</b> |
| <b>As at March 31, 2019</b> |                    |                    |                    |                    |                    |
| Borrowing                   | 7,19,06,186        | 59,71,810          | 5,18,27,796        | 1,41,06,580        | 7,19,06,186        |
| Trade payable               | 54,31,416          | 54,31,416          | -                  | -                  | 54,31,416          |
| Other financial liabilities | 40,17,927          | 40,17,927          | -                  | -                  | 40,17,927          |
|                             | <b>8,13,55,529</b> | <b>1,54,21,153</b> | <b>5,18,27,796</b> | <b>1,41,06,580</b> | <b>8,13,55,529</b> |

**(C) Market risk**

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in the market prices. The Company is exposed in the ordinary course of its business to risks related to changes in foreign currency exchange rates. The Company's exposure to foreign currency risk and other price risk is not significant.

**Interest rate risk**

Interest rate risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in the market interest rates. The Company's exposure to the risk of changes in the market interest rates relates primarily to the Company's debt obligations with floating interest rates.

However, the company does not expect any material change in the interest rates in the foreseeable future and therefore does not expects any significantly risk on account of change in interest rate as at the respective reporting dates.

**Interest rate sensitivity**

The following table demonstrates the sensitivity to a reasonably possible change in interest rates on that portion of loans and borrowings taken at floating rates. With all other variables held constant, the Company's profit/ (loss) before tax is affected through the impact on floating rate borrowings, as follows:

| Particulars                                   | Impact on profit before tax |            |
|---|-----------------------------|------------|
|   | 2020-21                     | 2019-20    |
| Interest rates - increase by 50 basis points* | (2,35,406)                  | (3,45,233) |
| Interest rates - decrease by 50 basis points* | 2,35,406                    | 3,45,233   |

**TEJNAKSH HEALTHCARE LIMITED****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEAR ENDED MARCH 31, 2021***(Amount in INR, unless otherwise stated)***36. CAPITAL MANAGEMENT**

For the purpose of the company's capital management, capital includes issued equity capital, equity instruments, share premium and all other equity reserves attributable to the equity holders. The primary objective of the Company's capital management is to maximise the shareholder value.

The Company manages its capital to ensure that it will be able to continue as going concerns through the optimization of the debt and equity balance. The capital structure of the Company consists of net debt (i.e. borrowings offset by cash and bank balances) and equity of the Company (comprising issued capital, reserves and retained earnings). The Company monitors capital using a ratio of 'net debt' to equity. The Company's net debt to equity ratio is as follows.

| Particulars                     | March 31, 2021      | March 31, 2020      |
|---------------------------------|---------------------|---------------------|
| Borrowings                      | 4,18,21,518         | 6,59,34,377         |
| Less: cash and cash equivalents | (1,23,29,734)       | (1,29,39,866)       |
| <b>Net Debt</b>                 | <b>2,94,91,784</b>  | <b>5,29,94,510</b>  |
| Equity                          | 17,31,43,834        | 15,25,09,740        |
| <b>Total Capital</b>            | <b>17,31,43,834</b> | <b>15,25,09,740</b> |
| <b>Capital and net debt</b>     | <b>20,26,35,619</b> | <b>20,55,04,250</b> |
| <b>Net debt to equity ratio</b> | <b>0.15</b>         | <b>0.26</b>         |

See accompanying notes forming part of the consolidated financial statements  
In terms of our report attached.

**For P.D. Dalal & Co**

Chartered Accountants

Firm Registration No.102047W

Sd/-

**Aashish Kakaria**

Partner

Membership No.: 102915

Place: Mumbai

Date: June 29, 2021

UDIN:21102915AAAAEM6989

1 to 36

**For and on behalf of the Board of Directors**

Sd/-

**(Dr. A.V. Rawandale)**

Managing Director

Sd/-

**(Prakash Sogam)**

Company Secretary

Membership No.: ACS42727

Sd/-

**(Dr. P.A. Rawandale)**

Director

Sd/-

**(Ramesh Kuwar)**

Chief Finance Officer

Intentionally left blank

**Form AOC-1**

(Pursuant to first proviso to sub-section (3) of section 129 read with rule 5 of Companies (Accounts) Rules, 2014)

**Statement containing salient features of the financial statement of subsidiaries or associate companies or joint ventures**

**Part A Subsidiaries**

(Information in respect of each subsidiary to be presented with amounts in Rs.)

1. Sl. No. **1**
2. Name of the subsidiary :- **Tej Vedaant Healthcare Private Limited**
3. The date since when subsidiary was acquired :- **27.12.2016**
4. Reporting period for the subsidiary concerned, if different from the holding company's reporting period.  
**N.A.**
5. Reporting currency and Exchange rate as on the last date of the relevant financial year in the case of foreign subsidiaries. **N.A.**
6. Share capital: **10,00,000**
7. Reserves and surplus : **1,69,83,456**
8. Total assets: **2,38,52,473**
9. Total Liabilities: **58,69,017**
10. Investments: -
11. Turnover: **3,84,89,733**
12. Profit before taxation: **7,79,267**
13. Provision for taxation: **6,50,484**
14. Profit after taxation: **6,58,215**
15. Proposed Dividend : **Nil**
16. Extent of shareholding (in percentage) : **75%**

**Notes:** The following information shall be furnished at the end of the statement:

1. Names of subsidiaries which are yet to commence operations
2. Names of subsidiaries which have been liquidated or sold during the year.

**For P.D. Dalal & Co**

Chartered Accountants

Firm Registration No.102047W

Sd/-

**((Aashish S. Kakaria))**

Partner

Membership No.102915

Place: Mumbai

Date: June 29, 2021

**For and on behalf of the Board of Directors**

Sd/-

**(Dr. A.V. Rawandale)**

Managing Director

Sd/-

**(Ramesh Kuwar)**

Chief Finance Officer

Sd/-

**(Dr. P.A. Rawandale)**

Director

Sd/-

**(Prakash Sogam)**

Company Secretary

**BY COURIER**

To,

**If undelivered Please return to:-**

**TEJNAKSH HEALTHCARE LIMITED**

CIN - L85100MH2008PLC179034

Regd. Off.: A 601, Floor No.6, Kailash Business Park,  
Veer Savarkar Marg, Vikroli - West, Mumbai - 400079

Email: [instituteofurology@gmail.com](mailto:instituteofurology@gmail.com), Tel: 022-2754 2311; web: [www.tejnaksh.com](http://www.tejnaksh.com)

---